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Foreword 
 
This document was first published in March, 2008, setting the standards for the first Nationally 
Consistent Data and Measures (NCDMs) for the National Environmental Health Tracking 
Program. The purpose of these NCDMS was to ensure compatibility and comparability of data 
and measures useful for understanding the impact of our environment on our health. Version 2.0  
 reflect the lessons learned in implementing the first NCDMs across local, state, and 
national tracking networks 
 improve the utility of specific measures 
 identify recommended temporal and spatial resolution, specifically for health outcomes, 
based on confidentiality protection needs and data steward requests 
 
Specific updates included in version 2 include: 
 
 Clarified description of process for creating and adopting the first set of NCDMs 
 Clarified the meaning of indicator, measure, and data within the Tracking Network 
 Added columns to the table summarizing the indicators and measures in order to identify 
o minimum temporal and geographic resolution 
o data source 
o grantee requirements 
 Updated indicator templates to reflect minimum temporal and geographic resolution at 
which measures are to be displayed on public portals  
 
Version 3.0 includes a change from required to optional for the Fertility indicator and 
documentation for NCDMs adopted since the release of version 2 in August 2011. 
 
 Hospitalizations and ED visits for heat 
 ED visits for asthma 
 Blood lead levels by birth cohort and annual blood lead levels 
 Updates to drinking water NCDMs 
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Introduction 
 
Environmental Public Health Tracking is the ongoing collection, integration, analysis, 
interpretation, and dissemination of data from environmental hazard monitoring, human 
exposure, and health effects surveillance.  In financial year 2002, Congress appropriated funds to 
the Centers for Disease Control and Prevention (CDC) to develop a national environmental 
public health tracking network and to improve environmental health capacity at the state and 
local level. 
 
CDC established its National Environmental Public Health Tracking Program with the following 
goals:  
 
1. Build a sustainable national environmental public health tracking network (Tracking 
Network); 
2. Enhance environmental public health tracking workforce and infrastructure; 
3. Disseminate information to guide policy, practice, and other actions to improve the 
Nation’s health; 
4. Advance environmental public health science and research; 
5. Foster collaboration among health and environmental programs.  
 
In 2006, CDC transitioned from a piloting and planning phase to implementation.  The network 
was envisioned as a web-based, secure, distributed network of standardized electronic health and 
environmental data.  Sixteen states and New York City were funded in August 2006 to construct 
state-wide (city-wide) networks that will be components of the national network and to 
participate in a collaborative process to develop network standards development process. 
Additional funding from Congress allowed CDC to add 6 more states in 2009 and 1 in 2010.  
 
As part of the implementation process, CDC established a Content Work Group (CWG) to: 
1. Identify and recommend core measures for the Tracking Network;   
2. Examine the availability and applicability of existing data and identify approaches for 
deriving or collecting needed data; 
3. Identify and adapt standards and guidelines to facilitate nationally consistent data 
collection and ensure compatibility with existing standards efforts; 
4. Recommend metadata elements to describe data quality; 
5. Identify and recommend methods and tools for data integration, analysis and 
presentation. 
 
The CWG structure included a steering group made up of the principal investigators for grantee 
health departments and academic partners.  Content-specific teams advised the steering group  
These teams included content experts from: grantee states, cities and academic partners; non-
funded states and cities; CDC; other government agencies including the Environmental 
Protection Agency (EPA), the National Aeronautics and Space Administration (NASA), the US 
Geological Survey (USGS) and the National Institutes of Health (NIH); and non-governmental 
organizations including the American Association of Poison Control Centers (AAPCC), the 
National Birth Defects Prevention Network (NBDPN), the National Association of Health Data 
Organizations (NAHDO), the National Association for Public Health Statistics and Information 
 NCDM Recommendations Version 3.0  
Page 5   3/19/2013 
Systems (NAPHSIS) and the North American Association of Central Cancer Registries 
(NAACCR). 
 
Eight content teams were established, and each provided recommendations to CDC via the 
steering group for an initial set of Nationally Consistent Data and Measures (NCDMs)( Figure 
1). NCDMs consist of measures, grouped by indicators, and the data required to generate them. 
A measure is a summary characteristic or statistic, such as a sum, percentage, or rate. There may 
be several measures of a specific indicator which when considered in conjunction fully describe 
the indicator. An indicator is one or more items, characteristics or other things that will be 
assessed and that provide information about a population's health status, their environment, and 
other factors with the goal allowing us to monitor trends, compare situations, and better 
understand the link between environment and health. It is assessed through direct and indirect 
measures (e.g. levels of a pollutant in the environment as a measure of possible exposure) that 
describe health or a factor associated with health (i.e., environmental hazard, age) in a specified 
population. In general, content teams focused on developing measures specific to one of these 
areas, but they also considered both proven and potential linkages to the other areas. 
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Figure 1: Content Work Group (CWG) Structure and Process, 2006 - 2010 
 
 
 
Recommendations from content teams were separated into two parts; the first part concerned 
indicators, measures, and how-to-guides which described the methods for extracting necessary 
data and generating the measures. The second part was a data dictionary which described the 
data to be shared with CDC. Recommendations were reviewed by the CWG Steering Group for 
scientific rigor, utility for Tracking, and feasibility of each grantee generating the measures and 
where specified providing data to CDC for use on the National Tracking Portal. 
 
This document provides an updated summary of the NCDMs adopted by CDC as Tracking 
standards.  Section One of this document includes tables that summarize the indicators and 
measures and identify the requirements of Tracking grantees for creating measures and providing 
data to CDC. These Tracking standards incorporate discussions among the CWG steering group 
as well as the recommendations of content teams concerning the use of existing national datasets, 
where relevant.  
  
Section Two includes the indicator templates originally developed by the teams and updated by 
CDC.  An indicator template describes the indicator’s measures and their deviations, uses, and 
limitations.  Although teams generally adhered to the template there was some minor variation in 
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the submitted documents. In creating this document original recommendations were modified to 
ensure compatibility with the National Network and consistency across NCDMs.  
   
Details regarding the data needed to generate the measures are provided in the how-to-guides, 
data dictionaries, and schemas available from the CDC Tracking Program. Each set of 
documentation represents a data feed needed to generate one or more measures.   
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SECTION ONE: SUMMARY OF NATIONALLY CONSISTENT DATA AND MEASURES 
 
 
 
This section lists all NCDMs for the Tracking Network by indicator and measure name. The minimum temporal and geographic 
resolutions are provided for the display of each required measure. These resolutions were selected to provide the most granular view 
of the measure possible while considering the rarity of the outcome being measured and data steward requirements. Grantees able to 
publish more temporally or geographically resolved measures are encouraged to do so. Grantees unable to publish at least the 
minimum temporal and geographic resolutions should provide written documentation to CDC Tracking Program. The temporal and 
geographic resolutions of the measures in this document are not necessarily the temporal and spatial resolution of the data 
requirements. Information about the required fields and resolution of the data to generate the measures are provided in the 
how-to-guides and data dictionaries.  The source of the data required to generate each measure at the national level is provided in 
the summary table. Some data are provided by state and local grantees while other data are provided by national partners. Each 
measure is also listed as either required or optional for Tracking Grantees. Required means the grantees must (1) provide the data to 
CDC Tracking Program if the data are not available nationally and (2) publish the measure on their state or local portals.  
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Content Domain: Heart Attacks or Acute Myocardial Infarction (AMI) 
 
Indicator Measure 
Temporal 
Resolution 
Geographic 
Resolution 
Source of Data 
for National 
Network 
Grantee 
Required 
Heart Attacks Number of hospitalizations for 
heart attack 
Annual State and county Grantee Provided Required 
Average daily number of 
hospitalizations for heart attack, 
by month 
Annual State and county Grantee Provided Optional 
Maximum daily number of 
hospitalizations for heart attack 
by month  
 
Annual State and county 
Minimum daily number of 
hospitalizations for heart attack 
by month  
 
Annual State and county 
Rate of hospitalization for heart 
attack among persons 35 and over 
by age group (total, 35-64, 65+) 
per 10,000 population 
 
Annual State and county Grantee Provided Required 
Age-adjusted rate of 
hospitalization for heart attack 
persons 35 and over per 10,000 
population 
Annual State and county 
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Content Domain: Air Quality 
 
Indicator Measure Temporal 
Resolution 
Geographic 
Resolution 
Source of 
Data for 
National 
Network 
Grantee 
Required 
Ozone—Days 
Above 
Regulatory 
Standard  
Number of days with maximum 8-hour 
average ozone concentration over the 
National Ambient Air Quality Standard 
Annual  County Nationally 
Derived 
Required 
Number of person-days with maximum 
8-hour average ozone concentration over 
the National Ambient Air Quality 
Standard 
Annual  County 
Fine Particle 
(PM2.5)—
Days Above 
Regulatory 
Standard 
Percent of days with PM2.5 levels over 
the National Ambient Air Quality 
Standard (NAAQS) 
Annual  County Nationally 
Derived 
Required 
Number of person-days with PM2.5 over 
the National Ambient Air Quality 
Standard (NAAQS) 
Annual  County 
Annual PM2.5 
Level  
Average ambient concentrations of PM 
2.5 in micrograms per cubic meter (based 
on seasonal averages and daily 
measurement) 
Annual  County Nationally 
Derived 
Required 
Percent of population living in counties 
exceeding the National Ambient Air 
Quality Standard (compared to percent of 
population living in counties that meet 
the standard and percent of population 
living in counties without PM2.5 
monitoring) 
Annual  State 
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Content Domain: Asthma 
Indicator Measure 
Temporal 
Resolution 
Geographic 
Resolution 
Source of Data 
for National 
Network 
Grantee 
Required 
Hospitalizatio
ns for Asthma  Number of hospitalizations for asthma  
Annual State and county Grantee Provided Required 
Average daily number of 
hospitalizations for asthma, by month 
Annual State and county Grantee Provided Optional 
Maximum daily number of 
hospitalizations for asthma by month  
 
Annual State and county 
Minimum daily number of 
hospitalizations for asthma by month  
 
Annual State and county 
Rate of hospitalization for asthma by 
age group (total, 0-4, 5-14, 15-34, 35-
64, and 65+) per 10,000 population 
Annual State and county Grantee Provided Required 
Age-adjusted rate of hospitalization for 
asthma per 10,000 population  
 
Annual State and county 
Emergency 
Department 
Visits for 
Asthma 
Annual number of emergency 
department visits for asthma 
Annual State and county Grantee Provided Required 
Average number of emergency 
department visits for asthma as primary 
diagnosis per month 
Annual State and county 
Annual crude rate of emergency 
department visits for asthma by age 
group  (total, 0–4, 5–14, 15–34, 35–64, 
and 65+)  per 10,000 population by age 
group 
Annual State and county 
Annual age-adjusted rate of emergency 
department visits for asthma by age 
groups ( total, 0–4, 5–14, 15–34, 35–64, 
and 65+)  per 10,000 population 
Annual State and county 
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Content Domain: Birth Defects 
 
Indicator Measure 
Temporal 
Resolution 
Geographic 
Resolution 
Source of 
Data for 
National 
Network 
Grantee 
Required 
Prevalence 
of Birth 
Defects 
Prevalence of Anencephaly per 10,000 
live births  
5 year State and county Grantee 
Provided 
Required 
Prevalence of Spina Bifida (without 
Anencephaly) per 10,000 live births over  
5 year State and county 
Prevalence of Hypoplastic Left Heart 
Syndrome per 10,000 live births  
5 year State and county 
Prevalence of Tetralogy of Fallot per 
10,000 live births 
5 year State and county 
Prevalence of Transposition of the Great 
Arteries (vessels) per 10,000 live births  
5 year State and county 
Prevalence of Cleft Lip with or without 
Cleft Palate per 10,000 live births  
5 year State and county 
Prevalence of Cleft Palate without Cleft 
Lip per 10,000 live births  
5 year State and county 
Prevalence of Hypospadias per 10,000 live 
male births  
5 year State and county 
Prevalence of Gastroschisis per 10,000 
live births  
5 year State and county 
Prevalence of Upper Limb Deficiencies 
per 10,000 live births  
5 year State and county 
Prevalence of Lower Limb Deficiencies 
per 10,000 live births  
5 year State and county 
Prevalence of Trisomy 21 per 10,000 live 
births by maternal age at delivery (<35 
and >/=35) 
5 year State and county 
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Content Domain: Cancer 
 
Indicator Measure 
Temporal 
Resolution 
Geographic 
Resolution 
Source of 
Data for 
National 
Network 
Grantee 
Required 
Incidence of 
Selected 
Cancers 
Number of cases of Mesothelioma  
 
5 year State Nationally 
Derived 
Required 
Age-adjusted incidence rate of Mesothelioma per 100,000 
population 
 
5 year State 
Number of cases of Melanoma of the Skin 
 
Annual State 
5 year State and county 
Age-adjusted incidence rate of Melanoma of the Skin per 
100,000 population 
 
Annual State 
5 year State and county 
Number of cases of Liver and Intrahepatic Bile Duct 
Cancer 
 
Annual State 
5 year State and county 
Age-adjusted incidence rate of Liver and Intrahepatic Bile 
Duct Cancer per 100,000 population 
 
Annual State 
5 year State and county 
Number of cases of Kidney and Renal Pelvis Cancer 
 
Annual State 
5 year State and county 
Age-adjusted incidence rate of Kidney and Renal Pelvis 
Cancer per 100,000 population 
 
Annual State 
5 year State and county 
Number of cases of Breast Cancer in females by Age group 
(<50, ≥50, total) 
 
Annual State 
5 year State and county 
Age-adjusted incidence rate of Breast Cancer in females 
per 100,000 population by Age group (<50, ≥50, total) 
Annual State 
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 5 year State and county 
Number of cases of Lung and Bronchus Cancer  
 
Annual State 
5 year State and county 
Age-adjusted incidence rate of Lung and Bronchus Cancer 
per 100,000 population 
 
Annual State 
5 year State and county 
Number of cases of Bladder Cancer (including in situ)  
Annual State 
5 year State and county 
Age-adjusted incidence rate of Bladder Cancer (including 
in situ) per 100,000 population  
Annual State 
5 year State and county 
Number of cases of Brain and other nervous systems 
Cancer  
 
Annual State 
5 year State and county 
Age-adjusted incidence rate of Brain and other nervous 
systems Cancer per 100,000 population  
 
Annual State 
5 year State and county 
Number of cases of Brain and Central Nervous System 
Cancer in children (<15 years and <20 years)  
 
Annual State 
Age-adjusted incidence rate of Brain and Central Nervous 
System Cancer in children (<15 years and <20 years) per 
1,000,000 population  
 
Annual State 
Number of cases of Thyroid Cancer  
 
Annual State 
5 year State and county 
Age-adjusted incidence rate of Thyroid Cancer per 100,000 Annual State 
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population  
 
5 year State and county 
Number of cases of Non-Hodgkin’s Lymphoma  
 
Annual State 
5 year State and county 
Age-adjusted incidence rate of Non-Hodgkin’s Lymphoma 
per 100,000 population  
Annual State 
5 year State and county 
Number of cases of Leukemia 
 
Annual State 
5 year State and county 
Age-adjusted incidence rate of Leukemia per 100,000 
population  
Annual State 
5 year State and county 
Number of Leukemia in children (<15 years and <20 years)  
 
Annual State 
Age-adjusted incidence rate of Leukemia in children (<15 
years and <20 years) per 1,000,000 population  
 
Annual State 
Number of cases of Chronic Lymphocytic Leukemia  
 
Annual State 
Age-adjusted incidence rate of Chronic Lymphocytic 
Leukemia per 100,000 population  
 
Annual State 
Number of cases of Acute Myeloid Leukemia  Annual State 
Age-adjusted incidence rate of Acute Myeloid Leukemia 
per 100,000 population  
 
Annual State 
Number of Acute Myeloid Leukemia in children (<15 years 
and <20 years)  
 
Annual State 
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Age-adjusted incidence rate of Acute Myeloid Leukemia in 
children (<15 years and <20 years) per 1,000,000 
population  
 
Annual State 
Number of cases of Acute Lymphocytic Leukemia in 
children (<15 years and <20 years)  
Annual State 
Age-adjusted incidence rate of Acute Lymphocytic 
Leukemia in children (<15 years and <20 years) per 
1,000,000 population  
 
Annual State 
Incidence of 
Selected 
Cancers 
Number of cases of Oral Cavity and Pharynx Cancer Annual State Nationally 
Derived 
Optional 
5 year State and county 
Age-adjusted incidence rate of Oral Cavity and Pharynx 
Cancer per 100,000 population 
Annual State 
5 year State and county 
Number of cases of Larynx Cancer Annual State 
5 year State and county 
Age-adjusted incidence rate of Larynx Cancer per 100,000 
population 
Annual State 
5 year State and county 
Number of cases of Esophagus Cancer Annual State 
5 year State and county 
Age-adjusted incidence rate of Esophagus Cancer per 
100,000 population 
Annual State 
5 year State and county 
Number of cases of Pancreas Cancer Annual State 
5 year State and county 
Age-adjusted incidence rate of Pancreas Cancer per 
100,000 population 
Annual State 
5 year State and county 
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Content Domain: Carbon Monoxide 
 
Indicator Measure 
Temporal 
Resolution 
Geographic 
Resolution 
Source of Data 
for National 
Network 
Grantee 
Required 
Hospitalizations 
for Carbon 
Monoxide (CO) 
Poisoning 
Number of hospitalizations for CO 
poisoning by cause/intent (unintentional 
fire-related, unintentional non-fire 
related, and unknown intent) 
Annual State  Grantee 
Provided 
Required 
Crude rate of hospitalization for CO 
poisoning per 100,000 population by 
cause/intent (unintentional fire-related, 
unintentional non-fire related, and 
unknown intent) 
 
Annual State  
Age-adjusted rate of hospitalization for 
CO poisoning per 100,000 population  by 
cause/intent (unintentional fire-related, 
unintentional non-fire related, and 
unknown intent) 
 
Annual State  
Emergency 
Department Visits 
for CO Poisoning 
Number of emergency department visits 
for CO Poisoning by cause/intent 
(unintentional fire-related, unintentional 
non-fire related, and unknown intent) 
 
Annual State  
Grantee 
Provided 
Optional 
Crude rate of emergency department 
visits for CO poisoning per 100,000 
population by cause/intent (unintentional 
fire-related, unintentional non-fire 
related, and unknown intent) 
 
Annual State  
Age-adjusted rate of emergency 
department visits for CO poisoning per 
100,000 population by cause/intent 
(unintentional fire-related, unintentional 
Annual State  
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non-fire related, and unknown intent) 
 
CO Poisoning 
Mortality 
Number of deaths from CO poisoning  by 
cause/intent (unintentional fire-related, 
unintentional non-fire related, and 
unknown intent) 
 
Annual State Nationally 
Derived 
Required 
Crude rate of death from CO poisoning 
per 100,000 population by cause/intent 
(unintentional fire-related, unintentional 
non-fire related, and unknown intent) 
 
Annual State 
Age-adjusted rate of death from CO 
poisoning per 100,000 population by 
cause/intent (unintentional fire-related, 
unintentional non-fire related, and 
unknown intent) 
 
Annual State 
Reported 
Exposure to CO 
Number of unintentional CO exposures 
reported to poison control centers by 
resulting health effect and treatment in a 
healthcare facility 
 
Annual State Nationally 
Derived 
Optional 
Crude rate of unintentional CO exposures 
reported to poison control centers per 
100,000 population by resulting health 
effect and treatment in a healthcare 
facility 
 
Annual State  
Home CO 
Detector Coverage 
Percent of Behavioral Risk Factor 
Surveillance System (BRFSS) 
respondents reporting at least one CO 
detector in their household  
 
Annual State Nationally 
Derived 
Optional 
 NCDM Recommendations Version 3.0  
Page 19   3/19/2013 
Content Domain: Childhood Lead Poisoning 
 
Indicator Measure Temporal 
Resolution 
Geographic 
Resolution 
Source of Data 
for National 
Network 
Grantee 
Required 
Testing and 
Housing Age 
Number of children born in the same 
year and tested 
Annual State and county Nationally 
Derived 
Required 
Percent of children born in the same 
year and tested 
Annual State and county 
Number of homes built before 1950 
(as measured in the 2000 Census) 
Annual State and county 
Percent of homes built before 1950 
(as measured in the 2000 Census) 
Annual State and county 
Number of children younger than 5 
years living in poverty (as measured 
in 2000 census)  
Annual State and county Optional 
Percent of children younger than 5 
years living in poverty (as measured 
in 2000 census)  
 
Annual State and county 
Blood Lead 
Levels by Birth 
Cohort 
Number of children born in the same 
year and tested 
Annual State and county Nationally 
Derived 
Required 
Percent of children born in the same 
year and tested 
Annual State and county 
Number of children born in the same 
year and tested with confirmed blood 
lead levels ≥ 10 μg/dL 
Annual State and county 
Percent of children born in the same 
year and tested with confirmed blood 
lead levels ≥ 10 μg/dL 
Annual State and county 
Number of children born in the same 
year and tested with confirmed blood 
lead levels ≥ 10 μg/dL, by blood lead 
level category 
Annual State  
Percent of children born in the same Annual State  
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year and tested with confirmed blood 
lead levels ≥ 10 μg/dL, by blood lead 
level category 
PROPOSED *Number of children 
born in the same year and tested with 
blood lead levels between 5 and <10 
μg/dL  
Annual State and county 
PROPOSED*Percent of children 
born in the same year and tested with 
blood lead levels between 5 and <10 
μg/dL  
Annual State and county 
Annual Blood 
Lead Levels 
Number of children tested, by age 
group 
Annual State and county Nationally 
Derived 
Required 
Percent of children tested, by age 
group 
Annual State and county 
Number of children tested with 
confirmed blood lead levels ≥ 10 
μg/dL, by age group 
Annual State and county 
Percent of children tested with 
confirmed blood lead levels ≥ 10 
μg/dL, by age group 
Annual  State and county 
Number of children tested with 
confirmed blood lead levels ≥ 10 
μg/dL by blood lead level category, 
by age group 
Annual State  
Percent of children tested with 
confirmed blood lead levels ≥ 10 
μg/dL, by blood lead level category, 
by age group 
Annual State  
PROPOSED *Number of children 
tested with blood lead levels between 
5 and <10 μg/dL  
Annual State and county 
PROPOSED*Percent of children 
tested with blood lead levels between 
5 and <10 μg/dL  
Annual State and county 
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Content Domain: Climate Change 
Indicator Measure Temporal 
Resolution 
Geographic 
Resolution 
Source of Data for 
National Network 
Grantee Required 
Heat Stress 
Hospitalizations 
Number of hospitalizations for heat stress Annual from 
May–
September 
State and 
national 
Grantee Provided Required 
Crude rate of hospitalization for heat stress  
by age groups (total, 0–4, 5–14, 15–34, 
35–64, and 65+)  per 100,000 population 
Annual from 
May–
September 
State and 
national 
Age-adjusted rate of hospitalization for 
heat stress (by age groups 0–4, 5–14, 15–
34, 35–64, and 65+)  per 100,000 
population 
Annual from 
May–
September 
State and 
national 
Heat Stress 
Emergency 
Department 
Visits for Heat 
Stress 
Annual number of emergency department 
visits for heat stress 
Annual from 
May–
September 
State and 
county 
Grantee Provided Required 
Annual crude rate of emergency 
department visits for heat stress by age 
group (total, 0–4, 5–14, 15–34, 35–64, and 
65+)   per 100,000 
Annual from 
May–
September 
State and 
county 
Age-adjusted rate of emergency 
department visits for heat stress by age 
groups (total, 0–4, 5–14, 15–34, 35–64, 
and 65+)  per 100,000 population 
Annual from 
May–
September 
State and 
county 
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Content Domain: Drinking Water 
Indicator Measure 
Temporal 
Resolution 
Geographic 
Resolution 
Source of Data 
for National 
Network 
Grantee 
Required 
Atrazine Level and 
Potential 
Population 
Exposures 
Distribution of number of Community Water 
Systems (CWS) by mean atrazine concentration 
(micrograms per liter) 
Quarterly County Grantee Provided Required 
Distribution of number of CWS by maximum 
atrazine concentration (micrograms per liter) 
Annual County 
Distribution of number of CWS by mean atrazine 
concentration (micrograms per liter) 
Annual County 
Mean concentration of atrazine (micrograms per 
liter) at CWS-level 
Annual County 
Distribution of number of people served by CWS 
by mean atrazine concentration (micrograms per 
liter) 
Quarterly County 
Distribution of number of people served by CWS 
by maximum atrazine concentration (micrograms 
per liter) 
Annual County 
Distribution of number of people served by CWS 
by mean atrazine concentration  (micrograms per 
liter) 
Annual County 
Arsenic Level and 
Potential 
Population 
Exposures 
Distribution of number of community water 
systems by mean arsenic concentrations 
(micrograms per liter)  
Annual State  Grantee Provided Required 
Distribution of number of people served by 
community water systems by mean arsenic 
concentrations (micrograms per liter) 
Annual State  
Distribution of number of community water 
systems by maximum arsenic concentrations 
(micrograms per liter) 
Annual 
 
State   
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Distribution of number of people served by 
community water systems by maximum arsenic 
concentrations (micrograms per liter) 
Annual 
 
State   
 Mean concentration of Arsenic (micrograms per 
liter) at CWS-level 
 
  
Annual State   
Di (2-Ethylhexyl) 
phthalate (DEHP) 
Level and Potential 
Population 
Exposures 
Distribution of number of Community Water 
Systems (CWS) by maximum DEHP 
concentration (micrograms per liter) 
Annual County Grantee Provided Required 
Distribution of number of CWS by mean DEHP 
concentration (micrograms per liter) 
Annual County 
Mean concentration of DEHP (micrograms per 
liter) at CWS-level 
Annual County 
Distribution of number of people served by CWS 
by maximum DEHP concentration (micrograms 
per liter) 
Annual County 
Distribution of number of people served by CWS 
by mean DEHP concentration (micrograms per 
liter) 
Annual County 
Nitrate Level and 
Potential 
Population 
Exposures 
Distribution of number of community water 
systems by mean nitrate concentrations 
(milligrams per liter) 
Annual State  Grantee Provided Required 
Distribution of number of people served by 
community water systems by mean nitrate 
concentrations (milligrams per liter)  
Annual State  
Distribution of number of community water 
systems by maximum nitrate concentrations 
(milligrams per liter) 
 
Annual 
 
State  
Distribution of number of people served by 
community water systems by maximum nitrate 
concentrations (milligrams per liter) 
 
Annual 
 
State  
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 Distribution of number of community water 
systems by mean nitrate concentrations 
(milligrams per liter) 
 
Quarterly 
 
State  
 
Distribution of number of people served by 
community water systems by mean nitrate 
concentrations (milligrams per liter)  
Quarterly 
 
State  
 
Mean concentration of nitrate (milligrams per 
liter)  at CWS-level 
Annual State 
Disinfection 
Byproducts (DBP) 
Level and Potential 
Population 
Exposure (TTHM) 
Distribution of number of community water 
systems by mean trihalomethane (THM) 
concentrations (micrograms per liter) 
 
Annual State  Grantee Provided Required 
Distribution of number of people served by 
community water systems by mean 
trihalomethane (THM) concentrations 
(micrograms per liter)  
Annual State  
Distribution of number of community water 
systems by maximum trihalomethane (THM) 
concentrations (micrograms per liter)  
 
Annual 
 
State  
Distribution of number of people served by 
community water systems by maximum 
trihalomethane (THM) concentrations 
(micrograms per liter)  
 
Annual 
 
State  
 
Distribution of number of community water 
systems by mean trihalomethane concentrations 
(micrograms per liter) 
 
Quarterly 
 
State  
 
Distribution of number of people served by 
community water systems by mean 
trihalomethane (THM) concentrations 
(micrograms per liter)  
Quarterly 
 
 
State  
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Disinfection 
Byproduct:  Levels 
and Potential 
Population 
Exposures (HAA5) 
 
 
Distribution of number of community water 
systems by mean haloacetic acids (HAA5) 
concentrations (micrograms per liter)  
 
Annual State  Grantee Provided Required 
Mean concentration of HAA5 (micrograms per 
liter) at CWS-level 
Annual 
 
State  
 
Distribution of number of community water 
systems by maximum haloacetic acids (HAA5) 
concentrations (micrograms per liter)  
Annual 
 
State  
 
Distribution of number of CWS by maximum 
TTHM concentration (micrograms per liter) 
Annual 
 
State  
 
Distribution of number of people served by 
community water systems by mean haloacetic 
acids (HAA5) concentrations (micrograms per 
liter)  
Quarterly 
 
State  
 
Distribution of number of CWS by mean TTHM 
concentrations (micrograms per liter) 
Quarterly 
 
State  
 Distribution of number of CWS by mean TTHM 
concentration (micrograms per liter) 
Annual State   
Mean concentration (micrograms per liter)  of 
TTHM at CWS-level 
Annual State   
Public Water Use Number of people receiving water from 
community water systems 
Annual State  Grantee Provided Required 
Combined 
Radium-226 and -
228 Levels and 
Potential 
Population 
Distribution of number of Community Water 
Systems (CWS) by maximum Radium 
concentration picoCuries per Liter 
Annual County Grantee Provided Required 
Distribution of number of CWS by mean Radium 
concentration picoCuries per Liter 
Annual County 
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Exposure Mean concentration of Radium picoCuries per 
Liter at CWS-level 
Annual County 
Distribution of number of people served by CWS 
by maximum Radium concentration picoCuries 
per Liter 
Annual County 
Distribution of number of people served by CWS 
by mean Radium concentration picoCuries per 
Liter 
Annual County 
Tetrachloroethene 
(PCE) Levels and 
Potential 
Population 
Exposure  
Distribution of number of Community Water 
Systems (CWS) by maximum PCE concentration 
(micrograms per liter)   
Annual County Grantee Provided Required 
Distribution of number of CWS by mean PCE 
concentration (micrograms per liter)   
Annual County  
Mean concentration of PCE (micrograms per 
liter) at CWS-level 
Annual County 
Distribution of number of people served by CWS 
by maximum PCE concentration (micrograms per 
liter)   
Annual County 
Distribution of number of people served by CWS 
by mean PCE concentration (micrograms per 
liter)   
Annual County  
Trichloroethene 
(TCE) Levels and 
Potential 
Population 
Exposure 
Distribution of number of CWS by maximum 
TCE concentration (micrograms per liter)   
Annual County Grantee Provided Required 
Distribution of number of CWS by mean TCE 
concentration (micrograms per liter)    
Annual County 
Mean concentration of TCE (micrograms per 
liter)  at CWS-level 
Annual County 
Distribution of number of people served by CWS 
by maximum TCE concentration (micrograms 
per liter)    
Annual County 
Distribution of number of people served by CWS 
by mean TCE concentration (micrograms per 
liter)    
Annual County 
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Uranium Levels 
and Potential 
Population 
Exposure 
Distribution of number of Community Water 
Systems (CWS) by maximum Uranium 
concentration (micrograms per liter)   
Annual County Grantee Provided Required 
Distribution of number of CWS by mean 
Uranium concentration (micrograms per liter)   
Annual County 
Mean concentration of Uranium (micrograms per 
liter)   at CWS-level 
Annual County 
Distribution of number of people served by CWS 
by maximum Uranium concentration 
(micrograms per liter)   
Annual County 
Distribution of number of people served by CWS 
by mean Uranium concentration (micrograms per 
liter)   
Annual County 
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Content Domain: Reproductive Health Outcomes 
 
Indicator Measure Temporal 
Resolution 
Geographic 
Resolution 
Source of Data 
for National 
Network 
Grantee 
Required 
Prematurity Percent of preterm (less than 37 weeks 
gestation) live singleton births 
Annual State and 
county 
Nationally 
Derived 
Required 
Percent of very preterm (less than 32 
weeks gestation) live singleton births 
5 year Annual 
Average 
State and 
county 
Low 
Birthweight 
Percent of low birthweight (less than 
2500 grams) live term singleton births  
Annual State and 
county 
Nationally 
Derived 
Required 
Percent of very low birthweight (less than 
1500 grams) live singleton births  
5 year Annual 
Average 
State and 
county 
Mortality  Average Infant (less than 1 year of age) 
Mortality Rate per 1000 live births  
5 year Annual 
Average 
State and 
county 
Nationally 
Derived 
Required 
Average Neonatal (less than 28 days of 
age) Mortality Rate per 1000 live births  
5 year Annual 
Average 
State and 
county 
Average Perinatal (equal to or greater 
than 28 weeks gestation to less than 7 
days of age) Mortality Rate per 1000 live 
births (plus fetal deaths equal to or 
greater than 28 weeks gestation)  
5 year Annual 
Average 
State and 
county 
Average Postneonatal (equal to or greater 
than 28 days to less than 1 year of age) 
Mortality Rate per 1000 live births  
5 year Annual 
Average 
State and 
county 
Fertility Total Fertility Rate per 1000 women of 
reproductive age  
Annual State and 
county 
Nationally 
Derived 
Optional 
Sex Ratio at 
Birth 
Male to Female sex ratio at birth (term 
singletons only)  
Annual State and 
county 
Nationally 
Derived 
Required 
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SECTION TWO: INDICATOR TEMPLATES 
 
 
This section contains an indicator template for each indicator and corresponding measures listed 
in section one. The indicator template provides basic information about the indicator including: 
 
1. Measures 
2. Derivations of the measures 
3. Units 
4. Geographic Scope 
5. Geographic Scale 
6. Time Period 
7. Time Scale 
8. Rationale 
9. Use of the Measure 
10. Limitations of the Measure 
11. Data Sources 
12. Limitations of Data Sources 
13. References 
 
 
Additional information about the underlying data needed for the indicator and steps for 
extracting the data and generating the measures can be found in the how-to-guides and data 
dictionaries.  
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CONTENT DOMAIN: HEART ATTACK 
INDICATOR: HOSPITALIZATIONS FOR HEART ATTACK 
 
Type of EPHT Indicator Health Outcome 
Measures 
1. Number of hospitalizations for acute myocardial infarction (AMI) 
2. Minimum daily number of hospitalizations for AMI by month 
3. Maximum daily number of hospitalizations for AMI by month 
4. Average daily number of hospitalizations for AMI by month 
5. Crude rate of hospitalizations for AMI among persons 35 and older 
by age group (total, 35-64, 65+) per 10,000 population 
6. Annual age-adjusted rate of hospitalizations for AMI among 
persons 35 and older per 10,000 population 
 
When supported by sufficient data volume, the measures may also be 
reported stratified by sex, race, and ethnicity. 
Derivation of Measures 
Numerator:  
Resident hospitalizations for AMI, ICD-9-CM: 410.00–410.92 by 
gender and total for state and by county 
 
Denominator: 
Midyear resident population by gender, for state and by county 
 
Adjustment: 
Age-adjustment by the direct method to Year 2000 U.S. Standard 
population 
Unit Hospital admission (categorized by discharge diagnosis) 
Geographic Scope State and national (tracking network states) 
Geographic Scale  State and county 
Time Period 
Hospital admissions from January 1 through December 31 for each 
year, 2000–current 
Time Scale Daily, monthly, and annually (as appropriate for the measure) 
Rationale 
There currently is no single AMI surveillance system is in place in the 
United States, nor does such a system exist for coronary heart disease 
(CHD) in general.  Mortality is the sole descriptor for national data for 
AMI.  Estimates of incidence and prevalence of AMI and CHD are 
largely based on survey samples (e.g., NHANES) or large cohort 
studies such as the Atherosclerosis Risk in Communities (ARIC) 
study.   
 
In 2007, the American Heart Association estimated 565,000 new 
attacks and 300,000 recurrent attacks of MI annually (National Heart, 
Lung, and Blood Institute: based on unpublished data from the ARIC 
study and the Cardiovascular Health Study [CHS]).  Among 
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Americans aged ≥20 years, new and recurrent MI prevalence for both 
men and women represented 3.7% of the U.S. population, or 7,900,000 
(4.9 million men and 3.0 million women). Corresponding prevalence 
by race and ethnicity is 5.4% for white men, 2.5% for white women, 
3.9% for black men, and 3.3% for black women. 
 
The well-documented risk factors for AMI include diabetes, 
hypertension, obesity, hypercholesterolemia, and cigarette smoking.  
Increasingly, investigators both in the United States and abroad have 
shown significant relationships between air pollutants and increased 
risk of AMI and other forms of CHD. Studies have often focused on 
persons aged >65 years. A number of epidemiologic studies have 
reported associations between air pollution (ozone, PM10 , CO,  PM 
2.5, SO2 ) and hospitalizations for AMI and other forms of heart 
disease. Models have demonstrated increases in AMI hospitalization 
rate in relation to fine particles (PM2.5), particularly in sensitive 
subpopulations such as the elderly, patients with pre-existing heart 
disease, and particularly persons who are survivors of MI or persons 
with COPD.  An increase of 10 ug/m
3
 in PM 2.5 was associated with a 
4.5% elevation in risk of acute ischemic coronary events (unstable 
angina and AMI) (95% CI, 1.1–8.0). Mortality statistics have been 
linked for a 16-year period to chronic exposure of multiple air 
pollutants in 500,000 adults residing throughout the United States. 
Each 10 ug/m3 in annual PM2.5 was related to a 12% increased 
mortality risk.   
Use of the Measures 
Developing a standardized analytic method for AMI hospital 
admissions among residents in each state will provide more uniform 
information for multiple users at the national, state, and local levels.  
These measures will allow monitoring of trends over time, identify 
high risk groups, and inform prevention, evaluation, and program 
planning efforts. 
 
These measures will address the following surveillance functions: 
 
 Examination of time trends in AMI hospitalizations. 
 Identification of seasonal trends. 
 Assessment of geographic differences in hospitalizations. 
 Evaluation of differences in AMI hospitalizations by age, gender, 
and race/ethnicity. 
 With further analysis … evaluation of disparities in AMI 
hospitalizations by factors such as age, race/ethnicity, gender, 
education, and/or income. 
 Determination of populations in need of targeted interventions. 
 Identification of possible environmental relationships that warrant 
further investigation or environmental public health action when 
AMI data are linked with environmental variables.  
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Limitations of the 
Measures 
Hospitalization data for AMIs omit persons who do not receive 
medical care or who are not hospitalized, including those who die in 
emergency rooms, in nursing homes, or at home without being 
admitted to a hospital, and those treated in outpatient settings. 
 
Differences in rates by time or area may reflect differences or changes 
in diagnostic techniques and criteria and in the coding of AMI or in 
medical care access. 
 
Differences in rates by area may be due to different sociodemographic 
characteristics and associated behaviors. 
 
When rates across geographic areas are compared, a variety on non-
environmental factors, such as access to medical care and diet, can 
affect the likelihood of persons hospitalized for AMI. 
 
Reporting rates at the state and/or county level will not show the true 
AMI burden at a more local level (i.e., neighborhood). 
 
Reporting rates at the state and/or county level will not be resolved 
geographically enough to be linked with many types of environmental 
data. 
 
When looking at small geographic levels (e.g., ZIP code), users must 
consider appropriate cell suppression rules imposed by the data 
providers or individual state programs. 
 
Although duplicate records and transfers from one hospital to another 
are excluded, the measures are based upon events, not individuals, 
because no unique identifier is always available.  When multiple 
admissions are not identified, the true prevalence will be 
overestimated.  
 
Even at the county level, the measures generated will often be based 
upon numbers too small to report or present without violating state and 
federal privacy guidelines and regulations. Careful adherence to cell 
suppression rules in cross tabulations is necessary, and methods to 
increase cell sizes by combining data across time (e.g., months, years) 
and geographic areas may be appropriate. 
Data Sources 
Numerator: 
State inpatient hospitalization data (using admission date) 
 
Denominator: 
U.S. Census Bureau population data  
Limitations of Data 
Sources 
State hospital discharge data: 
Using a measure of all AMI hospitalizations will include some 
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 transfers between hospitals for the same person for the same AMI 
event. Variations in the percentage of transfers or readmissions for the 
same AMI event may vary by geographic area and impact rates. 
However, efforts were made to identify and exclude transfers based on 
unique identifiers consisting of date of birth, zip code, gender, and 
encrypted social security number when available. 
 
Without reciprocal reporting agreements with abutting states, 
statewide measures and measures for geographic areas (e.g., counties) 
bordering other states may be underestimated because of health care 
utilization patterns. 
 
Each state must individually obtain permission to access and, in some 
states, provide payment to obtain the data. 
 
Veterans Affairs, Indian Health Services, and institutionalized (prison) 
populations are not usually included in hospitalization datasets. 
 
Practice patterns and payment mechanisms may affect diagnostic 
coding and decisions by health care providers to hospitalize patients 
 
Street address is not available in many states. 
 
Sometimes mailing address of patient is listed as the residence address 
of the patient. 
 
Patients may be exposed to environmental triggers in multiple 
locations, but hospital discharge geographic information is limited to 
residence. 
 
Since the data capture hospital discharges (rather than admissions), 
patients admitted toward the end of the year and discharged the 
following year will be omitted from the current year dataset. 
 
Data will need to be de-duplicated (i.e., remove duplicate records for 
the same event). 
 
There is usually a two-year lag period before data are available from 
the data owner. 
 
Census data: 
Available only every 10 years; thus, postcensal data will be estimated 
for calculating rates for years following the census year. 
 
Postcensal estimates at the ZIP code level are not available from the 
Census Bureau. These estimates should be extrapolated or purchased 
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from a vendor. 
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CONTENT DOMAIN: AIR QUALITY 
INDICATOR: OZONE-DAYS ABOVE REGULATORY 
STANDARD 
 
Type of EPHT Indicator Hazard 
Measures 1. Number of days with maximum 8-hour average ozone concentration 
over the National Ambient Air Quality Standard (NAAQS) 
2. Number of person-days with maximum 8-hour average ozone 
concentration over the National Ambient Air Quality Standard 
(NAAQS) 
Derivation of Measures This overview provides the key technical points in how EPA and CDC 
processed EPA’s air quality data for use in the EPHT air indicators.   
 
Processing raw data 
First, EPA extracts the air quality data from the Air Quality System 
(AQS).  EPA uses the following steps in developing the air data and 
measures for EPHT air quality indicators. 
 
Step 1: EPA accesses daily maximum 8-hour average ozone 
concentrations (ppm) (parameter code ‘44201’ and duration code ‘W’) 
and supplemental data fields (e.g. latitude, longitude, elevation) for all 
the monitoring sites across the US from the EPA’s Data Mart.  The data 
are obtained only from monitors that are designated as Federal Reference 
Methods or equivalent.  The data include any flagged values associated 
with exceptional events (high winds, fires, construction, etc) regardless 
of concurrence by the EPA Regional Office.  EPA retains data from 
monitors that meet the minimum data completeness criteria set forth in 
the national air quality standard (i.e. if valid 8-hour averages are 
available for at least 75% of possible hours in a day or the maximum 8-
hour average is above ozone 8-hr NAAQS).  
 
Step 2:  For each monitoring site, retain the maximum concentration at 
the site for each monitored day.  The pollutant occurrence code (poc) 
which distinguishes multiple monitors at a single site is listed in the 
output data set.  
  
Step 3: Site-level daily monitoring data are used to create ozone 8-hr 
maximum daily county-level dataset. Daily county-level dataset is 
created by retaining the maximum concentration among all monitors 
within the county for each monitored day. The county-level daily dataset 
is used to create number of days and number of person-days with ozone 
levels over the daily NAAQS measures. 
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Creating Measures 
Step 3: Ozone levels decrease significantly in the colder parts of the year 
in many areas, ozone is required to be monitored at monitoring sites only 
during the ozone season, which is defined on a state by state basis. Only 
counties that have at least 75% of the days monitored during the ozone 
seasons are considered complete. The measures are computed only for 
counties that satisfy the completeness criteria.   
 
Number of days with Ozone levels over the NAAQS: 
Step 4: Select counties which pass the completeness criteria mentioned 
in Step 3. 
 
Step 5: To calculate the annual number of days over the daily NAAQS, 
sum the number of days with ozone levels over the daily 8-hr NAAQS 
for the entire year. 
 
Number of person-days with ozone levels over the NAAQS: 
Step 4:  To calculate Person-days with ozone levels over the daily 8-hr 
NAAQS, multiply the number of days over the daily NAAQS by the 
total population of the county. 
 
Units 1. Exceedance days 
2. Population-weighted exceedance days 
Geographic Scope United States 
Geographic Scale County (where monitors exist) 
Time Period 2001-current 
Time Scale Calendar year 
Rationale According to the published literature, air pollution is associated with 
premature death, increased rates of hospitalization for respiratory and 
cardiovascular conditions, adverse birth outcomes, and lung cancer (2, 
3). Air pollution places a large economic burden on the country. In a 
report prepared for the American Lung Association,(2) estimated that air 
pollution related illness was estimated to cost approximately $100 billion 
annually (2) (1988 dollars) in the United States, with an estimated 
number of excess deaths ranging from 50,000 to 100,000 annually (3).  
More than half of the U.S. population, approximately 159 million 
persons, live in counties with unhealthy levels of air pollution in the 
form of either ozone or particulate matter (1). Elevated pollution levels 
depend on sources, transport, season geography, and atmospheric 
conditions.  Each part of the country has its own level of pollution 
concentrations that can be exacerbated by many conditions, including 
stagnation, fire, or wind.  The seasons for peak concentrations also vary 
between geographical regions. (4) 
 
The Clean Air Act, which was last amended in 1990, requires EPA to set 
NAAQS for widespread pollutants from numerous and diverse sources 
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considered harmful to public health and the environment. The Clean Air 
Act established two types of national air quality standards. Primary 
standards set limits to protect public health, including the health of 
"sensitive" populations such as asthmatics, children, and the elderly. 
Secondary standards set limits to protect public welfare, including 
visibility impairment and damage to animals, crops, vegetation, and 
buildings. (5) 
 
Our indicator is based on comparing measured levels of ozone by county 
to the primary ozone 8-hr NAAQS, which is set at 75 ppb  The Clean Air 
Act requires periodic review of the science upon which the standards are 
based and the standards themselves. Primary air quality standards 
indicate the acceptable level of substances in the air before harm will 
occur based on proven scientific and medical research. State 
governments also set air quality standards. In several cases, California's 
standards or other benchmarks are more stringent than the EPA NAAQS. 
Use of Measure The indicator for the number of days with maximum 8-hour average 
ozone concentration over the standard is similar to EPA’s analyses on 
number of days with air quality index (AQI) levels higher than 100 (for 
ozone) – see www.epa.gov/airtrends/aqi_info.html.  This measure is 
consistent with the EPA and state AQI program efforts to communicate 
an area’s air quality levels to the public.  In addition, this indicator can 
be used to inform policy makers and the public of the degree of hazard 
within a state (by county or MSAs with monitors) during a year.  For 
example, the number of days per year that ozone is higher than the 
NAAQS can be used to communicate to sensitive populations (such as 
asthmatics) the number of days that they may be exposed to unhealthy 
levels of ozone; this is the same level used in the air quality alerts that 
inform these sensitive populations when and how to reduce exposure.  
See http://www.epa.gov/air/airtrends/2007/report/groundlevelozone.pdf 
and http://www.epa.gov/air/airtrends/aqtrnd00/pdffiles/aqioz.pdf. 
In the use of the measure, it is important to explain that not all counties 
have monitors although most populated areas are monitored. 
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Limitations of The 
Measure 
Since ozone levels decrease significantly in the colder parts of the 
year in many areas, ozone is required to be monitored only during the 
ozone season., which are designated on a State by State basis.(6)  
 
The number of high ozone days per year varies, which makes tracking 
trends over time difficult to analyze or interpret.  The variability results 
from the following: a) the number of high ozone days is related to 
temperature; there will be more high days in hotter summers; and b) 
there are a small number of events per year, so for statistical reasons this 
type of measure will bounce around more than an average. c) When 
creating measures, we only consider monitors with 75% completeness 
during the ozone season and ozone seasons are designated on a state by 
state basis.  
Variation within counties may exist but will not be captured in this 
measure.  Within these areas, the monitor with the highest reading on 
any day is used in the measure.   Larger areas will have a broader range 
of pollution values and perhaps more monitors that may measure a high 
value on a given day. Thus, day and person-day estimates for larger 
areas may be biased higher than estimates for smaller areas.  The relative 
variation among county populations in many states may be large enough 
relative to the variation in the number of days greater than the ozone 
NAAQS that the population component can dominate the calculation of 
the number of person-days.  Thus, careful investigation of the underlying 
data to properly identify changes in population and air quality is needed 
when comparing person-days in space and time. 
 
The data for this indicator represent only counties that have air monitors; 
thus the data tend to reflect urban air quality (where most people live). 
Although populations in areas without monitors also may be exposed to 
ozone that exceeds the standard, they are not counted.   The number of 
days that exceed the EPA NAAQS or other health benchmarks does not 
provide information regarding the severity (max concentrations) of 
potential exposures. The relationship between ambient concentrations 
and personal exposure is largely unknown and variable depending upon 
pollutant, activity patterns, and microenvironments.  
 
This indicator is not for use compliance determination with NAAQS or 
reasonable further progress toward attaining compliance.   
Data Sources Air quality data: EPA Air Explorer http://epa.gov/mxplorer/index.htm 
Limitations of Data 
Sources 
The AQS monitoring data, which are used in the calculation of measures, 
are not present for all counties and days.  
References 
 
1. American Lung Association. State of the Air 2004; 2004 [cited 
2008 Dec 4]. Available from:  
http://lungaction.org/reports/sota04_full.html  
 
2. Cannon J. The Health Costs of Air Pollution: A Survey of 
 NCDM Recommendations Version 3.0  
Page 39   3/19/2013 
Studies Published 1984– 1989. New York: American Lung 
Association; 1990. 
 
3. Dockery DW and Pope CA. Acute respiratory effects of 
particulate air pollution. Annu Rev Public Health 1994;15:107–
132. 
 
4. US Environmental Protection Agency. US EPA general site on 
ozone effects. Available from: 
http://www.epa.gov/air/ozonepollution/health.html 
 
5. Criteria document for ozone NAAQS: 
http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=149923 
 
6. Ozone Season definition by state: 
http://www.epa.gov/ttn/naaqs/ozone/ozonetech/40cfr58d.htm 
 
 
 
 
 
 
 
 
 
 
 
  
 NCDM Recommendations Version 3.0  
Page 40   3/19/2013 
CONTENT DOMAIN: AIR QUALITY 
INDICATOR: PM2.5—DAYS ABOVE REGULATORY STANDARD 
 
Type of EPHT Indicator Hazard 
Measures 1. Percent of days with PM2.5 levels over the National Ambient Air 
Quality Standard (NAAQS) 
2. Number of person-days with PM2.5 over the National Ambient Air 
Quality Standard (NAAQS) 
Derivation of Measures  
This overview provides the key technical points in how EPA and CDC 
processed EPA’s air quality data for use in the EPHT air indicators.   
 
Processing raw data: 
First, EPA extracts the air quality data from the Air Quality System 
(AQS).  EPA uses the following steps in developing the air data and 
measures for EPHT air quality indicators. 
 
Step 1: EPA accesses PM2.5 
3
) (parameter 
code ‘88101’ and duration code ‘7’) and daily maximum 8-hour 
average ozone concentrations (ppm) (parameter code ‘44201’ and 
duration code ‘W’) and supplemental data fields (e.g. latitude, 
longitude, elevation) for all the monitoring sites across the US from 
the EPA’s Data Mart.  The data are obtained only from monitors that 
are designated as Federal Reference Methods or equivalent.  The data 
include any flagged values associated with exceptional events (high 
winds, fires, construction, etc) regardless of concurrence by the EPA 
Regional Office.  
 
Step 2:  For each monitoring site, retain the maximum concentration at 
the site for each monitored day.  The pollutant occurrence code (poc) 
which distinguishes multiple monitors at a single site is listed in the 
output data set.  
  
Step 3: Site-level daily monitoring data are used to create 24-hr 
maximum daily county-level PM2.5 dataset. Daily county-level dataset 
is created by retaining the maximum concentration among all monitors 
within the county for each monitored day. The county-level daily 
dataset is used to create percent of days and number of person-days 
with PM2.5 levels over the daily NAAQS measures. 
 
Creating Measures 
Percent of days with PM2.5 levels over the NAAQS: 
Step 4: To calculate the annual percent of days over the daily NAAQS, 
sum the number of days with PM2.5 levels over the daily NAAQS and 
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divide by the total number of monitored days. Multiply this 
exceedance fraction by 100 to get percent of days. 
 
Number of person-days with PM2.5 levels over the NAAQS: 
Step 5:  To calculate person-days with PM2.5 levels over the NAAQS 
multiply the exceedance fraction from Step 4 by 365 to get the annual 
days and then multiply by the total population of the county. 
 
For PM2.5 - days above regulatory standard indicator, tracking portal 
only displays counties that have year-round monitoring. 
 
Unit 1. Exceedance days 
2. Population weighted exceedance days 
Geographic Scope Contiguous United States 
Geographic Scale County (where monitors exist)  
Time Period 2001-current 
Time Scale Calendar year 
Rationale According to the published literature, air pollution is associated with 
premature death, increased rates of hospitalization for respiratory and 
cardiovascular conditions, adverse birth outcomes, and lung cancer 
(2,3,4). Air pollution places a large economic burden on the country. 
In a report prepared for the American Lung Association, (2) estimated 
that air pollution related illness was estimated to cost approximately 
$100 billion annually (2) (1988 dollars) in the United States, with an 
estimated number of excess deaths ranging from 50,000 to 100,000 
annually (3).  More than half of the U.S. population, approximately 
159 million persons, live in counties with unhealthy levels of air 
pollution in the form of either ozone or particulate matter (1). Elevated 
pollution levels depend on sources, transport, season geography, and 
atmospheric conditions.  Each part of the country has its own level of 
pollution concentrations that can be exacerbated by many conditions, 
including stagnation, fire, or wind.  The seasons for peak 
concentrations also vary between geographical regions.  
 
The Clean Air Act, which was last amended in 1990, requires EPA to 
set NAAQS for widespread pollutants from numerous and diverse 
sources considered harmful to public health and the environment. The 
Clean Air Act established two types of national air quality standards. 
Primary standards set limits to protect public health, including the 
health of "sensitive" populations such as asthmatics, children, and the 
elderly. Secondary standards set limits to protect public welfare, 
including visibility impairment and damage to animals, crops, 
vegetation, and buildings.  
 
Our indicator is based on comparing measured levels of PM2.5 by 
county to the 24-hr NAAQS for PM2.5, 
3
. The 
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Clean Air Act requires periodic review of the science upon which the 
standards are based and the standards themselves. Primary air quality 
standards indicate the acceptable level of substances in the air before 
harm will occur based on proven scientific and medical research. State 
governments also set air quality standards. In several cases, 
California's standards or other benchmarks are more stringent than the 
EPA NAAQS. (5) 
Use of the Measure This indicator can be used to inform the public and policy makers of 
the degree of potential exposures within a state (for counties with 
monitors) during a year.  For example, the percentage of days per year 
that PM2.5 is higher than the NAAQS can be used to communicate to 
sensitive populations (such as asthmatics) the percentage of days that 
they may be exposed to unhealthy levels of PM2.5; this is similar to the 
level used in the Air Quality Alerts that inform these sensitive 
populations when and how to reduce exposure. 
 
The number of person-days may be directed toward policy makers 
who are interested in roughly comparing population exposure between 
areas, to determine the areas most in need of prevention and pollution 
control activities.  
Limitations of the Measure The data for this indicator represent highly populated counties that 
have PM2.5 monitors. As a result, the data tend to reflect urban air 
quality and longer-term average air quality levels. Populations in 
counties without monitors may also be exposed to concentrations that 
exceed a standard.  
 
The percentage of days during which the EPA NAAQS or other health 
benchmarks are exceeded does not provide information regarding the 
severity (maximum concentrations) of potential exposures.  Even with 
these limitations, trends in PM2.5 levels are a useful measure to 
describe public health concerns within these areas. We identify several 
limitations with this indicator below. 
 
This indicator is based on the percentage of high days rather than the 
total number of high days to highlight the fact that PM2.5 monitors 
follow different operating schedules. Most operate on a once-every-
third day schedule, but a small proportion operates on a daily or once-
every-sixth day schedule. Because most  of the monitors do not take 
measurements every day, the number of short-term events (e.g., days 
in which the NAAQS is exceeded ) is uncertain, and except where 
PM2.5 levels vary uniformly throughout the year, estimating short-term 
measures that are representative of short-term exposures over a year is 
complex.  To address this limitation, the measure can be based on the 
percentage of monitored days. It should be noted that state air 
programs will be evaluating the daily PM2.5 NAAQS by using a 
frequency-based analysis to determine whether areas within the state 
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attain this NAAQS. 
 
 
Populations in counties without monitors may be exposed to 
concentrations that exceed a standard.  Person-day estimates for larger, 
highly populated counties may be biased higher than estimates for 
smaller and lower populated counties.  The indicator uses the highest 
value of all monitors in the area so that larger counties with more 
monitors may have a broader range of pollution values and greater 
potential to measure a high day than smaller counties with fewer 
monitors  
 
The relationship between ambient concentrations and personal 
exposure is largely unknown, and it varies depending upon pollutant, 
activity patterns, and microenvironments. 
 
Because the number of high PM2.5 days per year can vary considerably, 
tracking trends over time needs to be done carefully.  The variability 
results because: the number of high PM2.5 days is related to 
meteorological factors (e.g., temperature and mixing heights), and few 
events occur per year, so that this type of extreme value measure will 
vary considerably for statistical reasons. When creating measures, we 
only consider monitors, which have atleast 11 observations per 
calendar quarter. 
Data Sources Air–quality data: EPA Air Explorer http://epa.gov/mxplorer/index.htm 
 
Population data: county population data can be found at 
http://www.census.gov/popest/counties/CO-EST2006-01.html 
Limitations of Data 
Sources 
 
Air–monitoring data provides information regarding concentrations 
around the specific location of each monitor.  For PM2.5 this can be a 
rather large area, except when unusual local emissions (agricultural 
fires) occur.   Within-county variation in concentrations will likely 
exist but will not be captured in this measure.  Many PM2.5 monitors 
operate once-every third day (some once-every-sixth day); a few 
monitors operate every day. 
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CONTENT DOMAIN: AIR QUALITY 
INDICATOR: ANNUAL PM2.5 LEVEL 
 
Type of EPHT Indicator Hazard 
Measure  1. Annual average ambient concentrations of PM2.5 in micrograms per 
cubic meter (based on seasonal averages and daily measurement) 
2. Annual percent of population living in counties exceeding the 
National Ambient Air Quality Standard (compared to percent of 
population living in counties that meet the standard and percent of 
population living in counties without PM2.5 monitoring) 
Derivation of Measure  First, EPA extracts the air quality data from the Air Quality System (AQS).  
EPA uses the following steps in developing the air data and measures for 
EPHT air quality indicators. 
 
Processing raw data 
Step 1:  EPA accesses PM2.5 daily concentrations (mcg/m
3
) (parameter code 
‘88101’ and duration code ‘7’) and supplemental data fields (e.g. latitude, 
longitude, elevation) for all the monitoring sites across the US from the 
EPA’s Data Mart.  The data are obtained only from monitors that are 
designated as Federal Reference Methods or equivalent.  The data include 
any flagged values associated with exceptional events (high winds, fires, 
construction, etc) regardless of concurrence by the EPA Regional Office.   
 
Step 2:  For each monitoring site, retain the maximum concentration at the 
site for each monitored day.  The pollutant occurrence code (poc) which 
distinguishes multiple monitors at a single site is listed in the output data 
set.  
 
Creating Measures 
Step 3: The annual average measures of PM2.5 are created using the site-
level daily monitoring data. Only monitors that have at least 11 
observations for each of the four calendar quarters are considered complete. 
The annual averages are computed only for monitors that satisfy the 
completeness criteria.   
 
Annual average ambient concentrations of PM2.5 measure: 
Step 4: Select monitors with complete quarterly and annual data using the 
site-level monitoring data.  
 
Step 5: Calculate the quarterly average for each calendar quarter and then 
compute the annual average for each monitor with four valid quarters by 
averaging the quarterly averages.  If a county has more than one monitor 
then the maximum annual average among monitors with complete (4 valid 
quarters) data is assigned as the annual average for that county. 
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Annual percent of population living in counties exceeding the NAAQS 
(compared to percent of population living in counties that meet the 
standard and percent of population living in counties without PM2.5 
monitoring) measure: 
Step 6a:  This is a state-level measure and uses the county-level annual 
average concentrations calculated in step 3. 
Step 6b: To calculate the annual percent of population living in counties 
that exceed the annual NAAQS, sum the population of all counties that 
exceed the annual NAAQS and divide by the total population of the state. 
Multiply this fraction by 100 to get percent. 
 
Step 6c: To calculate the annual percent of population living in counties that 
meet the annual NAAQS, sum the population of all counties that meet the 
annual NAAQS and divide by the total population of the state. Multiply this 
fraction by 100 to get percent. 
 
Step 6d: To calculate the annual percent of population living in counties 
that do not have complete monitors, sum the population of all counties that 
do not have complete monitors and divide by the total population of the 
state. Multiply this fraction by 100 to get percent. 
Unit  1. Microgram per cubic meter (μg/m3) 
2. Population proportion by hazard level 
Geographic Scope  Contiguous United States 
Geographic Scale County (where monitors exist)  
Time Period 2001- current 
Time scale Calendar year 
Rationale According to work conducted by Pope et al. (1), long-term exposure to 
PM2.5 is related to many adverse health conditions. Each 10 ug/m
3
 elevation 
in PM2.5 is related to an 8% increase in lung cancer mortality, a 6% increase 
in cardiopulmonary mortality, and a 4% increase in death from general 
causes.(2) 
 
The annual average provides an indication of the long-term trends in overall 
PM2.5 burden, relevant to its long-term effects. 
 
The percent of the population living in counties that exceed the standard 
provides an indication of the population at risk for long-term exposure. 
 
Note: these indicators are similar to indicators developed by EPA and state 
air quality agencies for use in air quality stats and trends analyses and 
reports (see www.epa.gov/airtrends) 
Use of The Measure This indicator can be used to inform policy makers and the public about the 
degree of potential exposures to fine particles within a state during a year 
and over time (trends). This is appropriate, as many existing health studies 
have found the strongest association with health outcomes based on long-
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term studies; thus, EPA developed the annual NAAQS at  
15 ug/m
3
.  The indicator (annual average PM2.5 concentrations) can be 
compared to the National Ambient Air Quality Standard (NAAQS) level of 
15 ug/m
3
 or other health-based standards (although not in a regulatory 
manner) to communicate the degree of public health concern to policy 
makers and the general public. (3) 
Limitations of the 
Measure 
This measure provides a general indication of the overall trend in annual 
PM2.5 concentrations.  It may be affected by density and placement of 
monitors, and coverage will vary across the country and within states. It 
does not directly reflect exposure. Certain geographic areas, such as those 
near busy roads, are likely to have higher values. 
 
When creating measures we only consider monitors that have at least 11 
observations per calendar quarter. It is important to understand that this 
indicator is not for use–compliance determination with NAAQS or 
reasonable further progress toward attaining compliance.   
 
The relationship between ambient concentrations and personal exposure is 
largely unknown, and it varies depending upon pollutant, activity patterns, 
and microenvironments. 
 
The percent of state population living in counties with no PM2.5 
measurements must always be considered when attempting to estimate the 
proportion of population at risk. 
Data Sources EPA Air Quality System Monitoring Data, State Air Monitoring Data.  
http://www.epa.gov/air/data/aqsdb.html 
Limitations of Data 
Sources 
Air monitoring data provides information regarding concentrations around 
the specific location of each monitor.  For PM2.5 this can be a rather large 
area, except when unusual local emissions (agricultural fires) occur.   
Within-county variation in concentrations will likely exist but will not be 
captured in this measure.  Many PM2.5 monitors operate once-every-third 
day (some once-every-sixth day) and a few measure every day 
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CONTENT DOMAIN: ASTHMA 
INDICATOR: HOSPITALIZATIONS FOR ASTHMA  
 
Type of EPHT Indicator Health Outcome 
Measures 
1. Number of hospitalizations for asthma 
2. Minimum daily number of hospitalizations for asthma by month 
3. Maximum daily number of hospitalizations for asthma by month 
4. Average daily number of hospitalizations for asthma by month 
5. Crude rate of hospitalization for asthma by age group (total, 0-4, 5-
14, 15-34, 35-64, and 65+) per 10,000 population 
6. Age-adjusted rate hospitalizations for asthma per 10,000 
population (all ages) 
 
When supported by sufficient data volume, the measures may also be 
reported stratified by sex, race, and/or ethnicity.  
Derivation of Measures 
Numerator:  
Resident hospitalizations for asthma, ICD-9-CM: 493.XX. 
Denominator:  
Midyear resident population. 
 
Adjustment: 
Age-adjustment by the direct method to Year 2000 U.S. Standard 
population 
Unit Hospital admission (categorized by discharge diagnosis) 
Geographic Scope State and national (tracking network states) 
Geographic Scale  State and county 
Time Period 
Hospital admissions from January 1 through December 31 for each 
year, 2000–current 
Time Scale Daily, monthly, and annually (as appropriate for the measure) 
Rationale 
In 2004, 20.5 million people in the United States reported having 
asthma. In 2003, there were more than 574,000 hospitalizations for 
asthma. In 2002, there were more than 4,200 deaths in which asthma 
was the underlying cause. Asthma is the leading chronic health 
condition among children. There are also large racial, income, and 
geographic disparities in poor asthma outcomes.  Asthma causes lower 
quality of life, preventable undesirable health outcomes, and large 
direct and indirect economic costs.  Environment attributable fractions 
of the 1988–1994 economic costs for asthma were 39.2% for children 
aged <6 years and 44.4% for children aged 6–16 year, costing more 
than $400 million for each age group.   
 
A number of epidemiologic studies have reported associations between 
air pollution exposures and asthma. The association between ambient 
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air particulate matter (PM) concentrations and asthma, including 
increased hospital admissions, is well documented.  Models 
demonstrate 5–20% increases in respiratory-related hospital 
admissions per 50µg/m
3
 of PM10 and 5–15% per 25µg/m
3
 of PM2.5, 
with the largest effect on asthma admissions.
 
 
 
In the eastern United States, summer ozone pollution was associated 
with more than 50,000 hospital admissions per year for asthma and 
other respiratory emergencies. Large multi-city and individual city 
studies found a positive association between ozone and total 
respiratory hospital admissions, including asthma, especially during 
the warm season. Among U.S. and Canadian studies, the ozone-
associated increase in respiratory hospital admissions ranged from 2-
30% per 20 ppb (24 hour), 30 ppb (8-hour) or 40 ppb (1-hour) 
increment of ozone in warm seasons. 
 
In 2000, the Institute of Medicine concluded that allergens produced 
by cats, cockroaches, and house dust mites exacerbates asthma, as 
does exposure to environmental tobacco smoke (ETS) in pre-school 
aged children. A 2005 California Air Resources Board report 
concluded that ETS exacerbates asthma in children and adults (CARB, 
2005). That report also estimated 202,300 childhood asthma episodes 
occur each year in the United States as a result of exposure to ETS.  
Use of the Measures 
Developing a standardized analytic method for asthma hospital 
admissions among residents in each state will provide more uniform 
information for multiple users at the national, state, and local levels.  
These measures will allow monitoring of trends over time, identify 
high risk groups, and inform prevention, evaluation, and program 
planning efforts. 
 
These measures will address the following surveillance functions: 
 
 How many hospitalizations for asthma occur in every month? 
 
 Is there a seasonal or temporal trend of asthma hospitalizations? 
 
 What’s the distribution of asthma hospitalizations by place of 
residence? 
 
 How do hospitalizations for asthma differ between geographic 
areas (e.g., ZIP code, county, state, region)? 
 
 With further analysis … Are there disparities in asthma 
hospitalizations by factors such as age, race, ethnicity, gender, 
education, and/or income? 
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 Which populations need targeted interventions? 
 
 When asthma data are linked with environmental variables, do the 
linked measures identify environmental relationships that warrant 
further investigation or environmental public health action? 
Limitations of the 
Measures 
Hospitalization data, by definition, do not include asthma among 
individuals who do not receive medical care or who are not 
hospitalized, including those who die in emergency rooms, in nursing 
homes, or at home without being admitted to a hospital, and those 
treated in outpatient settings. 
 
Differences in rates by time or area may reflect differences or changes 
in diagnostic techniques and criteria and in the coding of asthma. 
 
Reporting rates at the state and/or county level will not show the true 
asthma burden at a more local level (i.e., neighborhood). 
 
Differences in rates by area may be due to different sociodemographic 
characteristics and associated behaviors. 
 
When rates across geographic areas are compared, many non-
environmental factors, such as access to medical care and diet, can 
affect the likelihood of a person being hospitalized for asthma. 
 
Reporting rates at the state and/or county level will not be resolved 
geographically enough to be linked with many types of environmental 
data. 
 
When looking at small geographic levels (e.g., ZIP code), users must 
consider appropriate cell suppression rules imposed by the data 
providers or individual state programs. 
 
Although duplicate records and transfers from one hospital to another 
are excluded, the measures are based upon events, not individuals, 
because no unique identifier is always available.  When multiple 
admissions are not identified, the true prevalence will be 
overestimated. 
 
Even at the county level, the measures generated will often be based 
upon numbers too small to report or present without violating state and 
federal privacy guidelines and regulations.  Careful adherence to cell 
suppression rules in cross tabulations is necessary, and methods to 
increase cell sizes by combining data across time (e.g., months, years) 
and geographic areas may be appropriate. 
Data Sources 
Numerator: 
State inpatient hospitalization data (using admission date) 
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Denominator: 
US Census Bureau population data  
Limitations of Data 
Sources 
 
State hospital discharge data: 
The use of a measure of all asthma hospitalizations will include some 
transfers between hospitals for the same person for the same asthma 
event.  Variations in the percentage of transfers or readmissions for the 
same asthma event may vary by geographic area and impact rates.  
However, efforts were made to identify and exclude transfers based on 
unique identifiers consisting of date of birth, zip code, gender, and 
encrypted social security number when available. 
 
Without reciprocal reporting agreements with abutting states, 
statewide measures and measures for geographic areas (e.g., counties) 
bordering other states may be underestimated because of health care 
utilization patterns. 
 
Each state must individually obtain permission to access and, in some 
states, provide payment to obtain the data. 
 
Veterans Affairs, Indian Health Services, and institutionalized (prison) 
populations are excluded. 
 
Practice patterns and payment mechanisms may affect diagnostic 
coding and decisions by health care providers to hospitalize patients 
 
Street address is not available in many states. 
 
Sometimes mailing address of patient is listed as the residence address 
of the patient. 
 
Patients may be exposed to environmental triggers in multiple 
locations, but hospital discharge geographic information is limited to 
residence. 
 
Since the data capture hospital discharges (rather than admissions), 
patients admitted toward the end of the year and discharged the 
following year will be omitted from the current year dataset. 
 
Data will need to be de-duplicated (i.e., remove duplicate records for 
the same event). 
 
There is usually a two-year lag period before data are available from 
the data owner. 
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Census data: 
Available only every 10 years; thus, postcensal data must be estimated 
when rates for years following the census year are calculated. 
 
Postcensal estimates at the ZIP code level are not available from the 
Census Bureau.  These need to be extrapolated or purchased from a 
vendor. 
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Indicator Template 
Content Area: Asthma 
Indicator: Emergency Department Visits for Asthma 
Environmental Public Health Tracking 
 
Type of EPHT 
Indicator 
Health outcome 
Measures 
1. Annual age-adjusted rate of emergency department visits for asthma per 
10,000 population 
2. Annual crude rate of emergency department visits for asthma per 10,000 
population 
3. Annual number of emergency department visits for asthma 
4. Average Number of emergency department visits for asthma as primary 
diagnosis per month 
 
Derivation of 
Measure(s) 
Numerator:  
 Emergency Department Visits during a calendar year with asthma (ICD-
9-CM 493) as the primary diagnosis (includes records for ED Visits 
resulting in a hospitalization) 
 Both inpatient and outpatient records with duplicates removed and 
transfers to other hospitals included 
 
Denominator:  
 Annual population estimates for state and county from U.S. Census 
Bureau 
 
Adjustment:  
 Age-adjustment by the direct method to the Year 2000 US Standard 
population  
 U.S. 2000 standard population by age categories from Surveillance 
Epidemiology and End Results (SEER), National Cancer Institute  
Unit 
1. Age-adjusted rate per 10,000 population 
2. Rate per 10,000 population 
3. Number 
4. Number 
 
Geographic Scope State and national 
Geographic Scale Residents of jurisdiction – State, County  
Time Period 
Hospital admissions between January 1 to December 31, inclusive, for each 
year, 2000– 
Time Scale Daily, monthly, and annually (as appropriate for the measure) 
Rationale 
Asthma continues to be a serious public health problem that affects over 23 
million people including 7 million children in the United States.
 
 In 2008, 
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there were 456,000 hospitalizations and 1.8 million emergency department 
visits (ED) for asthma.
3
 Asthma is the leading chronic health condition 
among children.
4
 There are also large racial, income, and geographic 
disparities in poor asthma outcomes.
5
 Asthma causes lower quality of life, 
preventable undesirable health outcomes, and large direct and indirect 
economic costs.  
 
As a chronic respiratory disease, asthma attacks interfere with everyday 
activities According to NCHS National Health Interview Survey, there were 
10.5 million missed school days among children age 5–17 years and over 
14.5 million missed work days in adult’s age 18 years or over in 2008. In 
2007, there were over 3,400 deaths in which asthma was the underlying 
cause.  
 
Environment Attributable Fractions of the 1988-1994 economic costs for 
asthma were 39.2% for children <6 years of age and 44.4% for 6- to 16-year-
olds, costing more than $400 million for each age group. According to a more 
recent estimation 30% of asthma exacerbations among children were related 
to the environment. This was associated with an annual cost of $2.0 billion. 
Despite the availability of effective prevention measures, asthma associated 
costs are increasing.
 
 
Associations between environmental exposures and asthma have been 
consistently demonstrated.  Many outdoor air pollutants have been associated 
with increased asthma ED visits.  There is strong scientific evidence for 
direct associations between increased ozone concentrations and increases in 
asthma ED visits, in children and adults. In one study, asthma ED visits 
increased by 33 percent when daily 1-hour maximum ozone concentrations 
exceeded 75 ppb. Associations between asthma-related ED visits and ambient 
air particulate matter—both PM10 and PM2.5—have been repeatedly 
confirmed, and are especially robust for children. Other pollutants related to 
higher asthma ED visit totals include carbon monoxide (CO), nitrogen 
dioxide (NO2), and pollution from coal and petrochemical sources.  Other 
outdoor environmental triggers for asthma ED visits in children include weed 
and tree pollen, and ambient temperature. Increased asthma ED visits has also 
been associated with environmental tobacco smoke (ETS). Asthma ED visits 
in children are consistently higher in the fall, co-occurring with the start of 
the school year; increases in asthma ED visits in children have been shown to 
be related to increased respiratory viral infections.
 
The state emergency 
department visit data is electronically maintained and is available in almost 
every state in the U.S.  Data stewards for 18 grantees maintain ED data.   
 
The data has comparable basic information about each visit and can provide a 
better tracking measure of asthma burden than inpatient hospitalization data 
on its own. These measures can be used to evaluate the impact of ambient air 
pollution on respiratory health of children and adults. Also, the measures can 
be used for better resource management to further reduce the asthma related 
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expenditures.  Combined with inpatient asthma data, emergency department 
data will provide more complete spatial and temporal trends for asthma.  
 
Additionally, emergency department visits are believed to be largely 
preventable if managed properly through the use of Asthma Action Plans and 
avoiding environmental triggers.  This offers an outcome that may be a more 
measurable indicator of environmental events and of public health 
intervention 
 
Use of the 
Measure 
The development of a single analytic method for asthma emergency 
department visits among persons living in state will inform multiple users: 
 
State: 
 May be linked with other risk factors such as air pollution to identify 
susceptible populations and explore ecologic relationships  
 Allows for a better understanding of what the asthma surveillance data 
represents when interpreting number of inpatient hospitalizations  
 Permits the monitoring of trends temporally and spatially 
 
National: 
 It will allow for comparison across states which can be used to target 
interventions (especially for CDC and EPA). 
 
Public: 
 Public and concerned community members will be able to view the 
Tracking Network webpage and learn the annual rate of asthma 
emergency department visits and burden of asthma is high in their 
community from.  
Limitations of the 
Measure 
 Numbers may be too small in rural areas to calculate stable rates. 
 These measures do not account for other causes (triggers) of asthma or 
other reasons for visiting the ED. 
 The timing of the exposure may not correspond with the timing of the 
asthma exacerbation leading to the ED visit. 
 Individuals may have asthma exacerbations due to exposure to an 
environmental risk factor that does not result in an ED visit and thus are 
not captured in this measure. 
 Cannot combine counts from asthma ED visit measure with counts from 
asthma hospitalization measure because records for ED patients who are 
subsequently hospitalized are already counted as hospitalizations (i.e., 
would result in double-counting of events). 
 
 Differences in rates by time or area may reflect differences or changes in 
diagnostic techniques and criteria and in the coding of asthma. 
 Reporting rates at the state and/or county level will not show the true 
asthma burden at a more local level (i.e. neighborhood). 
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 Differences in rates by area may be due to different socio-demographic 
characteristics and associated behaviors. 
 When comparing rates across geographic areas, a variety on non-
environmental factors, such as access to medical care and diet, can 
impact the likelihood of persons hospitalized for asthma. 
 Reporting rates at the state and/or county level will not be geographically 
resolved enough to be linked with many types of environmental data. 
 When looking at small geographic levels (e.g. ZIP code), users must take 
into consideration appropriate cell suppression rules imposed by the data 
providers or individual state programs. 
 Although duplicate records and transfers from one hospital to another are 
excluded, the measures are based upon events, not individuals, because 
no unique identifier is always available.  When multiple admissions are 
not identified, the true prevalence will be overestimated.  
 Even at the county level it can be expected that the measures generated 
will often be based upon numbers too small to report or present without 
violating state and federal privacy guidelines and regulations.  Careful 
adherence to cell suppression rules in cross tabulations is necessary and 
methods to increase cell sizes by combining data across time (e.g., 
months, years) and geographic areas may be appropriate. 
Data Sources 
Numerator: State inpatient emergency department data  
Denominator: US Census Bureau population data  
Limitations of 
Data Sources 
 
State emergency department  data: 
 State emergency department data  
 Need to obtain permission to use; not publicly available 
 ED visits for asthma are only one piece of a larger picture that 
describes asthma burden.  
 Veteran’s Administration, Indian Health Service and institutionalized 
(e.g. prison) populations are excluded 
 In-state residents who visit in surrounding states would not be 
included unless states have emergency department data sharing 
agreements. 
 Practice patterns and payment mechanisms may affect diagnostic 
coding and decisions by health care providers. 
 Do not have a zip code for all patients. 
 Sometimes mailing address of patient  (e.g., P.O. Box) is listed as the 
residence address of the patient 
 Patients may be exposed to environmental triggers in multiple 
locations, but ED geographic information is limited to residence. 
 Data will need to be de-duplicated using a standardized method. 
 
Census data: 
 Only available every 10 years, thus postcensal estimates are needed 
when calculating rates for years following the census year. 
 Postcensal estimates at the ZIP code level are not available from the 
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Census Bureau.  These need to be extrapolated or purchased from a 
vendor. 
 
Related 
Indicators 
 Hospitalizations for Asthma 
 Asthma Prevalence among Adults and Children 
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CONTENT DOMAIN: BIRTH DEFECTS 
INDICATOR: PREVALENCE OF BIRTH DEFECTS 
 
Type of EPHT Indicator Health Outcome 
Measure Five year prevalence rates of 12 birth defects per 10,000 live births.  
 
1. Anencephaly 
2. Spina bifida (without anencephaly) 
3. Hypoplastic left heart syndrome 
4. Tetralogy of Fallot 
5. Transposition of the great arteries (vessels) 
6. Cleft lip with or without cleft palate 
7. Cleft palate without cleft lip 
8. Hypospadias (male births only) 
9. Gastroschisis 
10. Upper limb deficiencies 
11. Lower limb deficiencies 
12. Trisomy 21 
o Among mothers <35 years of age at delivery 
o Among mothers ≥35 years of age at delivery 
 
Five year prevalence rates at the state level are reported stratified by 
maternal age at delivery, maternal ethnicity/race, and infant sex.  Five 
year prevalence rates at the county level are reported stratified by one 
demographic variable at a time: maternal age at delivery, maternal 
ethnicity/race, or infant sex. 
Derivation of Measure(s) Denominator is composed of all live-born infants in geographic region 
of interest during a calendar year. 
 
Numerator is composed of all live-born infants, fetal deaths (where 
available), and terminations (where available) with birth defect ‘X’ in 
the geographic region of interest during a calendar year.  
 
For states that ascertain fetal deaths and/or terminations, two sets of 
birth prevalence estimates are to be calculated for each birth defect— 
one including and one excluding fetal deaths and/or terminations. 
 
Diagnosis of cases may be made up to one year of age—ascertainment 
may be at any time. 
Unit Defect present at birth 
Geographic Scope State and National (tracking network states) 
Geographic Scale State, county 
Time Period 1998-current 
Time Scale Five year 
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Rationale Birth defects pose a significant public health problem. One in 33 
babies is born with a structural birth defect in the United States. Birth 
defects are a leading cause of infant mortality; they are also 
responsible for considerable morbidity and disability with enormous 
economic and social costs. A lifetime of medical care and special 
education for a single child can cost more than $500,000.  
Approximately 60% of birth defects are of unknown etiology. The 
ambient environment remains a source of great public concern, but 
few environmental exposures have been well-studied. Most birth 
defects likely will be explained by a complex interaction between 
genetic predispositions and environmental factors. However, before 
the ability to conduct studies to explore these interactions is achieved, 
linking birth defects–outcome data with environmental hazard or 
exposure data is critical. The first step in effecting successful linkages 
of these data is the existence of high-quality birth defects prevalence 
data for which the geospatial and temporal patterns and distributions 
can be monitored. The environmental public health tracking (EPHT) 
initiative is well-positioned to bring together birth prevalence data 
from its state partners to begin analyses of these patterns, which will 
provide important clues to public health officials and researchers.  
Use of the Measure 
 
The basic procedure for calculating birth prevalence is the same for all 
the suggested birth defects. Once the input data are appropriately 
prepared, birth prevalence will be calculable for all defects at the same 
time. 
 
State 
Allow for consistent and rapid method for calculating and displaying 
(using GIS) prevalence at selected geographical areas (i.e., county 
level).   
 
Allow for a better understanding of spatial and temporal patterns of 
selected birth defects.  
 
National 
Allow for comparison of birth prevalence across states, which can be 
used to target interventions.  Any comparison of birth prevalence, 
however, will need to account for the variability in data collection 
methods between state surveillance systems. (See “Limitations of Data 
Sources” below and introductory text in appended team 
recommendations). 
 
Local 
Concerned community members will be able to view the tracking 
network Web page to see the birth prevalence of selected birth defects 
(while protecting confidentiality) at specified geographical areas. A 
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public health message will help interpret the results and provide more 
information on selected birth defects and prevention measures (i.e., 
folic acid for prevention of neural tube defects, smoking and clefts, 
alcohol and fetal alcohol syndrome, and known teratogenic 
medications).  A link to a list of known teratogens can be provided to 
users. 
Limitations of the Measure Ideally, incidence rates would be used instead of birth prevalence to 
measure birth defects occurrence. The numerator of the incidence 
would be the number of new cases of birth defect A in an area and 
time period and the denominator would be the number of conceptions 
at risk for developing birth defect A in that area and time period. 
Because both the number of conceptions and the number of cases 
“lost” through spontaneous abortions (as well as terminations and later 
fetal losses depending on the source of ascertainment for the specific 
surveillance system) is unknown, incidence cannot be calculated. Birth 
prevalence is the only appropriate measure that can be reported for 
birth defects occurrence.  
 
It is not feasible, at this time, to recommend that individual-level birth 
defects surveillance data be made available on even a secure national 
portal.  Most states have strict guidelines with respect to 
confidentiality, and even the publication of birth prevalence data based 
on <5 cases in a geographic region is generally not done.  
Data Sources State birth defects surveillance systems:  The data sources that 
contribute to birth defects surveillance systems include the following 
(this varies by system type): 
 Vital records 
 Hospital records (discharge summaries or disease indices, nursery 
logs, NICU logs) 
 Administrative databases (Medicaid, state hospital discharge, 
HMO) 
 Specialty data sources (specialty clinics, programs for children 
with special health care needs) 
 Prenatal diagnostic centers or genetics clinics 
 Clinical examination 
 Local or national laboratories for cytogenetic testing 
 
Denominator data will come from state vital records—number of live 
births, by year, by maternal age, and by race/ethnicity. These data may 
be aggregated and provided to the birth defects surveillance system for 
calculating birth prevalence, or it may be made available on an 
individual level to the birth defects surveillance system.  This varies by 
state.  
Limitations of Data 
Sources 
 
All states in the US do not have a birth defects surveillance program.  
Among those that do, there is significant variability between 
surveillance systems.  These include: 
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 Ascertainment method (active, passive, passive with follow-
up/verification) 
o Primary differences are with data sources, coding, 
availability of verbatim description, and case verification 
 Ascertainment of spontaneous fetal deaths and variability in 
gestational age for inclusion. 
 Ascertainment of prenatally diagnosed cases and elective 
terminations 
 Case definitions 
 Classification as isolated, multiple, or syndromic 
 
Data for specific birth defects may not be collected by each state or 
may only have been collected recently, limiting historical data for that 
birth defect.  
 
Address data tend to be based on address at delivery, not conception 
(more relevant time period for birth defects-related exposure). 
 
Approximately 50% of birth defects surveillance systems do not 
geocode their address data. 
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CONTENT DOMAIN: CANCER 
INDICATOR: INCIDENCE OF SELECTED CANCERS 
 
Type of EPHT Indicator Health Outcome 
Measure 1. Annual number of cases for selected cancers, by state 
2. Annual age-adjusted incidence rate for selected cancers per 
100,000 population or per 1,000,000 for childhood cancers (<15 & 
<20 years of age), by state 
3. Average annual number of cases for selected cancers over five 
year period, by county 
4. Age-adjusted incidence rate for selected cancers per 100,000 
population over a five year period, by county 
 
 Measures for each of the selected cancer types are provided by sex 
and race/ethnicity groups. Some measures are also provided by age 
group as defined below. 
Derivation of Measure(s) Numerator is composed of counts of unique invasive primary incident 
cases of cancer “x” (bladder cancer also includes in situ) diagnosed 
during a specified calendar year or five year period within residents 
of a specified geographic region.  Incident cancer data were originally 
collected by state and regional cancer registries.  It is proposed that 
data for the National EPHT Network be obtained from the NCI and 
CDC joint venture, State Cancer Profiles. 
 
Denominator is composed of counts of the population residing in the 
geographic region of interest during a specified calendar year or five 
year period.  Population data were originally collected by the U.S. 
Census.  For these national cancer indicators, population data is 
obtained from the NCI and CDC’s State Cancer Profiles, which use 
U.S. Census data as modified by SEER. 
 
Rates will be age-adjusted to year 2000 U.S. standard population.   
 
Cancer types: 
 
Mesothelioma: SEER Recode B 36010. ICD-O-3 codes: histologies 
9050-9055. Malignant cases: ICD behavior code ‘3’. 
 
Melanoma of the skin*: SEER Recode B 25010. ICD-O-3 codes: 
primary site C440-C449, histologies 8720-8790. Invasive melanoma 
(behavior code ‘3’). 
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Liver & Intrahepatic Bile Duct: SEER Recode B 21071, 21072. 
ICD-O-3 codes: primary sites C220, C221; excludes histologies: 
9590-9989, 9050-9055, and 9140. Malignant cases: ICD behavior 
code ‘3’. 
 
Kidney & Renal Pelvis: SEER Recode B 29021, 29022. ICD-O-3 
codes: C649, C659; excludes histologies: 9050-9055, 9140, 9590-
9989. Malignant cases: ICD behavior code ‘3’. 
 
Oral Cavity & Pharynx: SEER Recode B Site Groups 20010-20100 
(20010, 20020, 20030, 20040, 20050, 20060, 20070, 20080, 20090, 
20100). ICD-O-3 site codes: C000-C009, C019-C069, C079-C119, 
C129-C140, C142-C148; excludes histologies 9050-9055, 9140, 
9590-9989. 
 
Esophageal: SEER Recode B 21010. ICD-O-3 site codes: C150-
C159; excluding histologies 9050-9055, 9140, 9590-9989.  
 
Pancreas: SEER Recode B 21100. ICD-O-3 codes: C250-C259; 
excluding histologies 9050:9055, 9140, 9590:9989.  
 
Larynx: SEER Recode B 22020. ICD-O-3 codes: C320-C329; 
excluding histologies 9050:9055, 9140, 9590:9989. 
 
Lung & Bronchus: SEER Recode B 22030. ICD-O-3 Site codes 
C340-C349; excludes histologies 9050-9055, 9140, 9590-9989. 
 
Breast** (female): SEER Recode B 26001. ICD-O-3 Site codes 
C500-C509; excludes histologies 9050-9055, 9140, 9590-9989. 
 
Bladder: SEER Recode B 29010. ICD-O-3 Site codes C670-C679; 
excludes histologies 9050-9055, 9140, 9590-9989. [includes invasive 
and in-situ] 
 
Brain & ONS***: SEER Recode B 31010, 31040. ICD-O-3 Site 
codes C700-C709, C710-C719, C720-C729; excludes histologies 
9050-9055, 9140, 9590-9989. 
 
Thyroid: SEER Recode B 32010. ICD-O-3 Site codes C739; 
excludes histologies 9050-9055, 9140, 9590-9989. 
 
Non-Hodgkin Lymphoma: SEER Recode B 33041, 33042. ICD-O-3 
codes: histology 9590-9596, 9670-9671, 9673, 9675, 9678-9680, 
9684, 9687, 9689-9691, 9695, 9698-9702,9705,9708-9709, 9714-
9719, 9727-9729; histology 9823 or 9827 in all sites except C420, 
C421, C424. 
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Leukemia: SEER Recode B 35011, 35012, 35013, 35021, 35022, 
35023, 35031, 35041, 35043. ICD-O-3 codes: ALL – histology 
9826,9835-9837; Other lymphocytic – histology 9820, 9832-9834, 
9940; Acute monocytic – histology 9891; CML – histology 9863, 
9875, 9876, 9945, 9946; Other – histology 9860, 9930, 9801, 9805, 
9931, 9733, 9742, 9800, 9831, 9870, 9948, 9963, 9964. Site codes 
C420, C421, C424 – histology 9827. (Also include codes for CLL 
and AML.) 
 
Chronic Lymphocytic Leukemia (CLL): SEER Recode B 35012. 
ICD-O-3 codes: C420, C421, C424 with histology 9823. 
 
Acute Myeloid Leukemia (AML): SEER Recode B 35021. ICD-O-3 
codes: histology 9840, 9861, 9866, 9867, 9871-9874, 9895-9897, 
9910, 9920. 
 
Child cancers: SEER ICCC3 childhood cancer codes 
http://seer.cancer.gov/iccc/iccc3.html  
 
NOTE: SEER Recode B (Dec 2003) 
http://seer.cancer.gov/siterecode_b/icdo3_d12192003/  
Tobacco-related cancers: consistent with SEER Recode B, CWG Cancer Team 
NCDM specifies Histology Exclusions 9050-9055 (Mesothelioma), 9140 (Kaposi 
Sarcoma), 9590-9989 (Lymphoma, Leukemia, Miscellaneous).  
* Grantee portals may choose to additionally display In-situ cases, both 
disaggregated and aggregated with invasive cases (“All combined”). 
** Breast – Malignant/invasive only: The NEPHTN Metadata state “Counts and 
rates for in situ breast cancer cases among women are presented; these are reported 
separately and are not included in counts or rates for the "All Sites" category.” 
(CDC-EHTB plans to delete this sentence from national portal Metadata.) The 
NCDM states “Numerator is composed of counts of unique invasive primary 
incident cases of cancer …” (in “Derivation of Measure”). Grantee portals may 
choose to additionally display In-situ cases, both disaggregated and aggregated with 
invasive cases (“All combined”).  
*** Brain/ONS – Malignant/invasive only: The NEPHTN Metadata state 
“Incidence data on nonmalignant primary brain and central nervous system (CNS) 
tumors are available on this Web site.” (CDC-EHTB plans to delete this sentence 
from national portal Metadata.) The NCDM states “Numerator is composed of 
counts of unique invasive primary incident cases of cancer …” (in “Derivation of 
Measure”). 
 
Unit Newly reported cancer case 
Geographic Scope State and national (tracking network states) 
Geographic Scale State and county.   
Time Period 2000-current 
Time Scale Annual and 5 year period 
Rationale Approximately 1.4 million Americans are expected to be diagnosed 
with cancer during 2007.  The National Cancer Institute (NCI) 
estimated that in January 2003, there were approximately 10.3 million 
living Americans with a history of cancer.  The risk of being 
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diagnosed with cancer increases as a person ages, and 77 % of all 
cancers are diagnosed in Americans age 55 years or older.  Cancer, a 
diverse group of diseases characterized by the uncontrolled growth 
and spread of abnormal cells, is believed to be caused by both 
external and internal risk factors.  
 
Major risk factors for cancer include tobacco use, diet, exercise, and 
sun exposure (Clapp, Howe, Jacobs).  For example, male smokers are 
about 23 times more likely to develop lung cancer than male non-
smokers.  Researchers have also identified genetic risks for cancer. 
Female first degree relatives (mother, sisters, and daughters) of 
women with breast cancer are about twice as likely to develop breast 
cancer as women who do not have a family history of breast cancer 
(Cancer Facts and Figures, 2007; ACS, 2007). 
 
However, the etiology of many cancer types is not well established.  
The physical environment (e.g., air quality, chemical pollution, and 
water quality) remains a source of great public concern but few 
community-level environmental exposures have been well-studied.  
Studies of occupational cohorts have identified numerous suggestive 
epidemiological associations between certain occupational exposures 
and elevated cancer rates.  After reviewing the evidence regarding the 
causes of cancer in the United States, Doll and Peto published a 
seminal article in 1981 estimating that 35% of all U.S. cancer deaths 
were attributable to diet, 30%  to smoking, 4% to occupation, and 2% 
to pollution. While some authors have agreed with Doll and Peto 
(Ames and Gold 1998), and others have cautioned against their 
approach: “there is substantial evidence that occupational and 
environmental exposures contribute to the burden of cancer” (Clapp, 
Howe, and Jacobs 2006).   
 
One way to assess cancer burden is to study geographic variation.  In 
recent years, geographic information systems (GIS) have become an 
important tool for health and environmental research.  GIS can extend 
the analysis of data beyond simple mapping by enabling the linkage, 
visualization, and analysis of multiple layers of health and 
environmental data from both spatial and temporal perspectives.   
 
One important use of geographic analysis of health data is in the 
analysis of regional variations in cancer mortality and incidence.  The 
National Cancer Institute’s Atlas of Cancer Mortality for U.S. 
Counties: 1950–1969 (Mason et al. 1975), represented the first effort 
to map cancer mortality data at the county level throughout the 
United States.  In 1999, the national level analysis of cancer mortality 
was updated by the NCI (Atlas of Cancer Mortality in the United 
States, 1950–94, Devesa et al. 1999).  More recently, multiple Web-
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based data query systems have made U.S. cancer incidence and 
mortality datasets and or maps available at the county (NCI/CDC 
State Cancer Profiles:  http://statecancerprofiles.cancer.gov/;  NCI 
SEER data: http://seer.cancer.gov/data/; NJ DHSS cancer online: 
http://www.cancer-rates.info/nj/ ) and/or state level (NAACCR 
CINA+ Online: http://www.cancer-rates.info/naaccr/ ;  CDC U.S. 
Cancer Statistics: http://apps.nccd.cdc.gov/uscs/ ).  
Use of the Measure 
 
At the local and state levels, the EPHT Network will: 
Allow interested persons to obtain information on environmental 
exposures (air pollution and drinking water quality) and cancer or 
other health outcomes (birth defects, asthma, and birth weight) for a 
selected geographic area and time interval.  Standard suppression 
rules will be used to prevent the release of information that might 
reveal the identity of any person diagnosed with cancer.  Public 
health messages will help interpret the results and provide linkages to 
additional information on cancer prevention, cancer etiology, and 
cancer treatment options.  While many of these diverse health and 
environmental datasets are already available to the public, they are 
not currently available through “one-stop-shopping” via the Internet.  
 
Improve access to metadata regarding multiple health outcome 
datasets and environmental exposure datasets for public health 
practitioners and researchers.  Enhanced access will provide better 
understanding of the strengths and limitations of the available 
datasets and may increase the use of the collected data.   
 
Allow for a better understanding of spatial and temporal patterns of 
selected cancers suggested to be linked to environmental exposures 
within states. 
 
At the national level, the EPHT Network will: 
Enhance the opportunity for multi-state epidemiological research by 
improving access to cancer incidence rates and environmental 
exposure information.  This could be particularly helpful for 
uncommon cancer types or sub-types whereby incidence is too small 
for meaningful ecological studies in individual states.    
Limitations of the Measure Counts and rates will be calculated based upon residential address at 
time of diagnosis.  No information is available on prior residences. 
 
Geocoding accuracy, level of geocoding, and geocoding 
completeness may vary by time and space.  This could potentially 
create geographically non-random errors in calculated rates of cancer.  
 
No personal exposure information will be available, including 
smoking history, diet, lifestyle, or history of cancer. 
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Data that will reveal the identity of any individual diagnosed with 
cancer can not be released.  Suppression rules will govern the release 
of small case counts. 
 
No information will be available on the latency of cancer cases. 
Data Sources National Cancer Institute, Surveillance Epidemiology and End 
Results; CDC National Program of Cancer Registries  
Strengths and Limitations 
of Data Sources 
 
All of the 16 states and the 1 city participating in the EPHT Network 
are working with their state and/or regional cancer registry 
program(s).  Registry training, data collection, data coding, data 
cleaning, and quality control programs are highly standardized and 
subject to annual evaluation.  Documentation is available online from 
the North American Association of Centralized Cancer Registries 
(NAACCR). 
(http://www.naaccr.org/index.asp?Col_SectionKey=7&Col_ContentI
D=135). 
 
State cancer registry programs may vary, however, regarding the 
availability and quality of residential address information collected 
and completeness of geocoding efforts. 
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CONTENT DOMAIN: CARBON MONOXIDE 
INDICATOR: HOSPITALIZATIONS FOR CARBON MONOXIDE 
POISONING 
 
Type of EPHT Indicator Health Outcome/Exposure 
Measures  
1. Number of hospitalizations for carbon monoxide (CO) poisoning 
2. Crude rate of hospitalization for CO poisoning per 100,000 
population 
3. Age-adjusted rate of hospitalization for CO poisoning per 100,000 
population 
Derivation of measure 
Numerator: 
Resident hospitalizations for CO poisoning that meet the 1998 CSTE 
case definition for public health surveillance for a “Confirmed” or 
“Probable” case of acute CO poisoning in administrative data sets.  
Frequencies for three unique groups:  
1. Unintentional, non-fire related  
2. Unintentional, fire-related  
3. Unknown intent 
 
Denominator: Midyear resident population 
 
Adjustment: Age-adjustment by the direct method to year 2000 US 
Standard Population 
Unit Hospital admission (categorized by discharge diagnosis) 
Geographic Scope  State and national (tracking network states) 
Geographic Scale State; county when feasible 
Time Period  2000-current 
Time Scale Calendar year 
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Rationale 
Carbon monoxide (CO) is an odorless, colorless gas that usually remains 
undetectable until exposure results in injury or death. Each year in the 
United States, an estimated 10,000 persons seek medical attention or 
lose at least one day of normal activity because of CO intoxication. 
There is limited information on CO hospitalization. In Florida, 1,494 
were hospitalized with a diagnosis of CO poisoning from 1999–2007. 
Out of which 10% (n=143) were unintentional fire-related, 33% (n=493) 
were unintentional non-fire-related, and 17% (n=256) were from 
unknown cause of CO poisoning. During 2000–2009, a total of 68,316 
CO exposures were reported to poison centers across United States. 
          Persons hospitalized with CO poisoning are among the most 
severely poisoned cases. Unintentional CO poisoning is almost entirely 
preventable. These data are available in most states. 
Use of the Measure  
These data can be used to assess the burden of severe CO poisoning, 
monitor trends over time, identify high-risk groups, and enhance 
prevention, education, and evaluation efforts.  
Limitations of the 
Measure  
Hospitalization data, by definition, do not include:  persons treated in 
outpatient settings (e.g., emergency departments, urgent care clinics, 
clinicians’ offices or hyperbaric chambers but not hospitalized); persons 
who call poison control centers and are managed at the scene, and/or 
receive medical care but are not hospitalized; persons who do not seek 
any medical care; or persons who die immediately from CO exposure 
without medical care.  
Data Sources  
Numerator: 
State inpatient hospital discharge data 
Denominator: 
U.S. Census Bureau population data  
Limitations of the Data 
Source  
The use and quality of ICD9-CM coding varies across jurisdictions; this 
is especially true of the codes used to describe how an injury occurs, 
indicated as E-codes. Examples of this variation include:  
 The number of diagnostic fields available to specify cause of the 
injury;  
 Whether  E-codes are mandated;  
 The completeness and quality of E-coding; for example, the 
reliability of ICD-9-CM coding to distinguish between cases of 
CO poisoning that are intentional or unintentional, and/or fire-or  
non-fire related 
The toxic effects of CO exposure are nonspecific and easily 
misdiagnosed when CO exposure is not suspected. These misdiagnosed 
cases will not be counted.  
These data usually do not include data from federal facilities such as 
Veteran's Administration hospitals.  
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These data usually include only cases of state residents treated within 
the state. Health-care access is not restricted to these political 
boundaries so patients hospitalized for CO poisoning in another state 
may not be counted in their own state.  Likewise, they may not be 
counted in the jurisdiction in which they were treated. Currently, few 
states have access to, or agreements to obtain, hospital discharge data 
from other states where their state residents may be hospitalized. To the 
extent that patients are treated out of state, there is undercounting of the 
rate of state residents poisoned by CO. 
 
Differences in rates between jurisdictions may reflect differences in 
hospital admissions practices for treating persons with severe CO 
poisoning.  For example, some facilities may routinely admit all 
patients treated with hyperbaric oxygen; other facilities may release 
patients treated with hyperbaric oxygen after the treatment is completed 
if they are in stable condition. 
 
Race and ethnicity are important risk factors for CO poisoning, yet, 
many hospitalization data sets do not contain these data. Those that do 
may have data quality issues.  
 
Census data: 
 Only available every 10 years, thus postcensal estimates are needed 
when calculating rates for years following the census year. 
 Postcensal estimates at the ZIP code level are not available from the 
Census Bureau.  These need to be extrapolated or purchased from a 
vendor. 
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CONTENT DOMAIN: CARBON MONOXIDE 
INDICATOR: EMERGENCY DEPARTMENT VISITS FOR CARBON 
MONOXIDE POISONING 
 
Type of EPHT Indicator Health Outcome 
Measures  
1. Number of emergency department (ED)  visits for CO poisoning  
2. Crude rate of ED visits for CO poisoning per 100,000 population 
3. Age-adjusted rate of  ED visits for CO poisoning per 100,000 
population 
Derivation of measure 
Numerator: 
Resident emergency department visits for CO poisoning that meet the 
1998 CSTE case definition for public health surveillance for a 
“Confirmed” or “Probable” case of acute CO poisoning in 
administrative data sets.  
Frequencies for three unique groups:  
1. Unintentional, non-fire related  
2. Unintentional, fire-related  
3. Unknown intent 
 
Denominator: Midyear resident population 
Adjustment: Age-adjustment by the direct method to year 2000 US 
Standard Population 
Unit Emergency department visit 
Geographic Scope  State and national (tracking network states) 
Geographic Scale State 
Time Period  2000-current 
Time Scale Calendar year 
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Rationale 
Carbon Monoxide (CO) poisoning is preventable; nonetheless, 
unintentional, non-fire-related CO poisoning is responsible for 
approximately 15,000 emergency department visits and nearly 500 
deaths annually in the United States. During 2004–2006, an estimated 
average of 20,636 ED visits for nonfatal, unintentional, non-fire-
related CO exposures occurred each year. Approximately 73% of these 
exposures occurred in homes, and 41% occurred during winter months 
(December–February). Prevention efforts targeting residential and 
seasonal CO exposures can substantially reduce CO-related morbidity. 
During 2000–2009, a total of 68,316 CO exposures were reported to 
poison centers across United States. 
 
Persons admitted to emergency departments and diagnosed with CO 
poisoning range from suspected exposure to severe poisonings that 
may result in treatment and release, hospitalization, or death. 
Emergency department visits represent patients not counted in other 
clinical settings. Unintentional CO poisoning is usually preventable. 
Emergency department data are available in more than 50% of the 
states and that number is increasing. 
Use of the Measure  
These data can be used to assess the burden of CO poisoning and to 
monitor trends over time as well as to identify high risk groups, and 
enhance prevention, education, and evaluation efforts. 
Limitations of the Measure  
Measures based on emergency department data alone may 
underestimate its prevalence because these data may not include 
persons that are managed at the scene, persons who do not seek any 
medical care, persons admitted without first visiting an emergency 
department, or persons who die immediately from CO exposure 
without medical care. 
Data sources 
Numerator: 
State emergency department visit data 
 
Denominator: 
U.S. Census Bureau population data 
Limitations of the Data 
Source  
 Emergency department data have limitations for comparisons across 
jurisdictions because the use and quality of ICD-9-CM coding may 
vary across jurisdictions; this is especially true of the codes used to 
describe how an injury occurs, indicated as E-codes. Examples of this 
variation include:  
 The number of diagnostic fields available to specify cause of 
the injury vary from nine to unlimited (in some states reaching  
more than 100);  
 E-codes are mandated in some jurisdiction but not in others;  
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 The completeness and quality of E-coding vary by hospital as 
well as jurisdiction. In addition, the reliability of ICD-9-CM 
coding to distinguish between cases that are intentional or 
unintentional, fire-related, or of unknown intent is 
undocumented;  
 States are inconsistent in the use of intent codes. 
 
The toxic effects of CO exposure are nonspecific and easily 
misdiagnosed when CO exposure is not suspected. These 
misdiagnosed cases will not be counted.  
 
These data usually do not include data from federal facilities such as 
Veteran's Administration hospitals.  
 
These data usually include only cases of state residents who were 
treated within the state. Health care access is not restricted to these 
political boundaries so people discharged from the emergency 
department for CO poisoning in another state will neither be counted 
in their own state nor in the jurisdiction in which they were treated. 
Currently, few states have access to, or agreements to obtain, their 
emergency department data from other states in which their residents 
may have received treatment. To the extent that patients are treated 
out of state, there is undercounting of the rate of residents poisoned 
by CO.   
 
Regional variation between emergency departments in diagnosing CO 
poisoning may exist.  
 
Many emergency department visit data sets do not contain race or 
ethnicity information and those that do may have data quality issues. 
Yet, these characteristics are known risk factors for CO poisoning. 
 
Census data: 
 Only available every 10 years, thus postcensal estimates are 
needed when calculating rates for years following the census year. 
 Postcensal estimates at the ZIP code level are not available from 
the Census Bureau.  These need to be extrapolated or purchased 
from a vendor. 
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CONTENT DOMAIN: CARBON MONOXIDE 
INDICATOR: CARBON MONOXIDE POISONING MORTALITY 
 
Type of EPHT Indicator Health Outcome 
Measures 
1. Number of deaths from CO poisoning  
2. Crude rate of death from CO poisoning per 100,000 population 
3. Age-adjusted rate of death from CO poisoning per 100,000 
population 
Derivation of measure 
Numerator: 
Resident deaths from CO poisoning for three unique groups:  
1. Unintentional, non-fire related  
2. Unintentional, fire-related  
3. Unknown intent 
 
Denominator: Midyear resident population 
 
Adjustment: Rates age-adjusted by the direct method to the Year 
2000 U.S. Standard Population 
 
Unit Deaths due to CO poisoning 
Geographic Scope  State and National 
Geographic Scale State 
Time Period  2000-current 
Time Scale Calendar year 
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Rationale 
CO is an odorless, colorless gas that usually remains undetectable 
until exposure results in injury or death. Carbon monoxide (CO) 
poisoning is a leading cause of unintentional poisoning deaths in the 
United States. CO poisoning is preventable; nonetheless, 
unintentional, non–fire-related CO poisoning is responsible for 
approximately 15,000 emergency department visits and nearly 500 
deaths annually in the United States. During 1999–2004, CO 
poisoning was listed as a contributing cause of death on 16,447 death 
certificates in the United States and 2,631 (16%) were classified as 
both unintentional and non-fire-related deaths. The annual average 
age-adjusted death rate in the U.S. was 1.5 deaths per million 
persons.  The US Consumer Product Safety Commission’s historical 
data indicate that there is a statistically significant increasing trend in 
non-fire CO fatalities from 1999 through 2007. In 2007, 183 
unintentional consumer product–related, non–fire-related CO deaths 
were reported. Out of which heating systems were associated with the 
largest percentage of non-fire CO poisoning fatalities at 38 percent 
(estimated 70 deaths); Engine-Driven Tools-related CO fatalities 
were also associated with 38 percent (69 deaths), and the remaining 
six product categories [Charcoal Grills or Charcoal (7 deaths); 
Ranges, Ovens (7 deaths); Water Heaters (3 deaths); Grills, Camp 
Stoves (3 deaths); Other Products (1 death); and Multiple Products 
(24 deaths)] combined were associated with a total of 25 percent. 
 
Death is the most severe outcome of CO poisoning. Unintentional 
CO poisoning deaths are almost entirely preventable. Most localities 
have access to data on their resident deaths. 
Use of the Measure  
These data can be used to assess the burden of severe CO poisoning, 
monitor trends over time, and enhance prevention, education, and 
evaluation efforts. 
Limitations of the Measure  
This measure understates the burden of CO poisoning because most 
cases do not result in death.  Rates can be misleading (i.e., do not 
reflect risk of occurrence) if a relatively large proportion of deaths 
occur to non-residents poisoned within the jurisdiction (they are 
excluded from the rate calculation). Death investigation laws vary by 
locale. 
Data Sources  
Numerator: 
Death certificate records from vital statistics agency 
 
Denominator: 
Population counts or estimates from the U.S. Bureau of the Census 
 NCDM Recommendations Version 3.0  
Page 80   3/19/2013 
Limitations of the Data 
Source  
Death investigation laws vary by locale. In addition, variations may 
occur between localities in how medical 
examiners/coroners/physicians assign intentionality. Thus an area 
where the ME/coroner/physician is disinclined to attribute a CO 
poisoning to suicide will have a higher unintentional CO poisoning 
death rate than a comparable locale. Finally, CO poisonings that are 
unrecognized by the ME/coroner/physician will be attributed to 
other causes. 
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3. Mott, J.A., et al., National vehicle emissions policies and 
practices and declining US carbon monoxide-related mortality. 
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CONTENT DOMAIN: CARBON MONOXIDE 
INDICATOR: REPORTED EXPOSURE TO CARBON MONOXIDE 
 
Type of Indicator Exposure, Health Outcome 
Measures 1. Number of unintentional CO exposures reported to poison control 
centers by resulting health effect and treatment in a healthcare 
facility 
2. Crude rate of unintentional CO exposures reported to poison 
control centers per 100,000 population by resulting health effect 
and treatment in a healthcare facility 
Derivation of measures Number of reported cases of unintentional carbon monoxide exposure 
stratified by presence of subsequent health effect and consequential 
treatment in a healthcare facility 
Denominator used is Midyear resident population 
Unit Reported exposure to CO  
Geographic Scope  State and national (tracking network states) 
Geographic Scale County 
Time Period  2000- current 
Time scale  Annual 
Rationale  PCCs serve the public and healthcare providers in the management of 
actual or potential exposure to hazardous substances, including CO.  
PCC calls are fielded by certified specialists in poisoning information 
(SPIs), and recorded in a standard electronic format.  Regional PCC 
data are centralized nationally by AAPCC annually.   
PCC calls provide information about CO exposure that may not 
otherwise be captured in hospital discharge data or emergency 
department data.  These include events where CO exposure was 
detected but did not result in symptoms, where symptoms were mild 
and did not require follow-up in a health care facility, and where the 
event resulted in symptoms but the patient refused to seek medical 
treatment. Two state-based evaluations (Connecticut [1] and 
Wisconsin [2]) found minimal overlap between persons using PCCs 
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and persons treated in emergency departments. As such, tracking of 
PCC calls in addition to indicators of mortality, hospitalizations, and 
emergency room visits provides a more complete picture of the 
public health burden of CO exposure.  
Use of the Measure  These data may be used to estimate the population's exposure to CO 
and to monitor trends over time. They may also be used to estimate 
symptomatic CO exposures among exposed persons who may not be 
treated in a health care facility and therefore would not be captured in 
other health outcome datasets.   
Limitations of the Measure  Exposure status should not be considered confirmed.  In some cases, 
ambient air sampling results or the patient’s lab results may be 
reported in the case notes but only when this information is available 
or provided to the SPI. In addition, it should be noted that because 
they may contain identifiable and sensitive information, SPI notes are 
removed from case records by regional PCCs before submitting to the 
AAPCC and are therefore unavailable at the national level.  
Not all potentially hazardous CO exposures will be captured by PCC 
calls. For example, cases of moderately elevated exposure in the 
home are unlikely to be recognized if there are no acute symptoms 
and a CO alarm is not installed. Moreover, knowledge, attitudes, and 
practices around the use of PCCs likely vary both within and across 
jurisdictions. In the event of suspected exposure, callers may first 
notify their local fire department or call 911 or even their utility 
provider; in either case, the regional PCC may not be simultaneously 
notified. Practices by health care providers that use PCCs are also 
likely to vary from one jurisdiction to another. Generally speaking, 
healthcare providers use the PCC as a resource in the diagnosis and 
treatment of poisonings; in addition, in New York City, where CO 
poisoning was designated as an immediately reportable condition in 
2004, the PCC plays an integral role in the management of reports 
from healthcare providers and in the rapid referral of the fire 
department for investigation at the site of exposure for the prevention 
of secondary cases
 
(3).  For these reasons, caution should be 
exercised in comparing rates of reported exposure across states.  
Data Sources  Numerator: 
PCC calls (usually in standard Toxicall database) 
 
Denominator: 
U.S. Census Bureau population data  
Limitations of the Data 
Sources 
SPIs are not required to collect patient state/ZIP code unless the 
patient is the caller. Using caller state/ZIP code to determine 
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residency may cause the number of calls pertaining to state residents 
to be overestimated—for example, when the caller is an out-of-state 
health care provider.  
The number of cases may differ slightly between datasets obtained 
directly from the state’s PCC and the national AAPCC dataset for 
that state; this is typically due to calls that are re-routed to another 
state when the state’s PCC is overloaded.  The AAPCC national 
dataset is corrected for such instances. 
Age adjustment is not recommended since age is often estimated 
(such as "Adult > 19" or “50s”).  
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CONTENT DOMAIN: CARBON MONOXIDE 
INDICATOR: HOME CARBON MONOXIDE DETECTOR 
COVERAGE 
 
Type of Indicator Intervention  
Measure 
Percent of Behavioral Risk Factor Surveillance System (BRFSS) 
respondents reporting at least one CO detector in their household 
Derivation of Measure 
Numerator: 
The number of respondents reporting CO detector in household  
 
Denominator: 
The number of respondents reporting CO detector in household  plus 
respondents reporting no CO detector in household  
 
Proportion is adjusted using the survey’s household weight 
Unit CO detector presence 
Geographic Scope  State and national (tracking network states) 
Geographic Scale State 
Time Period  
2004; States’ BRFSS surveys should include this question every 3–5 
years and/or when implementing interventions, such as new 
legislation, to increase the use of CO alarms  
Time Scale Annual 
Rationale  
Correctly installed and maintained CO detectors can prevent injury 
and death from exposure to CO.  
Use of the Measure  
 
Collected data will determine the occurrence of CO detectors in 
homes. These data also can be combined with other data collected by 
the BRFSS survey, including respondent demographics (e.g., age, sex, 
and race of survey respondents and age and sex composition of 
household), socioeconomic characteristics (e.g., insurance status), and 
relevant health and prevention risk factors (e.g., smoking status, 
presence of fire alarms). The results of these analyses can be used to 
target and evaluate public health prevention strategies.  
 
Notes about conducting the analysis: 
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BRFSS data should be analyzed by experts in analysis of sample 
survey data and the software available to conduct this type of analysis 
(e.g., SUDAAN and SAS survey procedures). 
 
The BRFSS survey is designed so that the primary sampling unit is the 
respondent. As such, BRFSS data are typically directly weighted to 
account for sampling error based on data collected at the individual 
level. However, the question about CO detectors is based on the 
household rather than the individual as the sampling unit. Using the 
weighting designed for individuals may bias the prevalence estimate 
of household risk factors. The indicator will therefore use a weight 
based on the potential error associated with sampling the household 
rather than the individual.  
Limitations of the Measure  
Carbon monoxide alarms must be properly installed and maintained to 
be effective; a single question does not capture information about 
either. Maine has developed two questions that can be asked to get 
supplemental information on maintenance:  
1. Is your carbon monoxide detector battery powered or have a 
battery for back-up power? 
 
Response categories: Yes; No; Don’t Know; Refused 
 
2. When was the last time you checked the batteries? 
 
Response categories (Read only if needed): Within the past 
year; More than a year; Don’t know/Not sure; Refused  
Data Sources  
BRFSS  state-added question from the Indoor Air Pollution Module, 
question number 4:  
 
A carbon monoxide or CO detector checks the level of carbon 
monoxide in your home. It is not a smoke detector. Do you have a 
carbon monoxide detector in your home?  
Limitations of the Data 
Resources  
 
While the data collection methods are standardized to allow 
comparisons between states, there may still be bias introduced by 
“house-effects”—that is, the variation introduced by different 
organizations and individuals implementing the survey for different 
states.  
 
The BRFSS questionnaire is available in English or Spanish language 
versions; persons who are not conversationally fluent in English (or 
Spanish in the states that offer the Spanish-language option) are not 
eligible. This population of non-English speakers may differ 
systematically from English speakers in health and behavior 
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characteristics, including the presence of a CO detector in their homes.  
 
The BRFSS is a telephone survey.  While the effect of telephone non-
coverage on estimates derived from BRFSS is small, the population 
without telephones is not likely representative of the general 
population.  In particular, this population is less likely to have a CO 
detector in the household; therefore, these results should not be 
generalized to populations without telephone coverage.  
 
An increasing number of households use telephone technology that 
may result in changes in the population sampled and therefore may 
make the survey results less reliably generalized and introduce other 
bias. Two examples are:  
1. Households with cellular telephones and no traditional 
telephone. These households are  not in the sampling frame for 
the BRFSS  
2. Households that use Caller ID to screen calls; their members 
may be less likely to pick up the call.  
 
Surveys based on self-reported information are likely less accurate 
than those based on physical measurements. However, when 
measuring change over time, this type of bias is likely to be constant 
and therefore not a factor in trend analysis.  
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CONTENT DOMAIN: CHILDHOOD LEAD POISONING 
INDICATOR: TESTING COVERAGE AND HOUSING AGE 
 
Type of EPHT Indicator Hazard /Intervention 
Measures 1. Number of children born in the same year and tested for lead 
before age 3 
2. Percent of children born in the same year and tested before age 3 
3. Number of homes built before 1950 (as measured in the 2000 
Census) 
4. Percent of homes built before 1950 (as measured in the 2000 
Census) 
Derivation of Measure(s) Use birth year cohort to calculate the percentage of children with at 
least one test prior to age 36 months. 
 
Use 2000 Census, Summary file 3, to calculate the percentage of pre-
1950 housing units 
Unit Proportion of houses by age-based hazard assessment 
Geographic Scope State and national  
Geographic Scale county and state 
Time Period 
 
2000- 
Time Scale 
 
annual; birth cohort 
Rationale Elevated BLLs in young children have been associated with adverse 
health effects ranging from learning impairment and behavioral 
problems to death. Because children may have elevated BLLs and not 
have any specific symptoms, CDC recommends a blood-lead test for 
young children at risk for lead poisoning. Risk factors identified in the 
National Health and Nutrition Examination Surveys (NHANES) 
include living in housing built before 1950, especially deteriorating 
condition, being African American and living in a family in poverty.  
 
Many states have adopted a targeted testing strategy (test children at 
high risk), and some states recommend universal testing (test all 
young children). Nevertheless, studies have documented low blood-
lead testing rates among children at high risk.  CDC recommends that 
state and local childhood lead poisoning prevention programs 
(CLPPPs) evaluate testing among high-risk populations. All CLPPPs 
have assessed testing in their states but many methods have been used 
and it is not possible to compare across states.  
 
CLPPPs also administer education campaigns for physicians and 
parents about childhood lead poisoning to enable them to identify 
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children at risk. 
 
For both universal testing plans and targeted testing plans, children 
should be tested at least once before the age of 3 years. Some states 
require more than one test between the ages of 6 and 36 months. 
Using a birth cohort, the number of children born in a specific year 
tested before the age of 36 months can be determined.  
Use of the Measure 
 
State 
Identify populations that are not being tested adequately and improve 
testing 
 
Allow for a better understanding of what the blood-lead surveillance 
data represent 
 
National 
Allow for comparison across states; such comparison can be used to 
target interventions (especially CDC, EPA, HUD) 
 
Public/parents 
Determine if their community is at risk and the percentage of children 
being tested. There will be a public health message which will help 
interpret the results and provide more information on lead sources and 
prevention. 
 
Health care providers 
Identify children who should be tested for lead by identifying high-
risk communities 
Limitations of the Measure This measure estimates testing rates in children living in communities 
which may be at greater risk of exposure due to older housing. It is a 
surrogate for a child’s risk of lead poisoning due to lead paint in the 
home.  A more direct measure would be based on individual children 
and the actual age of their housing. 
 
Some tested children’s addresses are not in the CLPPP data system, 
while only the provider’s address is provided for other children. This 
can result in some tests being attributed to the wrong county or not 
being counted at all.  
Counties are not homogenous with respect to the distribution of lead 
hazards or risk factors for lead exposure. 
 
Using number of pre-1950s housing from Census does not account for 
houses that have been renovated or have had lead removed. 
 
This measure does not account for other lead sources in the 
community. 
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Children may be exposed to lead paint in neighboring counties 
(visiting family, day care) 
 
Many states require children be tested more than once. This indicator 
does not determine how many children are tested more than once to 
meet such state requirements. 
Data Sources  Childhood Blood Lead Surveillance Data  
 US Census (Summary file 3) for total number of housing units and 
number of pre-1950 units 
 Vital statistics birth data for number of births  
Limitations of Data 
Sources 
 
Childhood Blood Lead Surveillance Data  
 Surveillance data are not randomly sampled or representative 
of the population.  
 Addresses for all children tested are not included. 
 Address of the treating clinic is listed sometimes as the address 
of the child. 
 De-duplication by  a standardized method will be required 
 Race and ethnicity are not always captured. 
 
Census data 
 Data are available only every 10 years. 
 Does not have information on renovation of pre 1950 housing 
is not available.  
 Does not have information on the condition of the housing is 
not available. 
 Address level information on the year the housing was built is 
not available. 
 
Vital Statistics Birth Data 
 Children may move to another county after birth 
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CONTENT DOMAIN: CHILDHOOD LEAD POISONING 
INDICATOR: BLOOD LEAD LEVELS BY BIRTH COHORT 
  
ENVIRONMENTAL PUBLIC HEALTH TRACKING 
 
Type of EPHT Indicator Exposure 
Measure(s) 1. Number of children born in the same year and tested , by county 
and state 
2. Percent of children born in the same year and tested, by county and 
state 
3. Number of children born in the same year and tested with 
confirmed blood lead levels ≥ 10 μg/dL 2, by county and state 
4. Percent of children born in the same year and tested with confirmed 
blood lead levels ≥ 10 μg/dL 2, by county and state 
5. Number of children born in the same year and tested with 
confirmed blood lead levels ≥ 10 μg/dL2, by blood lead level 
category
3
, by state 
6. Percent of children born in the same year and tested with confirmed 
blood lead levels ≥ 10 μg/dL 2, by blood lead level category3, by state 
 
1 The current blood lead reference level is 5 μg/dL based on National 
Health and Nutrition Examination Survey (NHANES) 2007 – 2008 
and 2009 – 2010 data published in the Fourth National Report on 
Human Exposure to Environmental Chemicals, and updated in 2012. 
Blood Lead Levels (BLLs) are confirmed if there is either: (1) one 
elevated venous test or (2) two elevated capillary and/or unknown 
tests at least 1 day but less than 12 weeks apart. 
 
2
Details about selecting the appropriate test to classify a child are in 
the “How-To-Guide for Creating CLP-2 datasets.” 
 
3
 BLL categories (in units of μg/dL) are <10, 10-<15, 15-<20, 20-<25, 
25-<45, 45-<70, and ≥ 70. An additional category for unconfirmed 
single capillary or unknown specimen tests is used to calculate the 
total number of children tested. Data are presented by categories at the 
state level only. 
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Derivation of Measure(s) Create CLP-2 (county level) dataset using the “How-To-Guide for 
Creating CLP-2 datasets.” 
 Select children’s records from childhood lead poisoning 
database.  
 Classify test results.  
 Aggregate by county of residence and birth cohort.  
 Merge with total number of county to obtain the denominator.  
 
 
 
From CLP-2 dataset, calculate the measures: 
 
 
1. Number of children born in the same year and tested, by county and 
state  
 Sum all BLL categories including the unconfirmed  
2. Percent of children born in the same year and tested, by county and 
state  
 Divide number of children tested by the total number of 
children in the birth cohort 
3. Number of children born in the same year and tested with 
confirmed blood lead levels ≥ 10 μg/dL 2, by county and state 
 Sum number of children in BLL categories ≥ 10 μg/dL 
(BLLs10_14,…,BLLs70), excluding unconfirmed  
4. Percent of children born in the same year and tested with confirmed 
blood lead levels ≥ 10 μg/dL 2, by county and state 
 Divide number of children tested with BLLs ≥ 10 μg/dL by the 
total number of children tested and multiply by 100 
5. Number of children born in the same year and tested with 
confirmed blood lead levels ≥ 10 μg/dL2, by blood lead level 
category
3
, by state 
 Sum number of children by BLL categories ≥ 10 μg/dL 
(BLLs10_14,…,BLLs70), excluding unconfirmed  
6. Percent of children born in the same year and tested with confirmed 
blood lead levels ≥ 10 μg/dL2, by blood lead level category3, by state 
 BLL Categories = Divide number of children for each BLL 
category by the total number of children tested and multiply by 
100 
 
 
 
Unit 
 
Number and percent 
Geographic Scope 
 
State or National 
Geographic Scale County or State (measures 1-4 available by county and state; measures 
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 5 and 6 available by state) 
Time Period 
 
2000 (or first available) to current 
Time Scale Annual birth cohort 
 
Rationale 
 
Blood lead levels in young children have been associated with adverse 
health effects ranging from learning impairment and behavioral 
problems to death. No threshold for adverse effects has been 
identified. Because children may have elevated BLLs and not have 
any specific symptoms, CDC recommends blood lead testing for 
young children at risk for lead poisoning. The risk factors identified 
by the National Health and Nutrition Examination Surveys 
(NHANES) include living in housing built before 1950, especially 
housing in deteriorating condition, being African American, and living 
in poverty.  
 
Many states have adopted a targeted testing strategy (i.e., test children 
at high risk), whereas some states recommend universal testing (i.e., 
test all children), either statewide or within high-risk counties and 
cities. For both universal and targeted testing strategies, children 
should be tested at least once before the age of 3 years. Some states 
require more than one test between the ages of 6 and 36 months. In all 
states, a blood lead test is required for Medicaid-eligible children at 12 
and 24 months of age. 
 
CDC updated its recommendations on children’s blood lead levels in 
May 2012. The new recommendation is based on the U.S population 
of children aged 1-5 years who are in the top 2.5% of children tested 
for lead in their blood. This reference value is the 97.5
th
 percentile, 
which is currently 5 μg/dL based on NHANES 2007 – 2008 and 2009 
– 2010 data (CDC, 2012).  The recommendation that chelation therapy 
should be considered for children with BLLs ≥45 μg/dL has not 
changed. BLL results ≥70 μg/dL represent a medical emergency. 
Many states initiate environmental investigations at either BLLs ≥20 
μg/dL or persistent BLL results that are 15-19 μg/dL 
 
This indicator uses a birth cohort approach. Using these measures, it is 
possible to determine how many children born in a specific year were 
tested before the ages of 3 and how many of those tested had an 
elevated BLL. For children with more than one test before the age of 
3, this indicator uses the highest venous specimen result or if there is 
no venous specimen the highest confirmatory capillary/unknown 
result. Using the highest results allows for examination of the peak 
BLLs for the birth cohort. Inclusion of multiple cohorts will allow for 
the evaluation of trends in testing and BLLs greater than the reference 
value. 
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Use of the Measure(s) 
 
 To identify and monitor temporal and spatial changes in BLL 
testing and -BLLs by birth cohort. 
 To better understand BLL surveillance data when interpreting 
number of -BLLs. 
 To compare testing and BLLs within and across states for the 
purpose of targeting interventions. Comparisons should only be 
made between areas with similar testing and reporting rules. 
 To link data on risk factors and compare risk factors within and 
across states. 
 To guide interventions and allocation of resources related to BLL 
testing and prevention of lead exposure in young children.. 
 To develop and support public health policy and legislation related 
to BLL testing and prevention of childhood lead poisoning. 
 To monitor progress towards eliminating BLLs ≥5 μg/dL, the 
current reference value (NHANES 2007 – 2008 and 2009 – 2010 
data). 
 
Limitations of the 
Measure(s) 
 
 The analysis uses the county of the child’s residence at the time of 
the test, which may be different from the county where the child 
was exposed to lead. 
 Counties are not homogenous with respect to the distribution of 
lead hazards or risk factors for lead exposure. 
 Number and percent of BLLs cannot be interpreted as prevalence 
or incidence for the population. 
 State to state comparisons must be made cautiously and require 
additional information about the states’ testing practices, 
confirmatory testing practices, and reporting laws. 
 Because the capillary test is subject to contamination it can result 
in a false positive BLL. The number and percent of BLLs may be 
overestimated when non-venous test results are used. 
Data Sources Childhood Blood Lead Surveillance Data  
Vital Statistics Birth Data  
 
Limitations of Data Sources 
 
Childhood Blood Lead Surveillance Data  
 Surveillance data are not randomly sampled or representative 
of the population.  
 Complete residential addresses are not available for all 
children tested. 
 Sometimes the address of the provider or another address is 
listed as the child’s address when the data is not provided by 
the reporting authority.   
Vital Statistics Birth Data 
 The number of children born from Vital Statistics does not 
include children who have moved in or out of the area since 
birth. Therefore, as a denominator, it may under or over 
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estimate the number of children in a birth cohort.  
  
Presentation Small numbers of children tested, births, or BLLs may exist when the 
measures are calculated at the county levels. These small numbers are 
not accurate estimates for childhood lead poisoning in these polygons.  
In addition, these small numbers will require additional data 
processing steps to preserve confidentiality.  One or more of the 
following methods can be used:   
 Suppression of small numbers, 
 Aggregation of neighboring geographic units. 
 Aggregation to a lower resolved geographic level unit, 
 Aggregation of successive birth cohorts. 
 
Data on blood lead levels are presented by categories at the state level 
only. 
 
This indicator should be displayed with information about the lead 
testing program, including: 
 State and/or local testing policies or strategies (i.e., targeted or 
universal) 
 CDC-funded Childhood Lead Poisoning Prevention Program 
 Minimum BLL reported by laboratories to state or local lead 
program 
 
Related Indicators  Blood Lead Testing and Housing Age 
Annual Blood Lead Levels 
References Centers for Disease Control and Prevention (CDC). 2012. CDC 
Response to Advisory Committee on Childhood Lead Poisoning 
Prevention Recommendations in “Low Level Lead Exposure Harms 
Children: A Renewed Call of Primary Prevention”. 
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CONTENT DOMAIN: CHILDHOOD LEAD POISONING 
INDICATOR: ANNUAL BLOOD LEAD LEVELS  
  
ENVIRONMENTAL PUBLIC HEALTH TRACKING 
 
Type of EPHT Indicator Exposure 
Measure(s) 1. Number of children tested, by age group
1
, by county and state 
2. Percent of children tested, by age group
1
, by county and state 
3. Number of children tested with confirmed blood lead levels ≥ 10 
μg/dL3,4, by age group1,  by county and state 
4. Percent of children tested with confirmed blood lead levels ≥ 10 
μg/dL 3,4, by age group1, by county and state 
5. Number of children tested with confirmed blood lead levels ≥ 10 
μg/dL by blood lead level category2,3,4, by age group1, by state 
6. Percent of children tested with confirmed blood lead levels ≥ 10 
μg/dL, by blood lead level category2,3,4, by age group1, by state  
 
1
Measures are available stratified by two age groups: <36 months and 
36 to <72 months 
 
2 The current blood lead reference level is 5 μg/dL based on National 
Health and Nutrition Examination Survey (NHANES) 2007 – 2008 and 
2009 – 2010 data published in the Fourth National Report on Human 
Exposure to Environmental Chemicals, and updated in 2012. Blood 
Lead Levels (BLLs) ≥ 10 μg/dL are confirmed if there is either: (1) one 
elevated venous test or (2) two elevated capillary and/or unknown tests 
at least 1 day but less than 12 weeks apart.  
 
3 
Details about selecting the appropriate test to classify a child are in the 
“How-To-Guide for Creating CLP-4 datasets.” 
 
4
 BLL categories (in units of μg/dL) are <10, 10-14, 15-19, 20-24, 25-
44, 45-69, and ≥ 70. An additional category for unconfirmed elevated 
capillary or unknown specimen tests is used to calculate the total 
number of children tested. Confirmed BLLs ≥ 10µg/dL and BLLs 5-
9µg/dL, reflecting the NHANES reference value, will be included by 
Spring 2013. Data on confirmed BLLs ≥ 10µg/dL will be presented by 
blood lead categories at the state level only. 
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Derivation of Measure(s) Create CLP-4 (county level) dataset using the “How-To-Guide for 
Creating CLP-4 datasets.” 
 Select children’s records from childhood lead poisoning 
database.  
 Classify test results.  
 Aggregate by county of residence and year  
 Merge with total number of children by county to obtain the 
denominator.  
 
 
From CLP-4 dataset, calculate the measures: 
 
1. Number of children tested  
 Sum all BLL categories including the unconfirmed  
2. Percent of children tested 
 Divide number of children tested by the total number of children  
3. Number of children tested with confirmed blood lead levels ≥ 10 
μg/dL4 
 Sum number of children in BLL categories ≥ 10 μg/dL (BLLs 
10-14,…,BLLs70), excluding unconfirmed  
4. Percent of children tested with confirmed blood lead levels ≥ 10 
μg/dL4  
 Divide number of children tested with blood lead levels ≥ 10 
μg/dL by the total number of children tested and multiply by 100 
5. Number of children tested with confirmed blood lead levels ≥ 10 
μg/dL4 
 Sum number of children for each BLL category  
6. Percent of children tested with confirmed blood lead levels ≥ 10 
μg/dL4  
 Divide number of children for each BLL category by the total 
number of children tested and multiply by 100 
 
Unit 
 
Number and percent 
Geographic Scope 
 
State or National 
Geographic Scale 
 
County or State (measures 1-4 available at county and state; measures 5 
and 6 available only at state) 
Time Period 
 
2000 to current  
Time Scale Annual 
 
Rationale 
 
Blood lead levels in children have been associated with adverse health 
effects ranging from learning impairment and behavioral problems to 
death. Lead can affect almost every organ and system in your body. The 
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effects of lead are the same whether it enters the body through breathing 
or swallowing.  Small children can be exposed by eating lead-based 
paint chips, chewing on objects painted with lead-based paint or 
swallowing house dust or soil that contains lead. Children are more 
vulnerable to lead poisoning than adults. The main target for lead 
toxicity is the nervous system in young children.  A child who swallows 
large amounts of lead may develop blood anemia, severe stomachache, 
muscle weakness, and brain damage.  If a child swallows smaller 
amounts of lead, much less severe effects on blood and brain function 
may occur. Even at much lower levels of exposure, lead can affect a 
child’s mental and physical growth.  
 
Since children may have higher BLLs and not display any specific 
symptoms, CDC recommends blood lead testing for young children at 
risk for lead poisoning. The risk factors identified by the National 
Health and Nutrition Examination Surveys (NHANES) include living in 
housing built before 1950, especially housing in deteriorating condition, 
being African American, and living in poverty.  
 
States have developed and implemented assessment protocols for 
children to determine the need for a blood lead test.  For both universal 
and targeted testing strategies, children should be tested at least once 
before the age of 3 years. Some states require more than one test 
between the ages of 6 and 36 months. Children not tested before the age 
of 3 should be tested at least once before the age of 6. In all states, a 
blood lead test is required for Medicaid-eligible children at 12 and 24 
months.  
 
CDC updated its recommendations on children’s blood lead levels in 
May 2012. The new recommendation is based on the U.S population of 
children aged 1-5 years who are in the top 2.5% of children tested for 
lead in their blood. This reference value is the 97.5
th
 percentile, which is 
currently 5 μg/dL based on NHANES 2007 – 2008 and 2009 – 2010 
data (CDC, 2012). The recommendation that chelation therapy should 
be considered for children with BLLs ≥45 μg/dL has not changed. BLL 
results ≥70 μg/dL represent a medical emergency. Many states initiate 
environmental investigations at either BLLs ≥20 μg/dL or persistent 
BLL results that are 15-19 μg/dL 
 
This indicator provides information on the number of children tested 
each year and the number of those children tested with confirmed blood 
lead levels above 10 μg/dL. This information is used to direct resources 
for testing and management of elevated cases and be linked with 
environmental or the risk factor data to monitor trends over time. 
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Use of the Measure(s) 
 
 To identify and monitor temporal and spatial changes in BLL testing 
and confirmed BLLs ≥ 10µg/dL4 by year. 
 To better understand BLL surveillance data when interpreting 
number of confirmed BLLs ≥ 10µg/dL4. 
 To compare testing and BLLs within and across states for the 
purpose of targeting interventions. Comparisons should only be 
made between areas with similar testing and reporting rules. 
 To link data on risk factors and compare risk factors within and 
across states. 
 To guide interventions and allocation of resources related to BLL 
testing and prevention of EBLLs in children. 
 To develop and support public health policy and legislation related 
to BL testing and prevention of childhood lead exposure. 
 To monitor progress towards eliminating BLLs ≥5 μg/dL, the 
current reference value (NHANES 2007 – 2008 and 2009 – 2010 
data). 
Limitations of the 
Measure(s) 
 
 The analysis uses the county of the child’s residence at the time of 
the test, which may be different from the county where the child was 
exposed to lead. 
 Counties are not homogenous with respect to the distribution of lead 
hazards or risk factors for lead exposure. 
 Number and percent of EBLLs through surveillance data cannot be 
interpreted as prevalence or incidence for the population as a whole 
 State to state comparisons must be made cautiously and require 
additional information about the states’ testing practices, 
confirmatory testing practices, and reporting laws. 
 Because the capillary test is subject to contamination it can result in 
a false positive EBLL. The number and percent of EBLLs would be 
overestimated if unconfirmed, non-venous test results are used. 
Data Sources Childhood Blood Lead Surveillance Data  
Census Population Data: Vintage bridged-race post-censal population 
estimates: http://www.cdc.gov/nchs/nvss/bridged_race.htm 
Limitations of Data Sources 
 
Childhood Blood Lead Surveillance Data  
 Surveillance data are not randomly sampled or representative of 
the population.  
 Complete residential addresses are not available for all children 
tested. 
 If the child’s address is not provided the address of the provider 
may be used. 
Related Indicators  Blood Lead Testing and Housing Age 
Blood Lead Levels by Birth Cohort 
References Centers for Disease Control and Prevention (CDC). 2012. CDC 
Response to Advisory Committee on Childhood Lead Poisoning 
Prevention Recommendations in “Low Level Lead Exposure Harms 
Children: A Renewed Call of Primary Prevention”. 
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INDICATOR TEMPLATE 
CONTENT AREA: CLIMATE AND HEALTH  
INDICATOR: HEAT STRESS HOSPITALIZATIONS 
 
Type of EPHT 
Indicator 
Health outcome 
Measures 1. Age-adjusted rate of hospitalization for heat stress per 100,000 population 
2. Crude rate of hospitalization for heat stress per 100,000 population 
3. Number of hospitalizations for heat stress 
 
Derivation of 
Measure(s) 
Numerator:  
Hospital admissions having any ICD-9 code in the range of 992.0-992.9, or cause of 
injury code E900.0 or E900.9, EXCLUDING cases with a code of E900.1 (man-
made source of heat) anywhere in the record. 
 
Denominator: 
Midyear resident population, by gender, for state and by county 
 
Adjustment:   
Age-adjustment by the direct method to year 2000 US standard population 
Unit 1. Age-adjusted rate per 100,000 population 
2. Rate per 100,000 population 
3. Number 
Geographic Scope State and national 
Geographic Scale Residents of jurisdiction – State  
Time Period Hospital admissions between May 1 to September 30, inclusive, for each year, 
2000– 
Time Scale May–September of each data year 
Rationale The Intergovernmental Panel on Climate Change (IPCC) projects with “virtual 
certainty” suggest that climate change will cause more frequent, more intense, and 
longer heat waves (1). Any individual, regardless of age, sex or health status can 
develop heat stress if engaged in intense physical activity and/or exposed to 
environmental heat (and humidity). Physiologic mechanisms maintain the core body 
temperature (i.e., the operating temperature of vital organs in the head or trunk) in a 
narrow optimum range around 37 °C (98.6 °F).
 
When core body temperature rises, 
the physiologic response is to sweat and circulate blood closer to the skin's surface 
to increase cooling. If heat exposure exceeds the physiologic capacity to cool, and 
core body temperature rises, then a range of heat-related symptoms and conditions 
can develop. Heat stress or Heat-related illness ranges from mild heat edema and 
rash, heat syncope, heat cramps, to the most common type, heat exhaustion (2). 
Heat-related cramps, rash, and edema are relatively minor readily treatable 
conditions; however, they should be used as important warning signs to immediately 
remove the affected individual from the exposure situation.   
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Heat cramps are brief, intermittent, and often severe muscular cramps occurring 
typically in muscles that are fatigued by heavy work (2). Individuals with heat 
cramp can also exhibit hyponatremia, hypochloremia (which are low serum sodium 
and chloride levels).  
 
Heat syncope is a temporary loss of consciousness as a result of prolonged heat 
exposure (2).  Individuals adapt to hot, humid environment by dilation of cutaneous 
vessels in the skin to radiate heat. Peripheral vasodilation along with blood volume 
loss, results in lowering the blood pressure which can result in inadequate central 
venous return and cerebral perfusion, causing light-headedness and fainting. 
 
Heat exhaustion is a consequence of extreme depletion of blood plasma volume, 
which may be coincident with hyponatremia and/or peripheral blood pooling (2).  
Heat exhaustion often does not present with definitive symptoms and may be 
misdiagnosed, often as an acute viral illness.  Symptoms include mild disorientation, 
generalized malaise, weakness, nausea, vomiting, headache, tachycardia (rapid 
beating of the heart), and hypotension.  Because untreated heat exhaustion can 
progress to heat stroke, the most serious form of heat-related illness, treatment 
should begin at the first signs of heat exhaustion (3).   
  
Heat stroke is an extreme medical emergency that if untreated can result in death or 
permanent neurological impairment (2). Heat stroke occurs when a person’s core 
body temperature rises above 40 °C (104 °F) as a result of impaired 
thermoregulation. High core body temperature and disseminated intravascular 
coagulation results in cell damage in vital organs, such as the brain, liver, and 
kidneys, which can lead to serious illness and death (3). Death may occur rapidly 
due to cardiac failure or hypoxia, or it can occur days later as a result of renal failure 
due to dehydration and/or rhabdomyolysis (i.e., the breakdown of muscle fibers with 
release into the circulation of muscle fiber contents, some of which are toxic to the 
kidney and can cause kidney damage) (4). Heat stroke is typically divided into two 
types.  The two types are in general clinically the same, except that the 
individuals/population groups affected require medical interventions specific to their 
unique physiology and medical status (3). “Exertional Heat Stroke,” as the name 
implies, involves strenuous physical activity under high temperature conditions to 
which the heat stroke victim was not acclimatized, and usually affects healthy young 
adults, such as athletes, outdoor laborers and soldiers.  “Classic” heat stroke, by 
definition does not involve exertion, and usually affects susceptible individuals, such 
as infants and young children, the elderly, or people with chronic illness. Because 
heat stroke, even if treated, can have a death rate as high as 33%, and up to 17% of 
heat stroke survivors suffer permanent damage, measures should be taken to prevent 
heat-related illness, especially among vulnerable populations.   
 
The relationship between extreme heat and increased daily morbidity and mortality 
is well established. This indicator captures hospital admissions directly attributed to 
heat stress (e.g., heat illness, heat stroke, and hyperthermia). It is a measure that can 
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be tracked easily and consistently across geography and time, and acts as a sentinel 
for the broader range of heat-related illness that is not recognized and/or coded as 
such. 
     
Use of the Measure 
 
Heat stress can manifest in a number of clinical outcomes, and people with chronic 
health problems (e.g., cardiovascular disease, diabetes, obesity) are more susceptible 
to the effects of heat than healthy individuals.  For these reasons, heat stress may not 
be listed as the primary diagnosis. This indicator therefore includes all cases where 
heat stress is explicitly listed as the primary diagnosis or any other diagnosis. 
Increases in the rates of hospital admission for heat stress are one potential impact of 
rising global temperatures. Tracking these data can help document changes over 
place and time, monitor vulnerable areas, and evaluate the results of local climate-
adaptation strategies. 
 
Limitations of the 
Measure 
Periods of extreme heat are frequently associated with increases in hospital visits 
and admissions for many causes. This measure does not capture the full spectrum of 
heat stress, especially where exposure to excess heat is not explicitly documented.        
Data Sources Numerator: State inpatient hospital discharge data (using admission date) 
 
Denominator: US Census Bureau population data  
Limitations of Data 
Sources 
State hospital discharge data: 
 Using a measure of all heat stress hospitalizations will include some transfers 
between hospitals for the same individual for the same heat stress event.  
Variations in the percentage of transfers or readmissions for the same heat 
stress event may vary by geographic area and impact rates. 
 Without reciprocal reporting agreements with abutting states, statewide 
measures and measures for geographic areas (e.g., counties) bordering other 
states may be underestimated because of health care utilization patterns.   
 Each state must individually obtain permission to access and, in some states, 
provide payment to obtain the data. 
 Veterans Affairs, Indian Health Services and institutionalized (e.g. Prison) 
populations are excluded. 
 Practice patterns and payment mechanisms may affect diagnostic coding and 
decisions by health care providers to hospitalize patients 
 Street address is currently not available in many states. 
 Sometimes mailing address of patient is listed as the residence address of the 
patient 
 Patients may be exposed to environmental triggers in multiple locations, but 
hospital discharge geographic information is limited to residence. 
 Since the data captures hospital discharges (rather than admissions), patients 
admitted toward the end of the year and discharged the following year will 
be omitted from the current year dataset 
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 Data will need to be de-duplicated (i.e. remove duplicate records for the 
same event)  
 There is usually a two year lag period before data are available from the data 
owner. 
 
Census data: 
 Only available every 10 years, thus postcensal estimates are needed when 
calculating rates for years following the census year. 
 Postcensal estimates at the ZIP code level are not available from the Census 
Related Indicators  Heat vulnerability 
 Heat-related mortality 
 Temperature distribution 
 Emergency department visits for heat stress 
References 1. Confalonieri U, Menne B, Akhtar R, Ebi KL, Hauengue M, Kovats RS, et al. 
2007. Human health In: Parry ML, Canziani OF, Palutikof JP, van der Linden 
PJ, Hanson CE. , editors. Climate Change 2007: Impacts, Adaptation and 
Vulnerability Contribution of Working Group II to: Fourth Assessment Report 
of the Intergovernmental Panel on Climate Change. New York: Cambridge 
University Press. pp. 391–431. 
 
2. Rosen’s Emergency Medicine: Concepts and Clinical Practice. 2010. Chapter 
139: Heat illness. In JA Marx Editor-in-Chief; RS Hockberger & RM Walls 
Senior Editors; JG Adams … [et al] Editors (7th ed). Philadelphia: Mosby 
Elsevier.  
 
3. American Medical Association.  Heat-related Illness During Extreme Weather 
Emergencies (Report 10 of the Council on Scientific Affairs (A97), 1997; 
www.ama-assn.org/ama/pub/category/13637.html).    
 
4. Centers for Disease Control and Prevention. Heat-related deaths--Los Angeles 
County, California, 1999-2000, and United States, 1979-1998. MMWR 
2001;50(29):623-6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 NCDM Recommendations Version 3.0  
Page 103   3/19/2013 
 
INDICATOR TEMPLATE 
CONTENT AREA: CLIMATE AND HEALTH 
INDICATOR: EMERGENCY DEPARTMENT  VISITS FOR HEAT STRESS 
 
Type of EPHT 
Indicator 
Health outcome 
Measures 
1. Annual age-adjusted rate of emergency department visits for heat stress per 100,000 
population 
2. Annual crude rate of emergency department visits for heat stress per 100,000 
population 
3. Annual number of emergency department visits for heat stress 
Derivation of 
Measure(s) 
Numerator: 
 Patients treated in an Emergency Department (ED) having any ICD-9 code in the 
range of 992.0-992.9, or cause of injury code E900.0 or E900.9.   
 Cases with a code of E900.1 (man-made source or heat) anywhere in the record are 
excluded. 
  
Denominator: 
Midyear resident population, by gender, for state and by county 
 
Adjustment: 
 Age-adjustment by the direct method to the Year 2000 US Standard population  
 U.S. 2000 standard population by age categories from Surveillance Epidemiology 
and End Results (SEER), National Cancer Institute 
Unit 
5. Age-adjusted rate per 100,000 population 
6. Rate per 100,000 population 
7. Number 
Geographic Scope State and national 
Geographic Scale State (annual), County (aggregate years) 
Time Period Hospital admissions between May 1 to September 30, inclusive, for each year, 2000– 
Time Scale May–September of each data year 
Rationale 
The Intergovernmental Panel on Climate Change (IPCC) projects with “virtual certainty” 
suggest that climate change will cause more frequent, more intense, and longer heat 
waves (1). Any individual, regardless of age, sex or health status can develop heat stress 
if engaged in intense physical activity and/or exposed to environmental heat (and 
humidity). Physiologic mechanisms maintain the core body temperature (i.e., the 
operating temperature of vital organs in the head or trunk) in a narrow optimum range 
around 37 °C (98.6 °F).
 
When core body temperature rises, the physiologic response is to 
sweat and circulate blood closer to the skin's surface to increase cooling. If heat exposure 
exceeds the physiologic capacity to cool, and core body temperature rises, then a range 
of heat-related symptoms and conditions can develop. Heat stress or Heat-related illness 
ranges from mild heat edema, rash, heat syncope, heat cramps, to the most common type, 
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heat exhaustion (2). Heat-related cramps, rash, and edema are relatively minor readily 
treatable conditions; however, they should be used as important warning signs to 
immediately remove the affected individual from the exposure situation.   
 
Heat cramps are brief, intermittent, and often severe muscular cramps occurring 
typically in muscles that are fatigued by heavy work (2). Individuals with heat cramp can 
also exhibit hyponatremia, hypochloremia, and low serum sodium and chloride levels.  
 
Heat syncope is a temporary loss of consciousness as a result of prolonged heat exposure 
(2).  Individuals adapt to hot, humid environment by dilation of cutaneous vessels in the 
skin to radiate heat. Peripheral vasodilation along with blood volume loss, results in 
lowering the blood pressure which can result in inadequate central venous return and 
cerebral perfusion, causing light-headedness and fainting. 
 
Heat exhaustion is a consequence of extreme depletion of blood plasma volume, which 
may be coincident with hyponatremia and/or peripheral blood pooling (2).  Heat 
exhaustion often does not present with definitive symptoms and may be misdiagnosed, 
often as an acute viral illness.  Symptoms include mild disorientation, generalized 
malaise, weakness, nausea, vomiting, headache, tachycardia (rapid beating of the heart), 
and hypotension.  Because untreated heat exhaustion can progress to heat stroke, the 
most serious form of heat-related illness, treatment should begin at the first signs of heat 
exhaustion (3).   
  
Heat stroke is an extreme medical emergency that if untreated can result in death or 
permanent neurological impairment (2). Heat stroke occurs when a person’s core body 
temperature rises above 40 °C (104 °F) as a result of impaired thermoregulation. High 
core body temperature and disseminated intravascular coagulation results in cell damage 
in vital organs, such as the brain, liver, and kidneys, which can lead to serious illness and 
death (3). Death may occur rapidly due to cardiac failure or hypoxia, or it can occur days 
later as a result of renal failure due to dehydration and/or rhabdomyolysis (i.e., the 
breakdown of muscle fibers with release into the circulation of muscle fiber contents, 
some of which are toxic to the kidney and can cause kidney damage) (4). Heat stroke is 
typically divided into two types.  The two types are in general clinically the same, except 
that the individuals/population groups affected require medical interventions specific to 
their unique physiology and medical status (3). “Exertional Heat Stroke,” as the name 
implies, involves strenuous physical activity under high temperature conditions to which 
the heat stroke victim was not acclimatized, and usually affects healthy young adults, 
such as athletes, outdoor laborers and soldiers.  “Classic” heat stroke, by definition does 
not involve exertion, and usually affects susceptible individuals, such as infants and 
young children, the elderly, or people with chronic illness. Because heat stroke, even if 
treated, can have a death rate as high as 33%, and up to 17% of heat stroke survivors 
suffer permanent be taken to prevent heat-related illness, especially among vulnerable 
populations.   
 
The relationship between extreme heat and increased daily morbidity and mortality is 
well established. This indicator captures hospital admissions directly attributed to heat 
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stress (e.g., heat illness, heat stroke, and hyperthermia). It is a measure that can be 
tracked easily and consistently across geography and time, and acts as a sentinel for the 
broader range of heat-related illness that is not recognized and/or coded as such. 
Use of the Measure 
 
Heat stress can manifest in a number of clinical outcomes, and people with chronic 
health problems (e.g., cardiovascular disease, diabetes, obesity) are more susceptible to 
the effects of heat than healthy individuals.  For these reasons, heat stress may not be 
listed as the primary diagnosis. This indicator therefore includes all cases where heat 
stress is explicitly listed as the primary diagnosis or any other diagnosis. 
 
Increases in the rates of ED visits for heat stress are one potential impact of rising global 
temperatures. Tracking these data can help document changes over place and time, 
monitor vulnerable areas, and evaluate the results of local climate-adaptation strategies. 
Limitations of the 
Measure 
Periods of extreme heat are frequently associated with increases in hospital visits and 
admissions for many causes. This measure does not capture the full spectrum of heat-
stress, where exposure to excess heat is not explicitly documented.      
Data Sources 
Numerator: State emergency department data 
Denominator: US Census Bureau population data 
Limitations of Data 
Sources 
 
Emergency Department data: 
 Data are not available for all states.   
 Number of diagnostic fields in hospital records varies from state to state. Utilization 
of EDs varies geographically. 
 
Census data: 
 Only available every 10 years, thus postcensal estimates are needed when 
calculating rates for years following the census year. 
Related Indicators 
 Heat vulnerability 
 Heat-related mortality 
 Temperature distribution  
 Heat stress hopitalizations 
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CONTENT DOMAIN: COMMUNITY WATER   
INDICATOR: ATRAZINE  
ENVIRONMENTAL PUBLIC HEALTH TRACKING 
Type of EPHT 
Indicator 
Hazard, Exposure 
Measures Level of Contaminant in Finished Water 
1. Quarterly distribution of number of Community Water Systems (CWS) by mean 
atrazine concentration (cut-points: 0-1, >1-3, >3-4, >4 µg/L atrazine). 
2. Yearly distribution of number of CWS by maximum atrazine concentration (cut-
points: 0-1, >1-3, >3-4, >4 µg/L atrazine). 
3. Yearly distribution of number of CWS by mean atrazine concentration (cut-
points:  0-1, >1-3, >3-4, >4 µg/L atrazine). 
4. Mean concentration of atrazine at CWS-level, by year. 
 
Potential Population Exposure to Contaminants in Finished Water 
1. Quarterly distribution of number of people served by CWS by mean atrazine 
concentration (cut-points: 0-1, >1-3, >3-4, >4 µg/L atrazine). 
2. Yearly distribution of number of people served by CWS by maximum atrazine 
concentration (cut-points: 0-1, >1-3, >3-4, >4 µg/L atrazine). 
3. Yearly distribution of number of people served by CWS by mean atrazine 
concentration (cut-points: 0-1, >1-3, >3-4, >4 µg/L atrazine). 
Derivation of 
Measures 
Atrazine measures will be developed from water system attribute and water quality 
data stored in state Safe Drinking Water Act (SDWA) databases such as the Safe 
Drinking Water Information System (SDWIS/State). Data will be cleaned and 
transformed to a standard format. Analytical results of drinking water samples 
(usually taken at entry points to the distribution system or representative sampling 
points after treatment) will be used in conjunction with information about each 
CWS (such as service population and latitude and longitude of representative 
location of the CWS service area) to generate the measures.   
Units µg/L of Atrazine  
Geographic Scope State and Community Water System by County 
Geographic Scale The finest detail will be approximate point location of the community water 
distribution system represented by water withdrawal point, water distribution 
extents, principal county served, or principal city served.  
Time Period 1999 or earliest year available to most current year of data abstraction. 
Time Scale Calendar year 
 
 
Rationale 
 
Atrazine and Public Health 
Atrazine is a widely used herbicide active against broadleaf and grassy weeds. Atrazine was 
first registered as an herbicide in 1958. More than 70 million pounds have been applied 
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annually in recent years, with about 75% of corn cropland receiving treatment. In addition 
to agricultural uses, atrazine is used in residential turf applications and on golf courses and 
sod farms to control weeds. Atrazine and its degradation products are the most commonly 
detected pesticides in ground and surface waters (Barr et al., 2007). The frequent detection 
of atrazine and its degradation products in streams, rivers, groundwater, and reservoirs is 
related directly to the volume of its use, its persistence in soils due to its resistance to 
photolysis and hydrolysis, and its ability to travel within water systems (Nelson et al., 
2001). In water systems, atrazine is transformed over time by various chemical reactions 
into other compounds or its degradation products or metabolites, including dealkylated 
compounds such as desethylatrazine (DEA), desisopropylatrazine (DIA), and 
diaminochlorotriazine (DACT).  In soil, atrazine degrades slowly to dealkylated 
compounds, which have half-lives of several months.  Bacteria and plants can metabolize 
atrazine to hydroxylated products. In plants, atrazine is absorbed by the root system and 
tends to form hydroxylated metabolites that cannot be removed by washing contaminated 
vegetables (Nelson et al., 2001). Atrazine does not bioaccumulate. Studies suggest that in 
animals, the degradation products that retain the chlorine have biologic activity similar to 
that of atrazine, while the hydroxylated metabolites do not retain its biologic activity 
(Nelson et al., 2001).  Use of atrazine in the presence of nitrogen fertilizers, has raised a 
possibility of N-nitrosation in soil (DeMarini and Zahm, 1999). There may also be 
endogenous formation of N-nitrosoatrazine from precursors ingested in the diet and 
drinking water. For the general population, drinking water is an infrequent source of 
atrazine exposure, but estimates of seasonal intakes from drinking water in a small number 
of communities have exceeded the recommended limits (U.S. EPA, 2003). As a result, 
atrazine use has progressively been restricted in an effort to reduce surface and ground 
water contamination.   
In an analysis of occurrence data from the EPA 6 Year Review of National Primary 
Drinking Water Regulations, atrazine was detected in 888 systems serving greater than 34 
million people (EPA, 2009). Concentrations of atrazine were greater than the MCL in 98 
systems serving 3.1 million people.  Atrazine was the second highest occurring regulated 
synthetic organic chemical found based on the percent of detections found from the 6 Year 
Review data (EPA, 2009). 
While it is used on many crops, atrazine has not been found in many food samples, and then 
only at very low levels. Therefore, it is very unlikely that people would be exposed to 
atrazine by eating crops from atrazine-accumulated soil. 
Most people are not exposed regularly to atrazine. People living near areas where atrazine 
was applied to crops may be exposed through contaminated drinking water. Atrazine has 
been found at about 20 Superfund sites in the United States. People living near those sites 
may be exposed to higher levels of atrazine. Factory workers who work with atrazine may 
be exposed to higher amounts of atrazine than other workers. The government has estimated 
that approximately 1,000 people may be exposed to atrazine in this way (ATSDR, 2003).  
Applicators of atrazine may be exposed dermally and by inhalation. Atrazine is well 
absorbed orally, metabolized, and then eliminated in the urine over a few days (Bradway et 
al., 1982; Catenacci et al., 1993; Timchalk et al., 1990).   
Metabolism of atrazine and its degradation products is complex and results in many 
potential metabolites (Barr et al., 2007).  As many as 8-12 metabolites of atrazine have been 
identified in animals and humans, with recent studies showing DACT as the primary 
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metabolite (Barr et al., 2007); therefore, earlier biomonitoring studies measuring atrazine 
mercapturate alone misrepresent and underestimate total atrazine exposure.  Panuwet et al., 
(2008) developed an analytical method that measures the seven primary urinary metabolites 
of atrazine, which are: hydroxyatrazine, DACT, DIA, DEA, desethylatrazine mercapturate, 
atrazine mercapturate, and atrazine itself.  
Human health effects of atrazine at environmental doses or at biomonitored levels from 
environmental exposure are unknown. In mammalian studies, atrazine is rated as having 
low acute toxicity. Atrazine product formulations can be mild skin sensitizers and irritants. 
Some human ecologic and epidemiologic studies of reproductive and cancer outcomes have 
shown either positive or no associations, but effects are difficult to attribute due to lack of 
exposure markers or due to mixed chemical or pesticide exposures (ATSDR, 2003; 
Gammon et al., 2005; Sathiakumar and Delzell, 1997). Studies of couples living on farms 
that use atrazine for weed control found an increase in the risk of pre-term delivery. These 
studies are difficult to interpret because most of the farmers were men who may have been 
exposed to several types of pesticides. A meta-analysis linked hypospadias to parental 
exposure to pesticides with possible endocrine-mediated effects (Rocheleau et al., 2009).  
Some epidemiological studies that looked at the potential impact of prenatal exposure to 
atrazine or its products of environmental degradation on pregnancy outcomes in the general 
population observed higher rates of babies born small-for gestational age (SGA) (Munger et 
al., 1997, Villanueva et al., 2005; Ochoa-Acuna et al., 2009).  They also linked exposure of 
mothers who lived closer to sites with high atrazine concentrations with a higher risk of 
gastroschisis (Waller et al., 2010).  Most of these studies were retrospective and relied on 
ecological assessment of exposure to atrazine.  However, the most recent study that 
measured urinary biomarkers of prenatal atrazine exposure and  was based on a prospective 
population-based cohort found associations between environmental exposure to atrazine and 
adverse effects on fetal growth, specifically birth weight, birth length,  and small head 
circumference (Chevrier et al., 2011).  Atrazine is not mutagenic and is not considered 
genotoxic. The International Agency for Research on Cancer (IARC) considers atrazine not 
classifiable with respect to human carcinogenicity, and the EPA considers atrazine unlikely 
to be a human carcinogen. However, IARC recommends future research to characterize the 
ability of atrazine to interfere with the hypothalamic-pituitary-ovarian axis in women. This 
research would help determine whether atrazine is a mammary carcinogen in women.  
Another area for future research is to explore atrazine’s ability to alter immune and 
aromatase function in humans.  Additional information is available from U.S. EPA at: 
http://www.epa.gov/pesticides/  ; from ATSDR at: http://www.atsdr.cdc.gov/toxpro2.html, 
and IARC at http://www.iarc.fr/ 
Children are likely to be exposed to atrazine in the same way as adults, primarily through 
contact with dirt that contains atrazine or by drinking water from wells that are 
contaminated with the herbicide.  Little information is available about the effects of atrazine 
in children. Maternal exposure to atrazine in drinking water has been associated with low 
fetal weight and heart, urinary, or limb defects in humans. It is not known whether atrazine 
or its metabolites can be transferred from a pregnant mother to a developing fetus through 
the placenta or from a nursing mother to her offspring through breast milk. 
Biomonitoring Information 
Urinary levels of atrazine mercapturate reflect recent exposure. In the NHANES 2001–2002 
subsample, levels of atrazine mercapturate were generally not detectable (CDC, 2005). In 
small studies of Maryland residents in 1995–1996 (MacIntosh et al., 1999) and 83 
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Minnesota children with multiple urine collections during 1997 (Adgate et al., 2001), 
atrazine mercapturate was infrequently detected at the detection limit of 0.3 µg/L. In a study 
of 60 farm worker children, atrazine was detected in only four children (Arcury et al., 
2007). Using immunoassay atrazine equivalents (detected mostly as atrazine mercapturate), 
the urinary geometric mean levels for herbicide applicators in Ohio and Wisconsin were 
about 6 µg/L (Hines et al., 2003; Perry et al., 2000). The geometric mean of urinary atrazine 
mercapturate was 1.2 µg/L in 15 farmers studied several days after spraying the pesticide 
(Curwin et al., 2005). In a small number of field workers, urinary concentrations ranged 
from 5-1756 µg/L (Lucas et al., 1993).   However, biomonitoring studies that have 
evaluated only one urinary metabolite of atrazine (such as atrazine mercapturate) probably 
underestimated exposure (Barr et al, 2007). 
Finding measurable amounts of atrazine or its metabolites in urine does not mean that the 
levels of atrazine and its metabolites (e.g., atrazine mercapturate) cause an adverse health 
effect. Biomonitoring studies on levels of atrazine mercapturate provide physicians and 
public health officials with reference values so that they can determine whether people have 
been exposed to higher levels of atrazine than are found in the general population. 
Biomonitoring data can also help scientists plan and conduct research on exposure and 
health effects.  
Sources of Atrazine 
Atrazine is the common name for an herbicide that is widely used to kill weeds. It is used 
mostly on farms. Pure atrazine—an odorless, white powder—is not very volatile, reactive, 
or flammable. It will dissolve in water. Atrazine is made in the laboratory; it does not occur 
naturally.  
Atrazine is used on crops such as sugarcane, corn, pineapples, sorghum, and macadamia 
nuts, and on evergreen tree farms and for evergreen forest re-growth. It has also been used 
to keep weeds from growing on both highway and railroad rights-of-way. Some of the trade 
names of atrazine are Aatrex®, Aatram®, Atratol®, and Gesaprim®. The scientific name 
for atrazine is 6-chloro-N-ethyl-N'-(1-methylethyl)-triazine-2,4-diamine. Atrazine is a 
Restricted Use Pesticide , which means that only certified herbicide users may purchase or 
use it. Certification for the use of atrazine is obtained through the appropriate state office 
where the herbicide user is licensed. Atrazine is usually used in the spring and summer 
months. For it to be active, atrazine needs to dissolve in water and enter the plants through 
their roots. It then acts in the shoots and leaves of the weed to stop photosynthesis. Atrazine 
is taken up by all plants, but in plants not affected by atrazine, it is broken down before it 
can affect photosynthesis. The application of atrazine to crops as an herbicide accounts for 
almost all of the atrazine that enters the environment, but some may be released from 
manufacture, formulation, transport, and disposal. 
Any atrazine that is washed from the soil into streams and other bodies of water will stay 
there for a long time, because chemical breakdown is slow in rivers and lakes. It also will 
persist for a long time in groundwater. This is one reason why atrazine is found commonly 
in the water collected from drinking water wells in some agricultural regions.  
If atrazine enters the air, it can be broken down by reactions with other reactive chemicals 
in the air. However, sometimes atrazine is on particles such as dust. When this happens, 
breakdown is not expected. Atrazine is removed from air mainly by rainfall. When atrazine 
is on dust particles, the wind can blow it long distances from the nearest application area. 
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For example, atrazine has been found in rainwater more than 180 miles (300 kilometers) 
from the nearest application area.  
Atrazine does not tend to accumulate in living organisms such as algae, bacteria, clams, or 
fish, and, therefore, does not tend to build up in the food chain.  
Atrazine Regulation and Monitoring 
Congress established the Safe Drinking Water Act in 1974, which set enforceable 
Maximum Contaminant Levels (MCLs) and non-enforceable Maximum Contaminant Level 
Goals (MCLGs) for certain, specified contaminants.  In the case of atrazine in drinking 
water, EPA has set an MCL of 3 µg/L.  Atrazine is designated as a Restricted Use Pesticide, 
which means that only certified pesticide applicators can use atrazine. The Occupational 
Safety and Health Administration (OSHA) has set a limit of 5 milligrams of atrazine per 
cubic meter of workplace air (5 mg/m3) for an 8_hour workday and 40-hour work week. 
EPA has determined maximum levels allowed in foods of 0.02-15 parts atrazine per million 
parts of food (0.02-15 ppm).  
Use of Measure These measures assist by providing data that can be used for surveillance purposes. 
 Distribution measures provide information on the number of CWS and the 
number of people potentially exposed to atrazine at different concentrations.  
 Maximum concentrations provide information on the peak potential 
exposure to atrazine at the state level. 
 Mean concentrations at the CWS level provide information on potential 
exposure at a smaller geographic scale.  
 
Limitations of the 
Measure 
The current measures are derived for CWS only. Private wells are another important 
source of population exposure to atrazine in some agricultural regions.  Transient 
non-community water systems, which are regulated by EPA, may also be an 
important source of atrazine exposure.  Measures do not account for the variability 
in sampling, numbers of sampling repeats, and variability within systems.  
Concentrations in drinking water cannot be converted directly to exposure, because 
water consumption varies by climate, level of physical activity, and between people 
(EPA 2004).  Due to errors in estimating populations, the measures may 
overestimate or underestimate the number of affected people. 
 
Data Sources State grantee  
Limitations of Data 
Sources 
Ground water systems may have many wells with different atrazine concentrations 
that serve different parts of the population. Compliance samples are taken at each 
entry point to the distribution system.  In systems with separate wells serving some 
branches or sections of the distribution system, the system mean would tend to 
underestimate the atrazine concentration of people served by wells with higher 
atrazine concentrations. 
Exposure may be higher or lower than estimated if data from multiple entry points 
for water with different atrazine levels are averaged to estimate levels for the PWS. 
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Related Indicators Public Water Use 
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CONTENT DOMAIN: COMMUNITY WATER   
INDICATOR: ARSENIC  
ENVIRONMENTAL PUBLIC HEALTH TRACKING 
Type of EPHT Indicator Hazard, Exposure 
Measures Level of Contaminant in Finished Water 
1.  Yearly distribution of number of Community Water Systems (CWS) by 
maximum arsenic concentration (cut-points: 0-5, >5-10, >10-30, >30 
µg/L arsenic). 
2. Yearly distribution of number of CWS by mean arsenic concentration 
(cut-points: 0-5, >5-10, >10-20, >20-30, >30 µg/L arsenic). 
3. Mean concentration of arsenic at CWS-level, by year. 
 
Potential Population Exposure to Contaminants in Finished Water 
1. Yearly distribution of number of people served by CWS by maximum 
arsenic concentration (cut-points: 0-5, >5-10, >10-20, >20-30, >30 µg/L 
arsenic). 
2. Yearly distribution of number of people served by CWS by mean arsenic 
concentration (cut-points: 0-5, >5-10, >10-20, >20-30, >30 µg/L 
arsenic). 
 
Derivation of Measures Arsenic measures will be developed from water system attribute and water 
quality data stored in state Safe Drinking Water Act (SDWA) databases such as 
the Safe Drinking Water Information System (SDWIS/State). Data will be 
cleaned and transformed to a standard format. Analytical results of drinking 
water samples (usually taken at entry points to the distribution system or 
representative sampling points after treatment) will be used in conjunction with 
information about each CWS (such as service population and latitude and 
longitude of representative location of the CWS service area) to generate the 
measures.   
Units Concentration of arsenic, µg/L 
Geographic Scope State and Community Water System by County 
Geographic Scale The finest detail will be approximate point location of the community water 
distribution system represented by water withdrawal point, water distribution 
extents, principal county served, or principal city served.  
Time Period 1999 or earliest year available to most current year of data abstraction. 
Time Scale Calendar year 
 
 
Rationale 
 
Arsenic and Public Health 
Exposures to higher than average levels of arsenic can come from elevated 
localized soil and ground water concentrations from application and runoff of 
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arsenical pesticides and leachate from coal ash and landfills (ATSDR 2005).  
Exposure to hundreds of micrograms per liter of arsenic found in drinking 
water of Taiwan, Chile, Argentina, Mexico, Bangladesh, and India has been 
associated with many adverse health effects including lung, bladder, liver and 
skin cancers (NRC, 1999; Rahman et al. 2005; Salazar et al. 2004; Fazal et al., 
2001).  Arsenic has been identified as a human carcinogen by the International 
Agency for Research in Cancer (IARC) (IARC, 2004).  Other adverse health 
effects include nausea, cardiovascular disease, (Chen et al., 2007; Chih-Hao et 
al., 2007; Bunderson et al., 2004), developmental and reproductive effects 
(Hopenhayn et al., 2003; Ahmad et al., 2001)), Diabetes Mellitus (Rahman et 
al., 1998), and skin keratosis and hyperpigmentation (Kapaj et al., 2006).  
Measured arsenic concentrations in finished drinking water can be used to 
understand the distribution of potential arsenic exposure levels for populations 
served by community water supplies. These measures allow for comparison of 
potential for arsenic exposures between the populations served by different 
water systems and water sources over time, and potentially across demographic 
groups. 
Sources of Arsenic 
Arsenic compounds (As (III) and As (V)) are found in both ground water and 
surface waters. The primary sources are geologic formations from which 
arsenic can be dissolved.  Higher levels of arsenic tend to be found in ground 
water (e.g. aquifers) as compared to surface waters (e.g., lakes, rivers).  
Arsenic Regulation and Monitoring 
In 2001 EPA reduced the regulatory drinking water standard Maximum 
Contaminant Level (MCL) to 10 μg/L from 50 μg/L (effective January 23, 
2006) on the basis of bladder and lung cancer risks (EPA 2001a). The cancer 
risks were extrapolated from the Taiwanese (Chen et al. 1985) study to U.S. 
risks.  Lowering the MCL from 50 to 10 ppb statistically reduces bladder and 
lung cancer mortality and morbidity by 37-56 cancers a year in the U.S. (EPA 
2001b).  Based on the current understanding of the health impacts from arsenic 
exposure, the potential for adverse health effects from drinking water exposure 
to arsenic is very low for most municipal drinking water systems.  
Use of Measure These measures assist by providing data that can be used for surveillance 
purposes. 
 Distribution measures provide information on the number of CWS and 
the number of people potentially exposed to arsenic at different 
concentrations.  
 Maximum concentrations provide information on the peak potential 
exposure to arsenic at the state level. 
 Mean concentrations at the CWS level provide information on potential 
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exposure at a smaller geographic scale.  
 
Limitations of The 
Measure 
Measures do not account for the variability in sampling, numbers of sampling 
repeats, and variability within systems.  Concentrations in drinking water 
cannot be directly converted to exposure, because water consumption varies by 
climate, level of physical activity, and between people (EPA 2004).  Due to 
errors in estimating populations, the measures may overestimate or 
underestimate the number of affected people. 
 
Data Sources State grantee  
Limitations of Data 
Sources 
Samples are taken once a year (surface sources), once every three years 
(groundwater sources), or once every nine years (for sources with a waiver).  
Frequency of sampling is based on compliance with the MCL; the lower the 
measured concentration the fewer samples will be taken and some years there 
may be no sampling for arsenic.   
Ground water systems may have multiple wells with different arsenic 
concentrations that serve different parts of the population. Compliance samples 
are taken at each entry point to the distribution system.  In systems with 
separate wells serving some branches or sections of the distribution system, the 
system mean would tend to underestimate the arsenic concentration of people 
served by wells with higher arsenic concentrations. 
Exposure may be higher or lower than estimated if data from multiple entry 
points for water with different arsenic levels are averaged to estimate levels for 
the PWS. 
Related Indicators Public Water Use 
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CONTENT DOMAIN: COMMUNITY WATER   
INDICATOR:  DI(2-ETHYLHEXYL)PHTHALATE (DEHP) 
ENVIRONMENTAL PUBLIC HEALTH TRACKING 
Type of EPHT Indicator Hazard, Exposure 
Measures Level of Contaminant in Finished Water 
1. Yearly distribution of number of Community Water Systems (CWS) by 
maximum DEHP concentration (cut-points: 0-2, >2-4, >4-6, >6-10, >10 
µg/L DEHP). 
2. Yearly distribution of number of CWS by mean DEHP concentration 
(cut-points:  0-2, >2-4, >4-6, >6-10, >10 µg/L DEHP). 
3. Mean concentration of DEHP at CWS-level, by year. 
 
Potential Population Exposure to Contaminants in Finished Water 
4. Yearly distribution of number of people served by CWS by maximum 
DEHP concentration (cut-points: 0-2, >2-4, >4-6, >6-10, >10 µg/L 
DEHP). 
5. Yearly distribution of number of people served by CWS by mean DEHP 
concentration (cut-points: 0-2, >2-4, >4-6, >6-10, >10 µg/L DEHP). 
Derivation of Measures DEHP measures will be developed from water system attribute and water 
quality data stored in state Safe Drinking Water Act (SDWA) databases such as 
the Safe Drinking Water Information System (SDWIS/State). Data will be 
cleaned and transformed to a standard format. Analytical results of drinking 
water samples (usually taken at entry points to the distribution system or 
representative sampling points after treatment) will be used in conjunction with 
information about each CWS (such as service population and latitude and 
longitude of representative location of the CWS service area) to generate the 
measures.   
Units DEHP, µg/L 
Geographic Scope State and Community Water System by County 
Geographic Scale The finest detail will be approximate point location of the community water 
distribution system represented by water withdrawal point, water distribution 
extents, principal county served, or principal city served.  
Time Period 1999 or earliest year available to most current year of data abstraction. 
Time Scale Calendar year 
Rationale Di (2-ethylhexyl)phthalate and Public Health 
DEHP is the most commonly used of a group of related chemicals called 
phthalates or phthalic acid esters. Some people who drink water containing 
DEHP well in excess of the maximum contaminant level (MCL) for many 
years may have problems with their livers or could experience reproductive 
difficulties and may have an increased risk of getting cancer. (U.S.EPA, 2010) 
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In an analysis of occurrence data from the EPA 6 Year Review of National 
Primary Drinking Water Regulations, DEHP was detected in 3,098 systems, 
which collectively serve more than 45 million people (EPA, 2009). 
Concentrations of DEHP were greater than the MCL in 460 systems serving 
11.5 million people.  DEHP was the highest occurring regulated synthetic 
organic chemical found based on the percent of detections found from the 6 
Year Review data.  This contamination could be due, in part, to sample 
contamination from older generation laboratory and field sampling equipment 
made of plastics that contained and released phthalates (EPA, 2009).    
Most of what we know about the health effects of DEHP comes from studies of 
rats and mice given high amounts of DEHP.  Brief oral exposure to very high 
levels of DEHP damaged sperm in mice. Although the effect reversed when 
exposure ceased, sexual maturity was delayed in the animals. High amounts of 
DEHP damaged the liver of rats and mice. Whether or not DEHP contributes to 
human kidney damage is unclear.  
The Department of Health and Human Services has determined that DEHP may 
reasonably be anticipated to be a human carcinogen. The EPA has determined 
that DEHP is a probable human carcinogen. These determinations were based 
entirely on liver cancer in rats and mice. The International Agency for Research 
on Cancer has stated that DEHP cannot be classified as to its carcinogenicity to 
humans. 
People are exposed through ingestion, inhalation, and, to a lesser extent, dermal 
contact with products that contain phthalates. For the general population, 
dietary sources have been considered as the major exposure route, followed by 
inhaling indoor air. Infants may have relatively greater exposures from 
ingesting indoor dust containing some phthalates (Clark et al., 2003). Human 
milk can be a source of phthalate exposure for nursing infants (Calafat et al., 
2004; Mortensen et al., 2005). The intravenous or parenteral exposure route can 
be important in patients undergoing medical procedures involving devices or 
materials containing phthalates. In settings where workers may be exposed to 
higher air phthalate concentrations than the general population, urinary 
metabolite and air phthalate concentrations are roughly correlated (Liss et al., 
1985; Nielsen et al., 1985; Pan et al., 2006). Phthalates are metabolized and 
excreted quickly and do not accumulate in the body (Anderson et al., 2001). 
Biomonitoring Information  
Four metabolites of DEHP were measured for the Fourth National Report on 
Human Exposure to Environmental Chemicals: mono-(2-ethyl-5-hexyl) 
phthalate (MEHP), mono- (2-ethyl-5-oxohexyl) phthalate (MEOHP), mono-(2-
ethyl- 5-hydroxyhexyl) phthalate (MEHHP) and mono-(2-ethyl- 5-
carboxypentyl) phthalate (MECPP). MEHP is primarily formed by the 
hydrolysis of DEHP in the gastrointestinal tract and then absorbed. By contrast, 
DEHP present in medical devices and parenteral delivery systems results in the 
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diester parent compound, rather than the  monoester metabolite. being directly 
introduced into the blood. After parenteral administration hydrolysis of DEHP 
most likely also occurs in the blood, and subsequent metabolism is similar to 
that following ingestion (Koch et al., 2005a, 2005b, 2005c). MEOHP, MEHHP, 
and MECPP are produced by the oxidative metabolism of MEHP and are 
present at roughly three- to five-fold higher concentrations than MEHP in urine 
(Barr et al., 2003; Fromme et al., 2007; Koch et al., 2003). MEHP is the 
putative toxic metabolite of DEHP.  Liver toxicity, decreased testicular weight, 
and testicular atrophy have been observed in rodents fed high doses over a short 
term or with chronic dosing (McKee et al., 2004; NTP-CERHR, 2000c, 2006). 
In contrast, marmoset monkeys fed high dose DEHP for longer than a year did 
not demonstrate testicular or liver toxicity (NTP-CERHR, 2006). Very high 
doses of DEHP have suppressed estradiol production in female rats 
(Lovecamp-Swan and Davis, 2003). The U.S. Food and Drug Administration 
determined that in adults, the amounts of DEHP or MEHP received from 
intravenous delivery systems or blood transfusions (DEHP is hydrolyzed to 
MEHP in stored blood) would result in short-term elevations similar to 
background levels (FDA, 2001). However, critically ill neonates and infants 
receiving selected or multiple intensive procedures, such as exchange 
transfusions, extracorporeal membrane oxygenation, and parenteral nutrition, 
could receive higher exposures than the general population (Calafat et al., 2004; 
FDA, 2001; Loff et al., 2000; Weuve et al., 2006). 
The levels of MEHP reported in NHANES 1999-2000, 2001-2002, and 2003-
2004 appear roughly comparable to those reported previously in several small 
U.S. studies involving adults (Blount et al., 2000), pregnant women in New 
York City (Adibi et al., 2003), and low income African-American women in 
Washington, DC (Hoppin et al., 2002).  In another sample of men attending an 
infertility clinic, the median and 95th percentile values of urinary MEHP were 
similar, but MEHHP and MEOHP were about three to five times higher than 
comparable values found in males in two NHANES survey periods (1999-2000, 
2001-2002) (CDC, 2005; Hauser et al., 2007). In separate analyses of 
NHANES 1999-2000 and NHANES 2001-2002, the adjusted geometric mean 
levels of urinary MEHP were significantly higher in children compared with 
adolescents and adults, and in females compared with males (CDC, 2005; Silva 
et al., 2004). Studies of hospitalized neonates have reported urinary geometric 
mean levels of MEHP, MEOHP, and MEHHP that were two to five times 
higher, or more (depending on the intensity of DEHP-product exposure), than 
the geometric means of children in the NHANES subsamples for all three 
survey periods (Calafat et al., 2004; Weuve et al., 2006). Small studies of 
plasma and platelet donors have reported very high levels of MEHP, MEOHP, 
MEHHP and MECPP in urine collected shortly after these procedures (Koch et 
al., 2005b, 2005c). Finding a measurable amount of one or more DEHP 
metabolites in urine does not mean that the levels of the metabolites or the 
parent compound cause an adverse health effect. Biomonitoring studies on 
levels of urinary DEHP metabolites provide physicians and public health 
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officials with reference values so that they can determine whether people have 
been exposed to higher levels of DEHP than are found in the general 
population. Biomonitoring data can also help scientists plan and conduct 
research on exposure and health effects. 
Sources of DEHP 
Phthalates are industrial chemicals, often called plasticizers, that are added to 
plastics make them more flexible and resilient. Phthalates are also used in other 
applications as solubilizing and stabilizing agents. Numerous products contain 
phthalates: adhesives; automotive plastics; detergents; lubricating oils; some 
medical devices and pharmaceuticals; plastic raincoats; solvents; vinyl tiles and 
flooring; and personal-care products, such as soap, shampoo, deodorants, 
lotions, fragrances, hair spray, and nail polish. Phthalates are often used in 
polyvinyl chloride-type plastics, such as plastic bags, garden hoses, inflatable 
recreational toys, blood product storage bags, intravenous medical tubing, and 
toys (ATSDR, 2001, 2002). Because they are not chemically bound to the 
plastics to which they are added, phthalates can be released into the 
environment during use or disposal of the product. Various phthalate esters 
have been measured in specific foods, indoor and ambient air, indoor dust, 
water sources, and sediments (Clark et al., 2003).  
DEHP is primarily used to produce flexibility in plastics, mainly polyvinyl 
chloride, which is used for many consumer products, toys, packaging film, and 
blood product storage and intravenous delivery systems. Concentrations in 
plastic materials may reach 40% by weight. DEHP has been removed from or 
replaced in most toys and food packaging in the United States. Following 
ingestion, DEHP is metabolized to more than 30 metabolites which are rapidly 
eliminated in urine, and in humans, as glucuronide conjugates (Albro et al., 
1982; Albro and Lavenhar, 1989; ATSDR, 2002; Peck and Albro, 1982). The 
major source of di(2-ethylhexyl) phthalate in drinking water is discharge from 
rubber and chemical factories (U.S. EPA, 2010).  
DEHP Regulation and Monitoring 
The EPA limits the amount of DEHP that may be present in drinking water to 6 
parts of DEHP per billion parts of water (6 ppb), or 6 ug/L. 
The Occupational Safety and Health Administration (OSHA) sets a maximum 
average of 5 milligrams of DEHP per cubic meter of air (5 mg/m
3
) in the 
workplace during an 8-hour shift. The short-term (15-minute) exposure limit is 
10 mg/m
3
. 
Use of Measure These measures assist by providing data that can be used for surveillance 
purposes. 
• Distribution measures provide information on the number of CWS and the 
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   number of people potentially exposed to DEHP at different 
   concentrations.  
• Maximum concentrations provide information on the peak potential  
   exposure to DEHP at the state level. 
• Mean concentrations at the CWS level provide information on potential  
   exposure at a smaller geographic scale.  
Limitations of The 
Measure 
The current measures are derived for CWS only. Private wells may be another 
source of population exposure to DEHP.  Transient non-community water 
systems, which are regulated by EPA, may also be an important source of 
DEHP exposure.  Measures do not account for the variability in sampling, 
numbers of sampling repeats, and variability within systems.  Concentrations in 
drinking water cannot be directly converted to exposure, because water 
consumption varies by climate, level of physical activity, and between people 
(EPA 2004).  Due to errors in estimating populations, the measures may 
overestimate or underestimate the number of affected people. 
 
Data Sources State grantee  
Limitations of Data 
Sources 
Ground water systems may have many wells with different DEHP 
concentrations that serve different parts of the population. Compliance samples 
are taken at each entry point to the distribution system.  In systems with 
separate wells serving some branches or sections of the distribution system, the 
system mean would tend to underestimate the DEHP concentration of people 
served by wells with higher DEHP concentrations. 
Exposure may be higher or lower than estimated if data from multiple entry 
points for water with different DEHP levels are averaged to estimate levels for 
the PWS. 
Related Indicators Public Water Use 
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CONTENT DOMAIN: COMMUNITY WATER   
INDICATOR: DISINFECTION BYPRODUCTS  
ENVIRONMENTAL PUBLIC HEALTH TRACKING 
Type of EPHT Indicator Hazard, Exposure 
Measures Level of Contaminant in Finished Water 
1. Quarterly distribution of number of Community Water Systems (CWS) 
by mean HAA5 concentration (cut-points: (0-15), (>15-30), (>30-45), 
(>45-60), (>60-75), (>75) mg/L HAA5). 
2. Yearly distribution of number of CWS by maximum HAA5 
concentration (cut-points: (0-15), (>15-30), (>30-45), (>45-60), (>60-
75), (>75) mg/L HAA5). 
3. Yearly distribution of number of CWS by mean HAA5 concentration 
(cut-points:  (0-15), (>15-30), (>30-45), (>45-60), (>60-75), (>75) mg/L 
HAA5). 
4. Mean concentration of HAA5 at CWS-level, by year. 
5. Quarterly distribution of number of CWS by mean TTHM concentration 
(cut-points: (0-20), (>20-40), (>40-60), (>60-80), (>80-100), (>100) 
mg/L TTHM). 
6. Yearly distribution of number of CWS by maximum TTHM 
concentration (cut-points:  (0-20), (>20-40), (>40-60), (>60-80), (>80-
100), (>100) mg/L TTHM). 
7. Yearly distribution of number of CWS by mean TTHM concentration 
(cut-points: (0-20), (>20-40), (>40-60), (>60-80), (>80-100), (>100)   
mg/L TTHM). 
8. Mean concentration of TTHM at CWS-level, by year. 
 
Potential Population Exposure to Contaminants in Finished Water 
9. Quarterly distribution of number of people served by CWS by mean 
HAA5 concentration (cut-points: (0-15), (>15-30), (>30-45), (>45-60), 
(>60-75), (>75) mg/L HAA5). 
10. Yearly distribution of number of people served by CWS by maximum 
HAA5 concentration (cut-points: (0-15), (>15-30), (>30-45), (>45-60), 
(>60-75), (>75) mg/L HAA5). 
11. Yearly distribution of number of people served by CWS by mean 
HAA5 concentration (cut-points: (0-15), (>15-30), (>30-45), (>45-60), 
(>60-75), (>75) mg/L HAA5). 
12. Quarterly distribution of number of people served by CWS by mean 
TTHM concentration (cut-points: (0-20), (>20-40), (>40-60), (>60-80), 
(>80-100), (>100) mg/L TTHM). 
13. Yearly distribution of number of people served by CWS by maximum 
TTHM concentration (cut-points: (0-20), (>20-40), (>40-60), (>60-80), 
(>80-100), (>100) mg/L TTHM). 
14. Yearly distribution of number of people served by CWS by mean 
TTHM concentration (cut-points:  (0-20), (>20-40), (>40-60), (>60-80), 
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(>80-100), (>100) mg/L TTHM). 
Derivation of Measures Disinfection byproducts measures will be developed from water system 
attribute and water quality data stored in state Safe Drinking Water Act 
(SDWA) databases such as the Safe Drinking Water Information System 
(SDWIS/State). Trihalomethanes comprise chloroform, bromodichloromethane, 
dibromochloromethane, bromoform and their sum, denoted total 
trihalomethanes (TTHM). Haloacetic acids comprise trichloroacetic acid, 
dichloroacetic acid, monochloroacetic acid, dibromoacetic acid, 
monobromoacetic acid, and their sum, denoted HAA5. Data will be cleaned 
and transformed to a standard format. Analytical results of drinking water 
samples (usually taken at entry points to the distribution system or 
representative sampling points after treatment) will be used in conjunction with 
information about each CWS (such as service population and latitude and 
longitude of representative location of the CWS service area) to generate the 
measures.   
Units concentration of HAA5, µg/L 
concentration of TTHM, µg/L 
Geographic Scope State and Community Water System by County 
Geographic Scale The finest detail will be approximate point location of the community water 
distribution system represented by water withdrawal point, water distribution 
extents, principal county served, or principal city served.  
Time Period 2002 or earliest year available to most current year of data abstraction. 
Time Scale Calendar year 
Rationale Disinfection By Products and Public Health 
Disinfection byproducts (DBP) are formed when disinfectants used to 
inactivate microbial contaminants in water react with materials, primarily 
organic matter, in the water (Bellar et al. 1974, Rook 1974, Cedergren et al. 
2002, Sadiq and Rodriguez 2004). Several hundred DBPs in over a dozen 
chemical classes have been identified (Woo et al. 2002, Krasner et al. 2006). 
Most commonly, DBPs form when chlorine reacts with naturally occurring 
organic matter in the source water. 
 
DBPs have been associated with both cancer and adverse pregnancy outcomes. 
High DBP levels, mainly for THMs, have been linked to bladder, colon and 
rectal cancer (King and Marrett 1996, Cantor et al. 1998, Amy et al. 2005, 
Villanueva et al. 2004, Villanueva et al. 2007), with bladder cancer reported 
most frequently. Although findings about adverse pregnancy outcomes have 
been less definitive, DBPs have been implicated in fetal loss (Swan et al. 1998, 
Waller et al. 1998, King et al. 2000, Dodds et al. 2004) and a variety of adverse 
birth outcomes involving growth (Bove et al. 1995, Gallagher et al. 1998, 
Wright et al. 2004, Infante-Rivard 2004, Toledano et al. 2005) and birth defects 
(Dodds et al. 1999, Klotz and Pyrch 1999, Dodds and King 2001, Cedergren et 
 NCDM Recommendations Version 3.0  
Page 127   3/19/2013 
al. 2002, Shaw et al. 2003). In contrast, however, other research has found little 
effect on birth outcomes (Savitz et al., 2006). 
 
Animal, microbial, in vitro and modeling studies have also pointed to toxicity 
or carcinogenicity of a wide variety of DBPs (Boorman 1999, Komulainen 
2004). Numerous studies have indicated that different DBPs among the THMs 
and HAAs have different health effects. A number of studies have suggested 
that iodinated and brominated DBPs are more toxic than their chlorinated 
counterparts (Plewa et al. 2002, 2004, Richardson 2005). It is therefore 
appropriate that the tracking network follow individual DBP species and not 
just class totals (c.f. Singer 2006). 
 
Sources of DBPs 
DPB levels tend to be highest in water derived from surface sources because 
ground water generally has little organic matter (Symons et al. 1975, Whitaker 
et al. 2003). Ground water can, however, produce relatively high levels of the 
more brominated DBPs when the water, due either to geological circumstances 
(Whitaker et al. 2003) or salt water intrusion in coastal areas (von Gunten 
2003), has elevated levels of bromide. 
 
Bromate and chlorite are formed primarily after disinfection by ozone and 
chlorine dioxide, respectively. Sampling for these DBPs is required only for 
treatment plants that use the disinfectants that form them. Ozonation and 
chlorine dioxide are less common mechanisms of disinfection so these two 
DBPs will not be tracked initially. The disinfection processes that produce 
these two byproducts are likely to be used more often in the future so bromate 
and chlorite should be considered for eventual incorporation into the tracking 
network. 
 
DBP Regulation and Monitoring 
Safe Drinking Water Act (SDWA) regulation of DBPs began with the 1979 
Total Trihalomethane Rule. This rule set an interim MCL for total 
trihalomethanes (TTHM), defined as the sum of four trihalomethanes, of 0.10 
mg/L for community water systems (CWS) serving 10,000 or more people and 
using a disinfectant. The Stage 1 Disinfectants and Disinfection Byproducts 
Rule of 1998 (US EPA 1998) reduced the MCL for TTHM to 0.080 mg/L, 
added MCLs for the sum of five haloacetic acids (HAA5) of 0.060 mg/L, 
bromate of 0.010 mg/L and chlorite of 1.0 mg/L, and increased the scope of the 
rule to cover all CWS that disinfect. The rule had phased compliance with a 
date of 1 January 2002 for public water systems (PWS) with 10,000 or more 
people with a surface water or ground water under direct influence source and a 
date of 1 January 2004 for all other affected PWSs. The Stage 2 Disinfectants 
and Disinfection Byproducts Rule of 2006 (US EPA 2006) did not alter MCLs 
but did change how compliance with MCLs will be calculated and requires that 
PWSs evaluate their distribution systems for appropriate sampling locations. 
The results of this evaluation may affect the number and location of samples. 
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The scope of the rule also increased to cover consecutive systems that receive 
finished water from other systems. The first reporting deadline for compliance 
with the Stage 2 rule was in 2006 but it will be a number of years before the 
rule requires the new compliance calculations based on routine DBP samples. 
 
Currently, therefore, Safe Drinking Water Act standards exist for two classes of 
halogenated organic DBPs, trihalomethanes (THM) and haloacetic acids 
(HAA), and for two inorganic compounds, bromate and chlorite (US EPA, 
2007). Given the near ubiquity of chlorine disinfection, the THMs and HAAs 
are useful indicators of risk for other DBPs because they occur at high levels 
and are easily measured.  
 
In summary, evidence suggests that disinfection byproducts adversely affect 
human health. The THMs and HAAs are the most commonly formed DBPs that 
are routinely tracked in state Safe Drinking Water Act databases. Measures 
based on these contaminants thus provide a window into potential human 
exposure to DBPs in publicly provided drinking water. They show where 
people are potentially exposed to high levels of DBPs. These water supply 
systems are candidates for enhancement of source water quality, infrastructure 
improvements or other interventions to reduce DBP exposure. 
Use of Measure These measures assist by providing data that can be used for surveillance 
purposes. 
 Distribution measures provide information on the number of CWS and 
the number of people potentially exposed to nitrate at different 
concentrations.  
 Maximum concentrations provide information on the peak potential 
exposure to nitrate at the state level. 
 Mean concentrations at the CWS level provide information on potential 
exposure at a smaller geographic scale.  
 
Limitations of The 
Measure 
The current measures are derived for CWS only. Transient non-community 
water systems, which are regulated by EPA, may also be an important source of 
DBPs exposure.  Measures do not account for the variability in sampling, 
numbers of sampling repeats, and variability within systems.  Concentrations in 
drinking water cannot be directly converted to exposure, because water 
consumption varies by climate, level of physical activity, and between people 
(EPA 2004).  Due to errors in estimating populations, the measures may 
overestimate or underestimate the number of affected people. 
Data Sources State grantee  
Limitations of Data 
Sources 
Safe Drinking Water Act compliance data include only a handful of the 
hundreds of known DBPs (Weinberg et al. 2002), most of which occur in 
chemical classes other than THMs and HAAs. While compliance sampling for 
THMs and HAAs is directed at the DBPs thought to be most commonly 
produced by chlorination, non-regulated DBPs exist even among the THMs and 
HAAs. 
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Concern has also been expressed about iodinated THMs and HAAs which, 
while present in lower concentrations than the brominated and chlorinated 
THMs, are thought to be toxic at lower doses (e.g. Plewa et al. 2004). 
THMs and HAAs may not be the most satisfactory indicators of DBP levels in 
waters subject to alternative disinfection methods that produce different DBPs 
in different proportions than chlorination (Richardson 2002, Weinberg et al. 
2002) and may result in high levels of unregulated DBPs. Little is known about 
the quantitative occurrence of these DBPs in the distribution system 
(Richardson et al. 2002, Krasner et al. 2006). While the health effects of 
different DBPs may vary, with some suspected to be hazardous, few have been 
characterized for their effects on human health (Woo et al. 2002).  
 
Correlations among different DBPs can be relatively low (King et al. 2004, 
Rodriguez et al. 2004a) so that the measured concentrations of THMs and 
HAAs may not be good predictors of exposure to other DBPs or overall DBP 
exposure. THM4 or HAA5, which are the only available data in some state 
databases, may therefore tell little about the relative concentrations of the 
THMs or HAAs. 
 
DBP levels vary seasonally (Singer et al. 1981, Whitaker et al. 2003, Rodriguez 
et al. 2004b). Quarterly samples may not capture maximum levels and may not 
even adequately reflect short term levels. They may therefore be inadequate for 
estimating exposure during critical periods of a pregnancy, which may be as 
short as tow to three weeks, especially if peak exposure matters more than 
average exposure. Furthermore, these fluctuations make it difficult to 
characterize levels with a single number such as an annual average and thus 
pose challenges to the development of meaningful synopses of patterns and 
trends. 
 
DBP levels are spatially and temporally labile within a distribution system 
(Rodriguez et al. 2004b). THM levels increase with time after disinfection and 
therefore with distance from the treatment plant (Chen and Weisel 1998, 
Rodriguez and Sérodes 2001). HAA levels may increase or decrease (Chen and 
Weisel 1998, Rodriguez et al. 2004b), depending upon distribution system 
conditions. Rechlorination further increases DBP levels. For all but small 
distribution systems it is therefore impossible to adequately characterize DBP 
levels with a single value. DBP sampling locations may change over time, 
making it more difficult to compare measurements from year to year. Better 
estimation of DBP levels will require spatial and hydraulic modeling of 
distribution systems. 
Water supply systems sample for DBPs on different schedules that range from 
quarterly to triennially. Different sampling frequencies complicate comparisons 
among different water supply systems. Long intervals between samples, 
although allowed only where THM and HAA levels have been found to be well 
under the MCL, create greater uncertainty about levels between sampling dates 
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and require stronger assumptions when estimating exposure during short term 
events such as pregnancies. When allowed, annual or triennial monitoring takes 
place during the month of warmest weather and may therefore overestimate 
average DBP levels. 
Water supply systems that have disinfection waivers generally have no DBP 
sample results. While the default assumption that these water supply systems 
have DBP concentrations of zero is generally reasonable, low levels of DBPs 
can be found in raw ground water, e.g., from surface contamination or from 
movement of chlorinated water from onsite wastewater treatment systems into 
ground water. 
Human behavior greatly influences exposure, complicating efforts to estimate 
exposure from tap water measurements (Nieuwenhuijen et al. 2000, Kaur et al. 
2004, Nuckols et al. 2005). Among the influences on exposure are showering 
and bathing time, consumption of tap water, use of bottled water, and exposure 
to water at workplaces or other locations outside the home. Moreover, 
ascertaining DBP levels in drinking water does not address other routes of 
exposure such as swimming (Villanueva et al. 2007, Zwiener et al. 2007). This 
consideration is not strictly a limitation of the measure but pertains to using the 
measure as an indicator of exposure. 
Some state SDWA databases may contain only totals for THMs and HAAs and 
may not record sample results for individual DBPs. Measures involving 
individual THMs and HAAs cannot be calculated for these states. 
Related Indicators Public Water Use 
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CONTENT DOMAIN: COMMUNITY WATER   
INDICATOR: NITRATE  
ENVIRONMENTAL PUBLIC HEALTH TRACKING 
Type of EPHT 
Indicator 
Hazard, Exposure 
Measures Level of Contaminant in Finished Water 
15. Quarterly distribution of number of Community Water Systems (CWS) by 
mean nitrate concentration (cut-points: (0-3), (>3-5), (>5-10), (>10-20), (>20) 
mg/L nitrate). 
16. Yearly distribution of number of CWS by maximum nitrate concentration 
(cut-points: (0-3), (>3-5), (>5-10), (>10-20), (>20) mg/L nitrate). 
17. Yearly distribution of number of CWS by mean nitrate concentration (cut-
points:  (0-3), (>3-5), (>5-10), (>10-20), (>20) mg/L nitrate). 
18. Mean concentration of nitrate at CWS-level, by year. 
 
Potential Population Exposure to Contaminants in Finished Water 
19. Quarterly distribution of number of people served by CWS by mean nitrate 
concentration (cut-points:  (0-3), (>3-5), (>5-10), (>10-20), (>20) mg/L 
nitrate). 
20. Yearly distribution of number of people served by CWS by maximum nitrate 
concentration (cut-points:   (0-3), (>3-5), (>5-10), (>10-20), (>20) mg/L 
nitrate). 
21. Yearly distribution of number of people served by CWS by mean nitrate 
concentration (cut-points: (0-3), (>3-5), (>5-10), (>10-20), (>20) mg/L 
nitrate). 
Derivation of 
Measures 
Nitrate measures will be developed from water system attribute and water quality data 
stored in state Safe Drinking Water Act (SDWA) databases such as the Safe Drinking 
Water Information System (SDWIS/State). Data will be cleaned and transformed to a 
standard format. Analytical results of drinking water samples (usually taken at entry 
points to the distribution system or representative sampling points after treatment) 
will be used in conjunction with information about each CWS (such as service 
population and latitude and longitude of representative location of the CWS service 
area) to generate the measures.   
Units Concentration of nitrate, mg/L 
Geographic Scope State and Community Water System by County 
Geographic Scale The finest detail will be approximate point location of the community water 
distribution system represented by water withdrawal point, water distribution extents, 
principal county served, or principal city served.  
Time Period 1999 or earliest year available to most current year of data abstraction. 
Time Scale Calendar year 
Rationale Nitrates and Public Health 
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Nitrate was first identified as a public health threat in drinking water in 1945 when 
high nitrate levels from private wells were shown to cause methemoglobinemia or 
“blue baby syndrome” in infants who received formula made from well water. When 
an individual is exposed to nitrate it can be converted to nitrite (NO2
-
) in the body 
and then oxidize the ferrous iron (Fe
+2
) in deoxyhemoglobin in the blood to form 
methemoglobin containing ferric iron (Fe
+3
).  Methemoglobin cannot transfer oxygen 
to tissues; thus nitrate or nitrite can starve the body of oxygen and produce a clinical 
condition known as cyanosis, where the lips and extremities turn gray or blue.  Infants 
younger than four months of age are more sensitive than adults, and can develop 
“blue baby” syndrome from intake of nitrate higher than 10 mg/L nitrate or 45 mg/L 
nitrate–nitrogen.  Blue baby syndrome is fatal in about ten percent of the cases 
(ATSDR, 2007).  Usually there are no outward signs of cyanosis at methemoglobin 
levels below 20 percent (Dabney et al, 1990).  
In addition, there is some evidence to suggest that exposure to nitrate in drinking 
water is also associated with adverse reproductive outcomes such as spontaneous 
abortions, intrauterine growth retardation, and various birth defects such as 
anencephaly, related to fetal exposures to nitrate. However, the evidence is 
inconsistent (Manassaram et al, 2006).   
Similarly, long term exposure to higher nitrate levels in drinking water has been 
suggested as a risk factor for cancer.  Cancer at several sites (i.e. gastric, colorectal, 
bladder, urothelial, brain, esophagus, ovarian and non-Hodgkins lymphoma  have 
been shown to be associated with nitrate in drinking water in some studies  (Sandor et 
al, 2001; Weyer et al, 2001; Gulis et al, 2002; De Roos et al, 2003; Volkmer et al, 
2005; Ward et al, 2005b; Chiu et al, 2007; ). Other studies have not found any 
association (Ward et al, 2003; Ward et al, 2005, 2005c; Ward et al, 2006; Zeegers et 
al, 2006).  Significant regional differences in cancer risk may occur (Mueller et al, 
2001). Occupational exposures are also of concern as nitrate fertilizer workers have 
shown increased risk for stomach cancer (Zandjani et al. 1994). 
Sources of Nitrate 
Nitrate is the most commonly found contaminant in groundwater aquifers worldwide 
(Ward, 2005  from: Spalding and Exner 1993). Nitrate (NO3
-
) originates in drinking 
water from nitrate-containing fertilizers, sewage and septic tanks, and decaying 
natural material such as animal waste. Nitrate is very soluble in water, can easily 
migrate, and does not evaporate (EPA Consumer Fact Sheet). Anthropogenic sources 
of nitrates are increasing resulting in increased nitrate levels in water resources.  
Surface water and shallow wells in both rural and urban areas can be affected. 
Consequently, private wells are especially vulnerable to excess levels of nitrates.  
Excess levels of nitrate and nitrite can occur in community water supplies. A U.S. 
Geological Survey (USGS) study found nitrate levels exceeded regulatory monitoring 
standards in 2% of a sample of 242 public drinking water wells between 1992 and 
1999 (Squillace et al, 2002). Levels of nitrates in private wells are less well known; 
private wells are not regularly monitored and are often more vulnerable to higher 
levels of nitrates because they draw water from shallower groundwater aquifers. The 
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USGS estimates approximately 22% of domestic wells in agricultural areas of the 
U.S. exceed the MCL (Ward, 2007).   
Nitrate Regulation and Monitoring 
Congress established the Safe Drinking Water Act in 1974, which set enforceable 
Maximum Contaminant Levels (MCLs) and non-enforceable Maximum Contaminant 
Level Goals (MCLGs) for certain specified contaminants.  In the case of nitrate in 
drinking water, the MCLG of 10 mg/L (ppm) was established from human data from 
studies of methemoglobinemia in young children. (Johnson and Kross 1990; Walton, 
1950).  The MCL is also set at 10 ppm, and any exceedance of the MCL is potentially 
serious as there is no additional margin of safety between the MCLG and the MCL. 
2002).  The MCLG and MCL for nitrite are 1 mg/L.  While evidence to suggest MCL 
exposures for chronic health endpoints remains inconclusive, there is some evidence 
to suggest that chronic exposure to nitrate levels below the MCL may be of concern 
(Ward, 2005). 
Use of Measure These measures assist by providing data that can be used for surveillance purposes. 
 Distribution measures provide information on the number of CWS and the 
number of people potentially exposed to nitrate at different concentrations.  
 Maximum concentrations provide information on the peak potential exposure 
to nitrate at the state level. 
 Mean concentrations at the CWS level provide information on potential 
exposure at a smaller geographic scale.  
 
Limitations of The 
Measure 
The current measures are derived for CWS only. Private wells are another important 
source of population exposure to nitrate. Transient non-community water systems, 
which are regulated by EPA, may also be an important source of nitrate exposure.  
Measures do not account for the variability in sampling, numbers of sampling repeats, 
and variability within systems.  Concentrations in drinking water cannot be directly 
converted to exposure, because water consumption varies by climate, level of 
physical activity, and between people (EPA 2004).  Due to errors in estimating 
populations, the measures may overestimate or underestimate the number of affected 
people. 
Data Sources State grantee  
Limitations of Data 
Sources 
Nitrate levels can vary substantially in groundwater; thus high levels may not be 
captured by even quarterly sampling. Estimates of the number of people potentially 
exposed may be unreliable as they are based on estimates made by the water system 
operator. Concentrations in drinking water cannot be directly converted to exposure 
because overall water consumption, and the proportion of water consumed that comes 
from the tap is quite variable (EPA 2004). In systems that have more than one Entry 
point to the Distribution system, the actual nitrate level at any given house is a 
mixture of the levels from all contributing sources. Compliance samples are taken at 
each entry point to the distribution system.  In systems with separate wells serving 
some branches or sections of the distribution system, the system mean would tend to 
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underestimate the nitrate concentration of people served by wells with higher nitrate 
concentrations. 
Exposure may be higher or lower than estimated if data from multiple entry points for 
water with different nitrate levels are averaged to estimate levels for the PWS. 
Related Indicators Public Water Use 
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CONTENT DOMAIN: COMMUNITY WATER   
INDICATOR: PUBLIC WATER USE  
ENVIRONMENTAL PUBLIC HEALTH TRACKING 
Type of EPHT Indicator Exposure 
Measures 22. Number of people receiving water from community water systems. 
 
Derivation of Measures This measure will be developed from water system attribute and water quality 
data stored in state Safe Drinking Water Act (SDWA) databases such as the 
Safe Drinking Water Information System (SDWIS/State). Data will be cleaned 
and transformed to a standard format.  
Units 1. Number of people 
Geographic Scope State  
Geographic Scale State 
Time Period 2009 or earliest year available to most current year of data abstraction.  
Time Scale Calendar year 
Rationale Public Water Use and Public Health 
The public water use index provides some data to explore the relative 
importance of community water supplies as sources of drinking water and to 
provide context for subsequent community drinking water system (CWS) 
indicators. SDWA collects data for a number of different types of public water 
systems of which community water systems (CWS) are a sub-set. The 
community water systems represent non-transient public water systems that 
serve year round community residents and are the focus of the initial indicators. 
The range of state populations served by CWS as their primary residential 
drinking water source varies from 95% to as low as 40% within the United 
States. Understanding the relative population coverage of these indicators by 
state helps to understand representativeness of these data for prioritization and 
evaluation across the United States and within individual states and 
communities. 
Use of Measure This measure can be useful in providing data for surveillance purposes.  
 
• Estimated population potentially exposed to contaminants in CWS.   
 
Limitations of The 
Measure 
The current measure is derived for CWS only. Private wells are another 
important source of population exposure to water contaminants. Transient non-
community water systems, which are regulated by EPA, may also be an 
important source of potential exposure.   
Data Sources State grantee 
Limitations of Data 
Sources 
Population estimates are rough and may overestimate or underestimate the 
number of affected people. 
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Related Indicators All other community water indicators. 
Additional Information  1. U.S. Environmental Protection Agency, Water On Tap, Office of Water (4601) 
EPA 816-K-09-002,  December 2009.  
http://water.epa.gov/drink/guide/upload/book_waterontap_full.pdf 
 
2. U.S. Environmental Protection Agency, Public Drinking Water Systems: Facts 
and Figures 
http://water.epa.gov/infrastructure/drinkingwater/pws/factoids.cfm 
 
3. U.S. Environmental Protection Agency, Public Drinking Water Systems 
Programs.  http://water.epa.gov/infrastructure/drinkingwater/pws/index.cfm 
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CONTENT DOMAIN: COMMUNITY WATER   
INDICATOR:  COMBINED RADIUM-226 AND -228  
ENVIRONMENTAL PUBLIC HEALTH TRACKING 
Type of EPHT 
Indicator 
Hazard, Exposure 
Measures Level of Contaminant in Finished Water 
1. Yearly distribution of number of Community Water Systems (CWS) by 
maximum Radium concentration (cut-points: 0-3, >3-5, >5-10, >10 pCi/L 
Radium). 
2. Yearly distribution of number of CWS by mean Radium concentration 
(cut-points:  cut-points: 0-3, >3-5, >5-10, >10 pCi/L Radium). 
3. Mean concentration of Radium at CWS-level, by year. 
 
Potential Population Exposure to Contaminants in Finished Water 
4. Yearly distribution of number of people served by CWS by maximum 
Radium concentration (cut-points: 0-3, >3-5, >5-10, >10 pCi/L Radium). 
5. Yearly distribution of number of people served by CWS by mean Radium 
concentration (cut-points: 0-3, >3-5, >5-10, >10 pCi/L Radium). 
Derivation of Measures Combined Radium-226 and -228 measures will be developed from water system 
attribute and water quality data stored in state Safe Drinking Water Act (SDWA) 
databases such as the Safe Drinking Water Information System (SDWIS/State). 
Data will be cleaned and transformed to a standard format. Analytical results of 
drinking water samples (usually taken at entry points to the distribution system or 
representative sampling points after treatment) will be used in conjunction with 
information about each CWS (such as service population and latitude and 
longitude of representative location of the CWS service area) to generate the 
measures.   
Units pCi/L combined Radium-226 & -228 
Geographic Scope State and Community Water System by County 
Geographic Scale The finest detail will be approximate point location of the community water 
distribution system represented by water withdrawal point, water distribution 
extents, principal county served, or principal city served.  
Time Period 1999 or earliest year available to most current year of data abstraction. 
Time Scale Calendar year 
 
Rationale 
 
Radium-226 and -228 and Public Health  
Radium is a naturally occurring silvery-white radioactive metal that can exist in 
several forms called isotopes. Radium is produced constantly by the radioactive 
decay of uranium and thorium. Uranium and thorium are found in small amounts 
in most rocks and soil. Some of the radiation from radium is being released 
constantly into the environment. It is this radioactive decay that causes concern 
 NCDM Recommendations Version 3.0  
Page 142   3/19/2013 
about the safety of radium and all other radioactive substances. Two of the main 
radium isotopes found in the environment are radium-226 and radium-228. The 
decay of radium-226 results in the formation of radon which exists as a gas and is 
mobile in environmental media. Radium has been used as a radiation source for 
treating cancer, in radiography of metals, and combined with other metals as a 
neutron source for research and radiation instrument calibration. Until the 1960s, 
radium was a component of the luminous paints used for watch and clock dials, 
instrument panels in airplanes, military instruments, and compasses (ATSDR, 
2010). 
 
Everyone is exposed to low levels of radium in the air, water, and food.  Higher 
levels may be found in the air near industries that burn coal or other fuels or near 
sites that mine or mill uranium.  It also may be found at higher levels in drinking 
water from groundwater wells. Miners, particularly miners of uranium and hard 
rock, are exposed to higher levels of radium. It may also be found at radioactive 
waste disposal sites (ATSDR, 1990). 
 
It is not known whether long-term exposure to radium at the levels that are 
normally present in the environment (for example, 1 pCi of radium per gram of 
soil) is likely to result in harmful health effects. However, exposure to higher 
levels of radium over a long period of time may result in harmful effects 
including anemia, cataracts, fractured teeth, cancer (especially bone cancer), and 
death.  Patients who were injected with radium in Germany, from 1946 to 1950, 
for the treatment of certain diseases including tuberculosis were significantly 
shorter as adults than people who were not treated. Some of these health effects 
may take years to develop and mostly are due to gamma radiation. Radium gives 
off gamma radiation, which can travel fairly long distances through air. 
Therefore, just being near radium at the high levels that may be found at some 
hazardous waste sites may be dangerous to your health.  
 
Exposure to high levels of radium results in an increased incidence of bone, liver, 
and breast cancer. The EPA and the National Academy of Sciences, Committee 
on Biological Effects of Ionizing Radiation, has stated that radium is a known 
human carcinogen. 
 
 
Biomonitoring Information 
Urine tests can determine if you have been exposed to radium. Another test 
measures the amount of radon (a breakdown product of radium) in exhaled air. 
Both types of tests require special equipment and cannot be done in a doctor's 
office. These tests cannot tell how much radium you were exposed to, nor can 
they be used to predict whether you will develop harmful health effects (ATSDR, 
1990).  Levels of radium in the U.S. population are unknown.   
 
Sources of Radium 
Radium forms from the decay of uranium or thorium in the environment.  
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Radium -226 is formed from the decay of uranium-238; Radium-228 is formed 
from the decay of thorium.  Radium is abundant in low levels everywhere 
because it originates from uranium which is commonly found in all rocks, soil 
and water.  (EPA, 2010) 
 
Radium Regulation and Monitoring 
The EPA has set a drinking water limit of 5 picocuries per liter (5 pCi/L) for 
radium-226 and radium-228 (combined) (EPA, 2009).  A gross alpha particle 
activity measurement may be substituted for the required radium-226 
measurement provided that the measured gross alpha particle activity does not 
exceed 5 pCi/L.  The EPA lifetime exposure cancer risk estimate for radium at 
the MCL, is approximately 1-2 cases per 10,000 people.  
 
Monitoring frequency 
Once a CWS has satisfied initial monitoring requirements (4 quarterly samples at 
every entry point to the distribution system within the first quarter after initiating 
the source); the required frequency for Combined Radium-226 and -228 
monitoring is once every three years if the average of the initial monitoring 
results for the contaminant is greater than one-half the MCL but at or below the 
MCL.  States may allow CWS to reduce the frequency of monitoring from once 
every three years to once every six or nine years at each sampling point, if the 
average of the initial monitoring results for each contaminant is below the 
detection limit. If a system has a monitoring result that exceeds the MCL while 
on reduced monitoring, the system must collect and analyze quarterly samples at 
that sampling point until the system has results from four consecutive quarters 
that are below the MCL, unless the system enters into another schedule as part of 
a formal compliance agreement with the State (CFR, 2002). 
 
Use of Measure These measures assist by providing data that can be used for surveillance 
purposes. 
• Distribution measures provide information on the number of CWS and the 
   number of people potentially exposed to combined Radium-226 and -228 at  
  different concentrations.  
• Maximum concentrations provide information on the peak potential  
   exposure to combined Radium-226 and -228 at the state level. 
• Mean concentrations at the CWS level provide information on potential  
   exposure at a smaller geographic scale.  
Limitations of The 
Measure 
The current measures are derived for CWS only. Private wells may be another 
source of population exposure to combined Radium-226 and -228.  Transient 
non-community water systems, which are regulated by EPA, may also be an 
important source of combined Radium-226 and -228 exposure.  Measures do not 
account for the variability in sampling, numbers of sampling repeats, and 
variability within systems.  Concentrations in drinking water cannot be directly 
converted to exposure, because water consumption varies by climate, level of 
physical activity, and between people (EPA 2004).  Due to errors in estimating 
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populations, the measures may overestimate or underestimate the number of 
affected people. 
Data Sources State grantee  
Limitations of Data 
Sources 
The required monitoring frequency for combined Radium-226 and -228 is 
infrequent and may be as intermittent as every nine years; therefore most states 
will have very little data on this contaminant.   
Ground water systems may have multiple wells with different combined Radium-
226 and -228 concentrations that serve different parts of the population. 
Compliance samples are taken at each entry point to the distribution system.  In 
systems with separate wells serving some branches or sections of the distribution 
system, the system mean would tend to underestimate the combined Radium-226 
and -228 concentrations of people served by wells with higher combined 
Radium-226 and -228 concentrations.  Exposure may be higher or lower than 
estimated if data from multiple entry points for water with different combined 
Radium-226 and -228 levels are averaged to estimate levels for the PWS. 
Related Indicators Public Water Use; Uranium 
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CONTENT DOMAIN: COMMUNITY WATER   
INDICATOR:  TETRACHLOROETHENE (TETRACHLOROETHYLENE) (PCE)  
ENVIRONMENTAL PUBLIC HEALTH TRACKING 
Type of EPHT Indicator Hazard, Exposure 
Measures Level of Contaminant in Finished Water 
6. Yearly distribution of number of Community Water Systems (CWS) by 
maximum PCE concentration (cut-points: 0-1, >1-2, >2-5, >5 µg/L 
PCE). 
7. Yearly distribution of number of CWS by mean PCE concentration 
(cut-points:  0-1, >1-2, >2-5, >5 µg/L PCE). 
8. Mean concentration of PCE at CWS-level, by year. 
 
Potential Population Exposure to Contaminants in Finished Water 
9. Yearly distribution of number of people served by CWS by maximum 
PCE concentration (cut-points: 0-1, >1-2, >2-5, >5 µg/L PCE). 
10. Yearly distribution of number of people served by CWS by mean PCE 
concentration (cut-points: 0-1, >1-2, >2-5, >5 µg/L PCE). 
Derivation of Measures PCE measures will be developed from water system attribute and water quality 
data stored in state Safe Drinking Water Act (SDWA) databases such as the 
Safe Drinking Water Information System (SDWIS/State). Data will be cleaned 
and transformed to a standard format. Analytical results of drinking water 
samples (usually taken at entry points to the distribution system or 
representative sampling points after treatment) will be used in conjunction with 
information about each CWS (such as service population and latitude and 
longitude of representative location of the CWS service area) to generate the 
measures.   
Units PCE, µg/L 
Geographic Scope State and Community Water System by County 
Geographic Scale The finest detail will be the approximate point location of the community water 
distribution system represented by water withdrawal point, water distribution 
extents, principal county served, or principal city served.  
Time Period 1999 or earliest year available to most current year of data abstraction. 
Time Scale Calendar year 
 
Rationale 
Tetrachloroethene (PCE) and Public Health 
Tetrachloroethene (PCE) is a volatile halogenated short-chain hydrocarbon. 
Tetrachloroethene is used in dry cleaning, metal cleaning, the synthesis of other 
chemicals, and household products such as water repellants, silicone lubricants, 
and spot removers. PCE is produced and used in high volumes in the U.S. and 
has been detected in urban and ambient air and occasionally in soils and 
drinking water most likely contaminated by industrial discharge (Moran et al., 
2007; Rowe et al., 2007). Because of its volatility, this solvent does not persist 
in the soil or water following the discontinuation of contamination.  
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Inhalation is the most common exposure route for the general population 
including indoor sources from paints, adhesives, and cleaning solutions. 
Volatilization from contaminated water (e.g., shower water) as well as the use 
of household products containing this solvent can result in higher indoor than 
outdoor air concentrations (ATSDR, 1997; Martin et al., 2005). Nearby dry 
cleaning establishments, industries producing PCE, and contaminated waste 
disposal sites can also contribute to human exposure (Armstrong and Green, 
2004; ATSDR, 1997 and 2000; Schreiber et al., 1993; Wallace et al., 1991). 
Drinking water may contribute to exposure when underground drinking water 
supplies have been contaminated. Workers in industries such as dry cleaning, 
aircraft maintenance, electronics manufacturing, and chemical production may 
be exposed by inhalation or by dermal contact with PCE. The EPA has 
established drinking water standards and other environmental standards for 
PCE, and the FDA regulates PCE and trichloroethene as indirect food additives. 
Workplace standards have been established by OSHA, and ACGIH has 
recommended occupational guidelines and biological exposure indices for 
monitoring workers. Human health effects from PCE at low environmental 
doses or at biomonitored levels from low environmental exposures are 
unknown. PCE is well absorbed by ingestion and inhalation, and animal studies 
have demonstrated that liquid forms can be dermally absorbed. Following 
absorption, part of the solvent dose is excreted into expired air; for PCE, about 
97-99% of the dose is eliminated unmetabolized into expired air, though it has 
an elimination half-life of several days (ATSDR 1997; Monster, 1986). The 
retained solvent can undergo hepatic metabolism. PCE is metabolized to 
trichloroacetic acid and trichloroethanol, which are eliminated in the urine.  
Accidental or intentional high dose acute exposure by ingestion or inhalation 
can result in loss of motor coordination, somnolence, and unconsciousness. 
Inhaling high doses of PCE may also produce cardiac arrhythmias attributed to 
enhanced sensitivity to catecholamines. High dose acute exposure to PCE has 
resulted in reversible kidney impairment, and prolonged, low level PCE 
exposure has been associated with altered renal enzyme excretion and liver 
enlargement (ATSDR, 1997). Chronic occupational exposure to PCE may be 
associated with mild degrees of neurological impairments, including reaction 
times, verbal skills, cognitive ability, and motor function (Armstrong and 
Green, 2004). Various epidemiologic studies of chronic PCE exposure in dry 
cleaning workers found increased incidences of esophageal and cervical 
cancers and non-Hodgkins lymphoma, but confounding exposures (e.g., other 
solvents and trichloroethene) were likely (IPCS, 2006). In animal studies, PCE-
induced kidney and liver tumors and caused leukemia (IARC, 1995). IARC 
classifies PCE as a probable human carcinogen, and NTP classifies it as 
reasonably anticipated to be a human carcinogen (IARC, 1995; NTP, 2004).  
Additional information about these solvents is available from ATSDR at: 
http://www.atsdr.cdc.gov/toxpro2.html. 
 
 In an analysis of occurrence data from the EPA 6 Year Review of National 
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Primary Drinking Water Regulations, PCE was detected in 1,262 systems 
serving close to 32 million people (EPA, 2009). Concentrations of PCE were 
greater than the MCL in 241 systems serving close to 15 million people.  PCE 
was the fifth highest occurring regulated volatile organic chemical found based 
on the percent of detections found from the 6 Year Review data (EPA, 2009).    
 
Biomonitoring Information 
Levels of halogenated solvents in blood reflect recent exposure. In the 
NHANES 2003-2004 subsample, the level of blood PCE for adults at the 75th 
percentile of the U.S. population appear similar to the levels at the 75th 
percentile reported for non-smoking adults in a subsample of NHANES 1999-
2000 participants (CDC, 2009; Lin et al., 2008) and were similar or slightly less 
than levels reported in a nonrepresentative subsample of the earlier NHANES 
III (1988-1994) (Ashley et al., 1994; Churchill et al., 2001). A recent study of 
low income, urban children in the Midwest reported slightly lower median PCE 
levels (Sexton et al., 2005; Sexton et al., 2006) than the NHANES III levels 
(Ashley et al., 1994; Churchill et al., 2001). 
 
Comparatively higher blood levels of PCE and trichloroethene have been noted 
for urban and industrial residential settings than for rural settings (Barkley et 
al., 1980; Begerow et al., 1996; Brugnone et al., 1994). Residing near dry-
cleaning facilities or storing recently dry-cleaned clothes at home can 
contribute to increased blood PCE levels (Begerow et al., 1996; Popp et al., 
1992). In contrast, PCE blood levels in occupationally exposed workers have 
been reported to be many thousand times higher than the general population 
(Begerow et al., 1996; Furuki et al., 2000; Monster et al., 1983). The 
occupational biological exposure index associated with an 8-hour exposure of 
25 ppm is 500 μg/L PCE in blood (ACGIH, 2007). Non-occupational exposures 
are usually well below this level. Finding a measurable amount of any of these 
solvents in blood does not mean that the level of the solvent causes an adverse 
health effect. Biomonitoring studies of blood halogenated solvents can provide 
physicians and public health officials with reference values so that they can 
determine whether or not people have been exposed to higher levels of 
halogenated solvents than levels found in the general population. 
Biomonitoring data can also help scientists plan and conduct research on 
exposure and health effects. 
 
Sources of PCE 
The major source of PCE in drinking water is discharge from factories and dry 
cleaners. A federal law called the Emergency Planning and Community Right 
to Know Act requires facilities in certain industries, which manufacture, 
process, or use significant amounts of toxic chemicals, to report annually on 
their releases of these chemicals. For more information on the uses and releases 
of chemicals in your state, contact the Community Right-to-Know Hotline: 
(800) 424-9346 (EPA, 2010). 
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PCE Regulation and Monitoring 
The EPA limits the amount of PCE that may be present in drinking water to 5 
parts of PCE per billion parts of water (5 ppb), or 5 ug/L. 
Use of Measure These measures assist by providing data that can be used for surveillance 
purposes. 
• Distribution measures provide information on the number of CWS and the 
   number of people potentially exposed to PCE at different 
   concentrations.  
• Maximum concentrations provide information on the peak potential  
   exposure to PCE at the state level. 
• Mean concentrations at the CWS level provide information on potential  
   exposure at a smaller geographic scale.  
Limitations of The 
Measure 
The current measures are derived for CWS only. Private wells may be another 
source of population exposure to PCE.  Transient non-community water 
systems, which are regulated by EPA, also may be an important source of PCE 
exposure.  Measures do not account for the variability in sampling, numbers of 
sampling repeats, and variability within systems.  Concentrations in drinking 
water cannot be directly converted to exposure, because water consumption 
varies by climate, level of physical activity, and between people (EPA 2004).  
Due to errors in estimating populations, the measures may overestimate or 
underestimate the number of affected people. 
 
Data Sources State grantee  
Limitations of Data 
Sources 
Ground water systems may have multiple wells with different PCE 
concentrations that serve different parts of the population. Compliance samples 
are taken at each entry point to the distribution system.  In systems with 
separate wells serving some branches or sections of the distribution system, the 
system mean would tend to underestimate the PCE concentration of people 
served by wells with higher PCE concentrations.  Exposure may be higher or 
lower than estimated if data from multiple entry points for water with different 
PCE levels are averaged to estimate levels for the PWS. 
Related Indicators Public Water Use 
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CONTENT DOMAIN: COMMUNITY WATER   
INDICATOR:  TRICHLOROETHENE (TRICHLOROETHYLENE) (TCE)  
ENVIRONMENTAL PUBLIC HEALTH TRACKING 
Type of EPHT Indicator Hazard, Exposure 
Measures Level of Contaminant in Finished Water 
3. Yearly distribution of number of CWS by maximum TCE concentration 
(cut-points: 0-1, >1-2, >2-5, >5 µg/L TCE). 
4. Yearly distribution of number of CWS by mean TCE concentration (cut-
points:  0-1, >1-2, >2-5, >5 µg/L TCE). 
5. Mean concentration of TCE at CWS-level, by year. 
 
Potential Population Exposure to Contaminants in Finished Water 
6. Yearly distribution of number of people served by CWS by maximum 
TCE concentration (cut-points: 0-1, >1-2, >2-5, >5 µg/L TCE). 
7. Yearly distribution of number of people served by CWS by mean TCE 
concentration (cut-points: 0-1, >1-2, >2-5, >5 µg/L TCE). 
Derivation of Measures TCE measures will be developed from water system attribute and water quality 
data stored in state Safe Drinking Water Act (SDWA) databases such as the 
Safe Drinking Water Information System (SDWIS/State). Data will be cleaned 
and transformed to a standard format. Analytical results of drinking water 
samples (usually taken at entry points to the distribution system or 
representative sampling points after treatment) will be used in conjunction with 
information about each CWS (such as service population and latitude and 
longitude of representative location of the CWS service area) to generate the 
measures.   
Units  TCE, µg/L 
Geographic Scope State and Community Water System by County 
Geographic Scale The finest detail will be the approximate point location of the community water 
distribution system represented by water withdrawal point, water distribution 
extents, principal county served, or principal city served.  
Time Period 1999 or earliest year available to most current year of data abstraction. 
Time Scale Calendar year 
 
 
Rationale 
Trichloroethene (TCE) and Public Health 
Trichloroethene (TCE) is a volatile halogenated short-chain hydrocarbon. TCE 
is used primarily as an industrial degreaser, solvent, and in the synthesis of 
other chemicals. In the past, it was used in dry cleaning, food processing, 
household cleaners, and as a general anesthetic. TCE is produced and used in 
high volumes in the U.S. and has been detected in urban and ambient air and 
occasionally soils and drinking water most likely contaminated by industrial 
discharge (Moran et al., 2007; Rowe et al., 2007). Because of its volatility, this 
solvent does not persist in the soil or water following the discontinuation of 
contamination.  
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Drinking or breathing high levels of TCE may cause nervous system effects, 
liver and lung damage, abnormal heartbeat, coma, and possibly death (ATSDR, 
2003). Inhalation is the most common exposure route for the general population 
including indoor sources from paints, adhesives, and cleaning solutions. 
Volatilization from contaminated water (e.g., shower water) as well as the use 
of household products containing this solvent can result in higher indoor than 
outdoor air concentrations (ATSDR, 1997b; Martin et al., 2005). Nearby dry 
cleaning establishments, industries producing this solvent, and contaminated 
waste disposal sites can also contribute to human exposure (Armstrong and 
Green, 2004; ATSDR, 1997a, 1997b, and 2000; Schreiber et al., 1993; Wallace 
et al., 1991). Drinking water may contribute to exposure when underground 
drinking water supplies have been contaminated. Workers in industries such as 
dry cleaning, aircraft maintenance, electronics manufacturing, and chemical 
production may be exposed by inhalation or dermal contact.  The EPA has 
established drinking water standards and other environmental standards for 
TCE, and the FDA regulates TCE as an indirect food additive. OSHA has 
established workplace standards , and ACGIH has recommended occupational 
guidelines and biological exposure indices for monitoring workers (ACGIH, 
2007). Human health effects from TCE at low environmental doses or at 
biomonitored levels from low environmental exposures are unknown. TCE is 
well absorbed by ingestion and inhalation, and animal studies have 
demonstrated that liquid forms can be dermally absorbed. Following 
absorption, part of the solvent dose is excreted into expired air (ATSDR1997a; 
Monster, 1986). The retained solvent can undergo hepatic metabolism. TCE is 
metabolized to trichloroacetic acid and tricholoroethanol, which are eliminated 
in the urine.  Accidental or intentional high dose acute exposure by ingestion or 
inhalation can result in loss of motor coordination, somnolence, and 
unconsciousness. Inhaling high doses of TCE may also produce cardiac 
arrhythmias attributed to enhanced sensitivity to catecholamines. Prolonged, 
low level exposure to TCE has been associated with altered renal enzyme 
excretion and liver enlargement (ATSDR, 1997a, b). Chronic occupational 
exposure to TCE may be associated with mild degrees of neurological 
impairments, including reaction times, verbal skills, cognitive ability and motor 
function (Armstrong and Green, 2004). In animal studies, TCE induced kidney 
and liver tumors; and caused lung and testicular tumors (IARC, 1995). A recent 
EPA toxicological review (EPA/635/R-09/011F) characterized TCE as 
carcinogenic in humans by all routes of exposure (EPA, 2011).  For cancer, the 
inhalation unit risk is 2 × 10
-2
 per ppm [4 × 10
-6
 per μg/m3], based on human 
kidney cancer risks (Charbotel et al.; 2006) and adjusted, using human 
epidemiologic data, for potential risk for non-Hodgkin lymphoma (NHL) and 
liver cancer. The oral unit risk for cancer is 5 × 10
-2
 per mg/kg/day, resulting 
from physiologically based pharmacokinetic model-based route-to-route 
extrapolation of the inhalation unit risk based on the human kidney cancer risks 
(Charbotel et al. 2006) and adjusted, using human epidemiologic data, for 
potential risk for NHL and liver cancer. There is high confidence in these unit 
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risks for cancer, as they are based on good quality human data, as well as being 
similar to unit risk estimates based on multiple rodent bioassays. Evidence is 
sufficient  to conclude that TCE operates through a mutagenic mode of action 
for kidney tumors.  Evidence is insufficient and TCE-specific quantitative data 
are lacking on early-life susceptibility.  
Additional information about TCE is available from ATSDR at: 
http://www.atsdr.cdc.gov/toxpro2.html. 
 
In an analysis of occurrence data from the EPA 6 Year Review of National 
Primary Drinking Water Regulations, TCE was detected in 1,013 systems 
serving 29.5 million people (EPA, 2009). Concentrations of TCE were greater 
than the MCL in 195 systems serving close to 12 million people.  TCE was the 
fifth highest occurring regulated volatile organic chemical found based on the 
percent of population served by systems with at least one sample detection 
found from the 6 Year Review data (EPA, 2009).    
 
Biomonitoring Information 
Levels of halogenated solvents in blood reflect recent exposure. Blood levels of 
TCE were generally not detected in the NHANES 2003-2004 subsample and 
were detected infrequently in previous U.S. surveys (CDC, 2009).   
 
Comparatively higher blood levels of tetrachloroethene and TCE have been 
noted for urban and industrial residential settings than for rural settings 
(Barkley et al., 1980; Begerow et al., 1996; Brugnone et al., 1994). Finding a 
measurable amount of any of these solvents in blood does not mean that the 
level of the solvent causes an adverse health effect. Biomonitoring studies of 
blood halogenated solvents can provide physicians and public health officials 
with reference values so that they can determine whether people have been 
exposed to higher levels of halogenated solvents than levels found in the 
general population. Biomonitoring data can also help scientists plan and 
conduct research on exposure and health effects. 
 
Sources of TCE 
TCE does not occur naturally in the environment. However, it has been found 
in underground water sources and many surface waters as a result of the 
manufacture, use, and disposal of the chemical (ATSDR, 2003).  
TCE Regulation and Monitoring 
The EPA has set a maximum contaminant level for TCE in drinking water of 
0.005 milligrams per liter (0.005 mg/L) or 5 parts of TCE per billion parts 
water. The EPA has also developed regulations for the handling and disposal of 
trichloroethylene. 
OSHA has set an exposure limit of 100 parts of TCE per million parts of air 
(100 ppm) for an 8-hour workday, 40-hour work week (ATSDR, 2003). 
Use of Measure These measures assist by providing data that can be used for surveillance 
purposes. 
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• Distribution measures provide information on the number of CWS and the 
   number of people potentially exposed to TCE at different 
   concentrations.  
• Maximum concentrations provide information on the peak potential  
   exposure to TCE at the state level. 
• Mean concentrations at the CWS level provide information on potential  
   exposure at a smaller geographic scale.  
Limitations of The 
Measure 
The current measures are derived for CWS only. Private wells may be another 
source of population exposure to TCE.  Transient non-community water 
systems, which are regulated by EPA, also may be an important source of TCE 
exposure.  Measures do not account for the variability in sampling, numbers of 
sampling repeats, and variability within systems.  Concentrations in drinking 
water cannot be directly converted to exposure because water consumption 
varies by climate, level of physical activity, and between people (EPA 2004).  
Due to errors in estimating populations, the measures may overestimate or 
underestimate the number of affected people. 
 
Data Sources State grantee  
Limitations of Data 
Sources 
Ground water systems may have multiple wells with different TCE 
concentrations that serve different parts of the population. Compliance samples 
are taken at each entry point to the distribution system.  In systems with 
separate wells serving some branches or sections of the distribution system, the 
system mean would tend to underestimate the TCE concentration of people 
served by wells with higher TCE concentrations.  Exposure may be higher or 
lower than estimated if data from multiple entry points for water with different 
TCE levels are averaged to estimate levels for the PWS. 
Related Indicators Public Water Use 
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CONTENT DOMAIN: COMMUNITY WATER   
INDICATOR:  URANIUM (U)  
ENVIRONMENTAL PUBLIC HEALTH TRACKING 
Type of EPHT Indicator Hazard, Exposure 
Measures Level of Contaminant in Finished Water 
1. Yearly distribution of number of Community Water Systems (CWS) by 
maximum Uranium concentration (cut-points: 0-5, >5-15, >15-30, >30 
µg/L Uranium). 
2. Yearly distribution of number of CWS by mean Uranium concentration 
(cut-points:  cut-points: 0-5, >5-15, >15-30, >30 µg/L Uranium). 
3. Mean concentration of Uranium at CWS-level, by year. 
 
Potential Population Exposure to Contaminants in Finished Water 
4. Yearly distribution of number of people served by CWS by maximum 
Uranium concentration (cut-points: 0-5, >5-15, >15-30, >30 µg/L 
Uranium). 
5. Yearly distribution of number of people served by CWS by mean 
Uranium concentration (cut-points: 0-5, >5-15, >15-30, >30 µg/L 
Uranium). 
Derivation of Measures Uranium measures will be developed from water system attribute and water 
quality data stored in state Safe Drinking Water Act (SDWA) databases such as 
the Safe Drinking Water Information System (SDWIS/State). Data will be 
cleaned and transformed to a standard format. Analytical results of drinking 
water samples (usually taken at entry points to the distribution system or 
representative sampling points after treatment) will be used in conjunction with 
information about each CWS (such as service population and latitude and 
longitude of representative location of the CWS service area) to generate the 
measures.   
Units Uranium, µg/L 
Geographic Scope State and Community Water System by County 
Geographic Scale The finest detail will be approximate point location of the community water 
distribution system represented by water withdrawal point, water distribution 
extents, principal county served, or principal city served.  
Time Period 1999 or earliest year available to most current year of data abstraction. 
Time Scale Calendar year 
Rationale Uranium (U) and Public Health 
Uranium is a silver-white metal that is extremely dense and weakly radioactive. 
It usually occurs as an oxide and is extracted from ores containing less than 1% 
natural uranium. Natural uranium is a mixture of three isotopes: 238U (greater 
than 99%), 235U (about 0.72%), and 234U (about 0.01%). Uranium has many 
commercial uses, including nuclear weapons, nuclear fuel, in some ceramics, 
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and as an aid in electron microscopy and photography. Depleted uranium (DU) 
refers to uranium in which the proportions of 235U and 234U isotopes have 
been reduced compared with the proportion in natural uranium. Since the 
1990's, DU has been used by the military in armor-piercing ammunition and as 
a component of protective armor for tanks. Natural and depleted uranium are 
primarily chemical toxicants, with radiation playing a minor role or no role at 
all (ATSDR, 2009).  
 
Everyone is exposed to uranium in food, air, and water as part of the natural 
environment.  (ATSDR, 2009). Variable concentrations of uranium occur 
naturally in drinking water sources.  In some locations the natural 
concentrations may have increased due to mining and milling of uranium. Thus, 
the primary exposure sources for non-occupationally exposed persons are likely 
dietary and drinking water. Populations most heavily exposed to uranium are 
those employed in mining and milling operations, or in uranium enrichment 
and processing activities (ATSDR, 2009).  In workplaces that involve uranium 
mining, milling, or processing, human exposure occurs primarily by inhaling 
dust and other small particles. Exposure to DU may occur in military personnel 
from retention of internal shrapnel that contains DU or exposure to dust 
generated from ammunition impact.  
 
Absorption of uranium compounds is low by all routes of exposure (i.e., 
ingestion, inhalation, and skin contact). Depending upon the specific compound 
and solubility, 0.1%-6% of an ingested dose may be absorbed. Inhaled 
uranium-containing particles are retained in the lungs, where limited absorption 
occurs (less than 5%).  After long term or repeated exposure, kidneys, liver, and 
bones can accumulate uranium with the largest amounts being stored in bones 
(Li et al., 2005). Uranium is eliminated in feces and urine; about 50% of the 
absorbed dose is eliminated in the urine within the first 24 hours. After 
exposure to soluble uranium salts, the initial half-life of uranium is about 15 
days (Bhattacharyya et al., 1992), which represents distribution and excretion, 
with much slower elimination from bone. After inhalation, the half-life of 
insoluble uranium in the lungs is several years (Durakovic et al., 2003).  
 
Human health effects from uranium at low environmental doses or at 
biomonitored levels from low environmental exposures are unknown. Health 
outcomes that may occur with uranium overexposure, based on both observed 
human effects and animal studies, include non-malignant respiratory disease 
(fibrosis, emphysema) and nephrotoxicity.   Studies of persons with chronic 
exposure to elevated uranium salts in drinking water have shown changes in 
urinary biomarkers potentially associated with impaired kidney function 
(Kurttio et al., 2006). IARC and NTP have no ratings for uranium human 
carcinogenicity. Radiation risks from exposure to natural uranium are very low. 
Alpha radiation (such as that from uranium) is classified as a human 
carcinogen. However, human studies have not found elevated rates of cancer 
from uranium exposure, and high-dose animal studies have not found cancer 
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following inhalation, oral, or dermal exposure to uranium.  
 
Workplace air standards and guidelines for external exposure to soluble and 
insoluble uranium compounds have been established by OSHA and ACGIH, 
respectively. Drinking water and other environmental standards have been 
established by U.S. EPA. Information about external exposure (i.e., 
environmental levels) and health effects is available from ATSDR at: 
http://www.atsdr.cdc.gov/toxpro2.html.  
 
 In an analysis of occurrence data from the EPA 6 Year Review of National 
Primary Drinking Water Regulations, uranium was detected in 4,101 systems 
serving close to 55 million people (EPA, 2009). Concentrations of uranium 
were greater than the MCL in 448 systems serving close to 8.4 million people 
(EPA, 2009).    
 
Biomonitoring Information 
Levels of urinary uranium reflect recent and ongoing or accumulated exposure. 
A previous nonrandom subsample from NHANES III (n = 499) (Ting et al., 
1999) and other small populations have shown urinary concentrations that are 
similar to those in NHANES 1999-2000, 2001-2002, and 2003-2004 (Dang et 
al.,1992; Galletti, 2003; Karpas et al.,1996; Tolmachev et al., 2006). Older 
studies have demonstrated urinary uranium concentrations that are consistent 
with levels in the U.S. population, in that the levels were below their respective 
detection limits (Byrne et al., 1991; Hamilton et al., 1994; Komaromy-Hiller et 
al., 2000). In a study of 105 persons exposed to natural uranium in well water, 
urinary levels of uranium were as high as 9.55 μg/L (median 0.162 μg/L) 
(Orloff et al., 2004). Eighty-five percent of those levels were above the 95th 
percentile of the NHANES 1999-2000 population. The U.S. Nuclear 
Regulatory Commission (NRC) has set an action level of 15 μg/L urinary 
uranium to protect people who are occupationally exposed (NRC, 1978).  
Finding a measurable amount of uranium in urine does not mean that the level 
of uranium causes an adverse health effect. Biomonitoring studies on levels of 
uranium provide physicians and public health officials with reference values so 
that they can determine whether people have been exposed to higher levels of 
uranium than are found in the general population. Biomonitoring data can also 
help scientists plan and conduct research on exposure and health effects. 
 
 
Sources of Uranium 
Uranium is a naturally-occurring element found in the earth’s crust.  It is 
naturally abundant in rocks, soil and water.  Significant concentrations of 
uranium can occur in phosphate rock deposits, and in minerals such as 
pitchblende and uraninite.  The total amount of Uranium on earth stays virtually 
the same because it has such a long half-life (4.47x109 years for U-238) (EPA, 
2010). 
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Uranium Regulation and Monitoring 
The EPA limits the amount of uranium that may be present in drinking water to 
30 ug/L (EPA, 2009).  A gross alpha particle activity measurement may be 
substituted for the required uranium measurement provided that the measured 
gross alpha particle activity does not exceed 15 pCi/l. 
 
Monitoring frequency 
Once a CWS has satisfied initial monitoring requirements (4 quarterly samples 
at every entry point to the distribution system within the first quarter after 
initiating the source); the required frequency for Uranium monitoring is once 
every three years if the average of the initial monitoring results for the 
contaminant is greater than one-half the MCL but at or below the MCL.  States 
may allow CWS to reduce the frequency of monitoring from once every three 
years to once every six or nine years at each sampling point, if the average of 
the initial monitoring results for each contaminant is below the detection limit. 
If a system has a monitoring result that exceeds the MCL while on reduced 
monitoring, the system must collect and analyze quarterly samples at that 
sampling point until the system has results from four consecutive quarters that 
are below the MCL, unless the system enters into another schedule as part of a 
formal compliance agreement with the State (CFR, 2002). 
Use of Measure These measures assist by providing data that can be used for surveillance 
purposes. 
• Distribution measures provide information on the number of CWS and the 
   number of people potentially exposed to Uranium at different  
   concentrations.  
• Maximum concentrations provide information on the peak potential  
   exposure to Uranium at the state level. 
• Mean concentrations at the CWS level provide information on potential  
   exposure at a smaller geographic scale.  
Limitations of The 
Measure 
The current measures are derived for CWS only. Private wells may be another 
source of population exposure to Uranium.  Transient non-community water 
systems, which are regulated by EPA, may also be an important source of 
Uranium exposure.  Measures do not account for the variability in sampling, 
numbers of sampling repeats, and variability within systems.  Concentrations in 
drinking water cannot be directly converted to exposure, because water 
consumption varies by climate, level of physical activity, and between people 
(EPA 2004).  Due to errors in estimating populations, the measures may 
overestimate or underestimate the number of affected people. 
Data Sources State grantee  
Limitations of Data 
Sources 
The required monitoring frequency for Uranium is infrequent (every 3 to 6 
years) and may be as intermittent as every nine years; therefore most states will 
have very little data on this contaminant.   
Ground water systems may have multiple wells with different Uranium 
concentrations that serve different parts of the population. Compliance samples 
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are taken at each entry point to the distribution system.  In systems with 
separate wells serving some branches or sections of the distribution system, the 
system mean would tend to underestimate the Uranium concentrations of 
people served by wells with higher Uranium concentrations.  Exposure may be 
higher or lower than estimated if data from multiple entry points for water with 
different Uranium levels are averaged to estimate levels for the PWS. 
Related Indicators Public Water Use; combined Radium-226 and -228 
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CONTENT DOMAIN: REPRODUCTIVE HEALTH OUTCOMES 
INDICATOR: PREMATURITY 
 
Type Of 
EPHT 
Indicator 
Health Outcome 
Measure 1. Percent of preterm (less than 37 weeks gestation) live singleton births  
2. Percent of very preterm (less than 32 weeks gestation) live singleton births  
Derivation 
of Measure 
1. Number of live singleton births before 37 weeks of gestation to resident mothers, 
divided by total number of live singleton births to resident mothers 
2. Number of live singleton births before 32 weeks of gestation to resident mothers, 
divided by total number of live singleton births to resident mothers 
Unit 1. Preterm live singleton births 
2. Very preterm live singleton births 
Geographic 
Scope 
State and national 
Geographic 
Scale 
State and County  
Time 
Period 
2000-current 
Time Scale Preterm: Annual 
Very Preterm: 5 yr annual average 
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Rationale Preterm birth (at less than 37 completed weeks of gestation and among all births regardless 
of plurality) affects more than 500,000, or 12.5%, of live births in the United States and is a 
leading cause of infant mortality and morbidity (8, 9, 13).  Of those births, the majority 
(about 84%) of premature babies are born moderately preterm (between 32 and 36 
completed weeks of gestation). The remaining 16% of those are born very preterm (at less 
than 32 weeks of gestation), representing more than 80,000, or 2%, of live births in the 
United States.  Of those infants born very preterm, about 63% are born between 28–31 
weeks of gestation, and about 37% are born at less than 28 weeks of gestation. 
 
The preterm birth rate rose 18% between 1990 and 2004 (from 10.6% in 1990 to 12.5% in 
2004) and more than 30% since 1981 (from 9.4%) (9). For 2003–2004, increases were seen 
among both moderately preterm and very preterm births. The percentage of infants born 
very preterm increased from 1.92% to 2.01% between 1990 and 2004 (9); it also increased 
between 2003 and 2004 from 1.97% to 2.01%, respectively.  
 
Preterm birth rates are higher among black mothers compared to Hispanic and white 
mothers. Between 2002 and 2003, the rates increased for the three largest race and ethnic 
groups: non-Hispanic white (11.0 to 11.3%), non-Hispanic black (17.7 to 17.8%), and 
Hispanic (11.6 to 11.9 %) (9). Since 1990, preterm birth rates have risen by one-third 
(about 33%) for non-Hispanic white births (from 8.5%) and by 8% for Hispanic births 
(11.0%).  In contrast, preterm rates among non-Hispanic black infants have declined 
slightly over this period (from 11.9%).  However, the preterm birth risk of non-Hispanic 
blacks continues to be substantially higher that the risk of other race and ethnic groups.  Of 
particular concern is the very preterm rate, about twice as high among non-Hispanic black 
infants compared to non-Hispanic white and Hispanic births (3.99% compared to 1.6% and 
1.73%, respectively). 
 
Preterm birth is a leading cause of infant mortality, morbidity, and long-term disability (8, 
9, 13, 14). All infants born preterm are at risk for serious health problems; however, those 
born earliest are at greater risk of medical complications, long-term disabilities, and death.    
 
Studies have shown that infants born prematurely, especially those with VLBW, have an 
increased risk for neurological problems ranging from attention deficit hyperactivity 
disorder to cerebral palsy or mental retardation compared with infants born at term 
gestation (1, 6, 8, 14).  Preterm birth is associated with nearly half of all congenital 
neurological defects such as cerebral palsy (9); it is also associated with congenital 
gastrointestinal defects such as gastroschisis. 
 
Preterm infants are at greater risk for serious health problems for several reasons: the earlier 
an infant is born, the less it will weigh, the less developed its organs will be, and the more 
medical complications it will likely face later in life.  Very preterm infants have the greatest 
risk of death and lasting disabilities, including mental retardation, cerebral palsy, 
respiratory (premature lung) and gastrointestinal problems (including birth defects such as 
gastroschisis), and vision and hearing loss.  Preterm births account for health care 
expenditure of more than $3 billion per year (14).  
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Studies have shown that major risk factors associated with preterm birth include (2, 4, 7, 8, 
10, 14):  
1. Plural births 
2. Previous preterm birth 
3. Certain uterine or cervical abnormalities of the mother 
4. Mother’s age, race, poverty (for example,  black women, women younger than 17 and 
older than 35 years, and poor women are at greater risk than other women) 
5. Male fetal gender (associated with singleton preterm birth) 
6. Certain lifestyles and environmental factors, including:  
o Late or no prenatal care, 
o Maternal smoking, alcohol consumption (especially in early pregnancy),  illegal 
drug use, exposure to the medication diethylstilbestrol (DES), domestic violence, 
lack of social support, stress, long working hours with long periods of standing, 
being underweight before pregnancy, obesity, marital status, and spacing (less 
than 6–9 months between giving birth and the beginning of the next pregnancy), 
o Neighborhood-level characteristics, 
o Environmental contaminants (e.g., exposure to air pollution and drinking water 
contaminated with chemical DBP or lead). 
 
Certain medical conditions during pregnancy (e.g., infections, diabetes, hypertension, blood 
clotting disorders/thrombophilia, vaginal bleeding, certain birth defects of the fetus) may 
also increase the risk of preterm birth.   
 
The strength of the association of each of these risk factors with preterm birth varies, and 
remains a subject of significant debate in the literature (14). 
 
The rise in the occurrence of multiple/plural births, which are much more likely than 
singleton births to be preterm, influenced the overall preterm birth rate over the past two 
decades.  However, preterm rates for singleton births have also increased, up to 11% since 
1990 (9). This increase in singleton preterm births was only in infants born moderately 
preterm; the singleton very preterm birth rate declined slightly, from 1.69% in 1990 to 
1.61% in 2004. 
 
Preterm births are associated with many modifiable risk factors, and prevention of preterm 
births may greatly contribute to the overall reduction in infant illness, disability, and death. 
Several studies are being conducted to improve our understanding of the precise causes of 
preterm births, especially those with VLBW, and to learn how to prevent them. These 
studies look at how genes, maternal stress, race, occupational and environmental factors, 
and infections may contribute to preterm birth (8). Better understanding of the specific 
causes of preterm births is needed before tailored interventions can be developed. 
 
Neighborhood-level characteristics have proven to be useful predictors of preterm birth 
risks (10). Neighborhoods are the geographic units where interventions can be targeted, and 
those interventions can be an effective way to reduce preterm birth rates and other adverse 
birth outcomes.  Neighborhood-level characteristics contributing to prematurity include the 
social, economic, and environmental risk factors such as certain aspects of the built 
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environment. 
 
Preterm births data are readily available in all state health departments and can be used to 
examine trends. These trends may reflect the contributions of environmental exposures and 
other modifiable risks to preterm births.  These trends can also be used to evaluate the 
effectiveness of existing and new prevention programs. 
 
“Live birth means the complete expulsion or extraction from its mother of a product of 
human conception, irrespective of the duration of pregnancy, which, after such expulsion or 
extraction, breathes, or shows any other evidence of life, such as beating of the heart, 
pulsation of the umbilical cord, or definite movement of voluntary muscles, whether or not 
the umbilical cord has been cut or the placenta is attached.  Heartbeats are to be 
distinguished from transient cardiac contractions; respirations are to be distinguished from 
fleeting respiratory efforts or gasps.”  All states require the reporting of live births 
regardless of length of gestation or birth weight (3). 
 
Use Of The 
Measure 
These measures can be utilized to enhance public health prevention actions and 
interventions, and inform policy makers and the public regarding risk factors management 
and mitigation.  
Limitations 
Of The 
Measure 
Uncertainties associated with gestational age estimates: 
The interval between the first day of the mother’s last normal menstrual period (LMP) and 
the day of birth is one method used to determine the gestational age of the newborn. 
However, this measurement is subject to error for many reasons, including imperfect 
maternal recall or misidentification of the LMP due to postconception bleeding, delayed 
ovulation, or intervening early miscarriage (9). Thus, for the purpose of calculating national 
statistics of preterm births, these data are being edited for gestational ages that are clearly 
inconsistent with the infant’s plurality and birth weight, but substantial inconsistencies in 
the data still persist (9). 
 
The National Center for Health Statistics (NCHS) and most state vital records offices report 
gestational age based on an algorithm that uses both the mother’s reported last normal 
menses and the clinician’s estimate of gestational age. The LMP indicator is used unless its 
value appears to be inconsistent with birthweight, falls outside likely parameters, or was not 
reported.  If any of these circumstances exist, the clinical estimate is used. Nationwide in 
2004, approximately 5.9% of gestational age values were based on the clinical estimate (9). 
 
Changes in reporting of the gestational age over time may affect trends in preterm birth 
rates, especially by race (9). These reporting problems may occur more frequently among 
some subpopulations and among births with shorter gestations.   
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Difficulties of interpreting preterm and very preterm birth rates: 
The preterm birth rates might be an indicator of pregnancy outcome that does not 
necessarily predict the true health risk associated with early birth.  Preterm rates based on 
live singleton births may be affected by maternal characteristics; a low preterm birth rate 
might indicate a low-risk population, and a high preterm birth rate might indicate maternal 
characteristics that predispose to preterm birth. 
 
Data 
Sources 
Birth certificate data from Vital Statistics state systems (both numerator and denominator); 
 
National Vital Statistics System (NVSS), CDC, NCHS 
http://www.cdc.gov/nchs/VitalStats.htm; 
 
CDC Wonder: Natality Data Request, CDC http://wonder.cdc.gov/natality.html 
 
CDC GIS Reproductive Health Atlas: http://cdc.gov/reproductivehealth/gisatlas/index.htm 
 
Limitations 
Of Data 
Sources 
 
Vital statistics data are readily available, of high quality, and useful for various purposes, 
including public health surveillance; however, they cannot be correctly interpreted unless 
various qualifying factors and classification methods are considered (see “Limitations of 
the Measure”). The factors to be considered will vary depending on the intended use of the 
data; however, most of the limiting factors result from imperfections in the original records, 
and they should not be ignored.  Yet, their existence does not lessen the value of the data 
for calculating/estimating this measure.  
 
One important limitation of the national data is the timeliness of when the data are 
available. The national file cannot be compiled until all states have submitted their data. 
Often times there is delay of 2‐3 years before national statistics are available. There are also 
some differences between national data and state data handling of unknowns, imputation 
rules, and close out dates. There may be differences or delays in processing resident births 
that occur out of state. These process issues, along with the need to close off national 
statistics at specified intervals following a reporting period, may lead to small discrepancies 
between national data compiled by NCHS and data maintained by state vital statistics 
registries.  
 
Related 
Indicators 
Low birthweight 
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CONTENT DOMAIN: REPRODUCTIVE HEALTH OUTCOMES 
INDICATOR: LOW BIRTHWEIGHT 
 
Type Of 
EPHT 
Indicator 
Health Outcome 
Measure 1. Percent of low birthweight (less than 2500 grams) live term singleton births 
2. Percent of very low birthweight (less than 1500 grams) live singleton births 
Derivation 
of Measure 
Number of  singleton infants live born at term (at or above 37 completed weeks of 
gestation) with a birthweight of less than 2,500 grams, divided by the total number of  
singleton infants live born at term to resident mothers 
Number of live singleton births with a birthweight of less than 1,500 grams, divided by 
total number of live singleton births to resident mothers 
Unit LBW: live singleton term births 
VLBW: live singleton births 
Geographic 
Scope 
State and national 
Geographic 
Scale 
State and County  
Time 
Period 
2000-current 
Time Scale Low birthweight: Annual 
Very low birthweight: 5 yr annual average 
Rationale 
 
LBW, a weight of less than 2,500 grams, or 5 pounds, 8 ounces, at birth (regardless of 
gestational age and plurality), affects about 1 of every 13 babies born each year in the 
United States (7).  Studies have shown that LBW is an important predictor of future 
morbidity and mortality.  Note however, that the percent of LWB babies among all births (a 
percentage that is confounded by gestational age and plurality) is not recommended as a 
population-level measure of perinatal morbidity and mortality (1, 11).  It is not 
recommended as a measure because preterm delivery, decreased fetal growth, and 
genetically determined small body size commonly occur in LBW infants (1).  Compared to 
infants of normal weight, LBW infants may be at increased risk of perinatal morbidity, 
infections, and the longer-term consequences of impaired development such as delayed 
motor and social development or learning disabilities. Mortality risk is lowest for infants 
born weighing 3,500–4,500 grams (8). 
 
Nationally, the percentage of LBW infants  (regardless of gestational age and plurality) has 
been increasing steadily; it reached 8.2% of all births in 2005, the highest level reported 
since 1968 (4). The 2005 rate was 17% higher than the 1970 (7%) rate, which was 22% 
higher than the 1984 low (6.7%).  In addition, this rate is 64% higher than the Healthy 
People 2010 goal of 5% (5).  The percentage of LBW births also increased among singleton 
births, from 5.9% in 1990 to 6.31% in 2004 (7% increase). 
 
Increases in the multiple birth rate, obstetric interventions (e.g., induction of labor and 
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cesarean delivery), older maternal age at childbearing, and increased use of infertility 
therapies likely have affected the trends toward lower birthweights (8).  Environmental 
exposures have also been implicated as possible risk factors for LBW, but the magnitude of 
the contribution to these increased rates remains relatively uncertain. The percentage of 
LBW increased among each of the largest racial and ethnic groups: non-Hispanic whites 
(from 7.0% in 2003 to 7.2% in 2004), non-Hispanic blacks (from 13.6% in 2003 to 13.7% 
in 2004), and Hispanics (from 6.7% in 2003 to 6.8% in 2004) (8). 
 
LBW in singleton births rose between 2003 and 2004 among non-Hispanic white and 
Hispanic infants; the increase for non-Hispanic black infants was not statistically significant 
(8). Since 1990, singleton LBW rates have risen 8% and 14% for Hispanic and non-
Hispanic white infants, respectively; the rates have declined 2% among non-Hispanic black 
infants. 
 
The youngest and oldest mothers are the most likely to deliver LBW infants. In 2004, the 
lowest LBW levels were reported for women aged 25–34 years (7.3% for women aged 25–
29 years and 7.5% for women 30–34 year old); the highest LBW levels were for teenagers 
younger than 15 years (13.6%) and women aged 45–54 years (21.2%) (8). However, much 
of the elevated LBW risk among older mothers can be attributed to their higher multiple 
birth rates; in fact, the LBW rate declined from 21% to 10% for the oldest mothers of 
singleton births. 
 
LBW rates also vary widely between states or reporting areas (8). In 2004,  more than 10% 
of all infants born in Alabama, Louisiana, Mississippi, South Carolina, and the District of 
Columbia were LBW., This compares with less than 6.5% of newborns in Alaska, Maine, 
Oregon, Vermont, and Washington that were LBW. Different demographic characteristics 
of these populations, including maternal age, race, or ethnicity, may explain some of these 
differences. 
 
Infants weighing less than 1,500 grams, or 3 pounds, 4 ounces, at birth are considered 
VLBW (3); most of them are also premature (born before 37 weeks gestation).  (Note that 
the percent of VLBW babies among all births is also confounded by plurality; therefore, the 
percent of VLBW births among singleton births is recommended as a population-level 
measure of prematurity.) Studies have shown that the infant’s birthweight is a predictor of 
future morbidity and mortality (8), especially for VLBW infants. VLBW infants have about 
a 25% chance of dying in the first year of life; this risk is estimated to be about 100 times 
higher for VLBW infants than for normal-weight infants (≥2,500grams) (8). VLBW infants 
have an increased risk for developing neurological and intellectual problems (including 
attention deficit hyperactivity disorder, cerebral palsy, developmental delay and mental 
retardation), visual problems (including blindness), hearing loss, infections, and chronic 
lung diseases compared  with infants of normal weight or infants born at term gestation  (2, 
5, 6, 7). 
 
Nationally, the percentage of VLBW infants  (regardless of plurality) increased slightly 
from 1.45% in 2003 to 1.49% in 2005, and has increased  from 1.27% in 1990 (5). The 
2005 rate is 66% higher than the Healthy People 2010 goal of 0.9% (5).  The VLBW has 
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increased since 1990 among whites, blacks, Puerto Ricans, American Indians, and other 
population groups (5). For 2004–2005, increases in VLBW rates were statistically 
significant for non-Hispanic black infants but not for non-Hispanic white infants (8).   
 
The increase in the rate of multiple births, in which the infants tend to be much smaller than 
in singleton births, has likely affected the upward trend in the VLBW rate (8). However, the 
VLBW rate among singleton births also increased slightly from 1.12% in 2004 to 1.14% in 
2005 (8). 
 
Increases in obstetric interventions (e.g., induction of labor and cesarean delivery), teenage 
pregnancy, and older maternal age at childbearing likely contributed to the increased 
VLBW rates.  Teen mothers, especially those younger than aged 15 years, have a higher 
chance of giving birth to a VLBW infant.  Environmental exposures, including exposure to 
air pollution, drinking water contaminated with chemical DBP, and exposure to pesticides, 
have also been implicated as possible risk factors for VLBW, but the exact magnitude of 
the contribution to the increased VLBW rates remains relatively uncertain 
 
Birthweight is a multifactorial and heterogeneous birth outcome.  Birthweight of an infant 
is directly related to its gestational age.  As noted above, multiple births are usually LBW, 
even those delivered at term.  Therefore, the focus of the measure is restricted to singleton 
term births.  As such, the measure distinguishes between preterm and multiple birth 
categories and decreased fetal growth that may be affected by other risk factors, including 
environmental factors.  
 
LBW rate is associated with many modifiable risk factors, and preventing LBW may 
contribute to the overall reduction in infant illness, disability, and death.  Several studies are 
being conducted that may help understand the biological, social, and environmental factors 
that contribute to LBW births and learn how to prevent them. These studies look at how 
genes, hormonal changes, maternal stress, race, occupational and environmental factors, 
and infections may contribute to prematurity and LBW (7).  Specific causes of LBW births 
must be better understood before tailored interventions can be developed. 
 
Neighborhood-level characteristics have proven to be useful predictors of LBW risks (9).  
Neighborhoods are the geographic units where interventions can be targeted, and those 
interventions can be an effective ways to reduce LBW rates, infant mortality, and other 
adverse birth outcomes.  Neighborhood-level characteristics contributing to LBW include 
social, economic, and environmental risk factors, such as certain aspects of the built 
environment. 
 
The percentage of LBW among term singleton births is a useful and feasible measure of 
perinatal health.  LBW, gestational age, and plurality data are readily available in all state 
health departments, and can be used to examine trends that occur over time and space. 
These trends may reflect the contributions of environmental exposures and other modifiable 
risk factors for LBW. 
 
Exposure to air pollution (both indoor and outdoor) and drinking water contaminated with 
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chemical DBPs or lead may serve as examples of environmental risk factors.  Maternal 
smoking, alcohol consumption, or inadequate weight gain are associated with an increased 
risk of intrauterine growth retardation and LBW.   Socioeconomic factors, including low 
income and lack of education, are reported as risk factors for LBW (10).  
 
Women younger than 15 years or older than 35 years, unmarried mothers, and women who 
have had previous preterm birth are at increased risk of having LBW babies.  Women who 
experience excessive stress, domestic violence, or other abuse also may be at increased risk 
of having a LBW baby (7). 
 
“Live birth means the complete expulsion or extraction from its mother of a product of 
human conception, irrespective of the duration of pregnancy, which, after such expulsion or 
extraction, breathes, or shows any other evidence of life, such as beating of the heart, 
pulsation of the umbilical cord, or definite movement of voluntary muscles, whether or not 
the umbilical cord has been cut or the placenta is attached.  Heartbeats are to be 
distinguished from transient cardiac contractions; respirations are to be distinguished from 
fleeting respiratory efforts or gasps.”  All states require the reporting of live births, 
regardless of length of gestation or birth weight (3). 
 
Birthweight is the first weight of the newborn obtained after birth (3).  
 
Low birthweight is defined as less than 2,500 grams or 5 pounds, 8 ounces (3).  Before 
1979, low birthweight was defined as 2,500 grams or less. 
 
Very low birthweight is defined as less than 1,500 grams or 3 pounds, 4 ounces (3).  Before 
1979, very low birthweight was defined as 1,500 grams or less. 
 
Term birth is defined here as the birth at or above 37 completed weeks of gestation. 
 
Use Of The 
Measure 
This indicator can be used to influence public health prevention actions and interventions 
and policy makers and inform the public regarding risk factors management and mitigation. 
 
The LBW measure can be used to track the perinatal health in states, regions, counties, and 
smaller geographic areas or communities, as needed.  Baseline data can be used to monitor 
changes or trends. 
 
This measure can also be used to evaluate the effectiveness of existing and new prevention 
programs. 
Limitations 
Of The 
Measure 
Difficulties of interpreting LBW birth rates among term singleton births: 
Using LBW rates alone as a pregnancy outcome measure might not inform the user about 
the true health risk associated with LBW.  
 
Difficulties of interpreting VLBW birth rates: 
Although the percentage of VLBW births has increased during the past 20 years, in large 
part this could be due to improvements in fetal health. Conditions that may have resulted in 
a fetal death decades ago might today result in fetal survival and a live VLBW birth (6). 
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Recommendations: 
LBW rates should be interpreted with caution. The LBW rate should be only one of the 
reproductive outcome measures being tracked, and it should be accompanied by the infant 
mortality rate (neonatal and postneonatal), fetal death rate if reliable, and morbidity 
measures.  If feasible, an infant’s anthropometric parameters should also be monitored; this 
could include a reduced head circumference measure because smaller head size may predict 
lower IQ and cognitive abilities and may be associated with ADD/ADHD.  
Data 
Sources 
Birth certificate data from Vital Statistics state systems (both numerator and denominator) 
 
National Vital Statistics System (NVSS), CDC, NCHS; 
CDC Wonder: Natality Data Request, CDC http://wonder.cdc.gov/natality.html 
 
CDC GIS Reproductive Health Atlas: http://cdc.gov/reproductivehealth/gisatlas/index.htm 
Limitations 
Of Data 
Sources 
 
Although vital statistics data are readily available, of high quality, and otherwise useful for 
various purposes, including public health surveillance, they cannot be correctly interpreted 
unless various qualifying factors and classification methods are considered (see also 
“Limitations of the Measure”). The factors to be considered will vary, depending of the 
intended use of the data; however, most of the limiting factors result from imperfections in 
the original records, and they should not be ignored.  Yet, their existence does not lessen 
the value of the data for the purpose of calculating this measure. At the minimum, the 
following data quality attributes should be evaluated: completeness of registration, 
reporting and quality control procedures, and records geocoding procedures and quality. 
 
One important limitation of the national data is the timeliness of when the data are 
available. The national file cannot be compiled until all states have submitted their data. 
Often times there is delay of 2‐3 years before national statistics are available. There are also 
some differences between national data and state data handling of unknowns, imputation 
rules, and close out dates. There may be differences or delays in processing resident births 
that occur out of state. These process issues, along with the need to close off national 
statistics at specified intervals following a reporting period, may lead to small discrepancies 
between national data compiled by NCHS and data maintained by state vital statistics 
registries.  
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Indicators 
Prematurity 
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CONTENT DOMAIN: REPRODUCTIVE HEALTH OUTCOMES 
INDICATOR: MORTALITY (USING PERIOD LINKED 
BIRTH/INFANT DEATH APPROACH) 
 
Type of EPHT Indicator Health Outcome 
Measures 1. Average Infant (less than 1 year of age) Mortality Rate per 1000 live 
births  
2. Average Neonatal (less than 28 days of age) Mortality Rate per 1000 live 
births  
3. Average Perinatal  (equal to or greater than 28 weeks gestation to less 
than 7 days of age) Mortality Rate per 1000 live births (plus fetal deaths 
equal to or greater than 28 weeks gestation)  
4. Average Postneonatal (equal to or greater than 28 days to less than 1 year 
of age) Mortality Rate per 1000 live births 
Derivation of Measures 1. Infants: Number of deaths occurring in infant residents under 1 
year of age (under 366 days during a leap year) in a given year 
divided by the number of live births in the same year. 
2. Neonates: Number of deaths occurring in infant residents less than 
28 days of age in a given year divided by the number of live births 
in the same year 
3. Perinates: Number of fetal deaths in infant residents greater than 
or equal to 28 weeks gestation plus infant deaths less than 7 days 
old in a given year divided by the number of live births plus fetal 
deaths at greater than or equal to 28 weeks gestation in the same 
year 
4. Postneonates: Number of deaths occurring in infant residents at 28 
days to less than1 year of age (under 366 days during a leap year) 
in a given year divided by the number of live births in the same 
year 
 
Both birth and death counts are geographically classified based on 
maternal residence at the time of birth. 
 
Units 1. Deaths per 1,000 live births 
2. Deaths per 1,000 live births 
3. Deaths per 1,000 live births plus fetal deaths at 28 or greater 
weeks gestation 
4. Deaths per 1,000 live births 
Geographic Scope State and national 
Geographic Scale State and County 
Time Period 
 
2000-current 
Time Scale 
 
Five year 
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Rationale Fetuses and young children may be particularly susceptible to harmful 
effects of environmental contaminants. Many environmental 
contaminants have been proposed to be particularly toxic in utero; 
many cross the placenta and make their way into the circulatory 
system of the developing fetus. However, specific health effects are 
often not well understood for years Therefore, gross indicators of 
childhood health—such as mortality—should be tracked as part of an 
EPHT system. Furthermore, data on births and deaths in a region may 
be far more complete than data on other health-related events. 
 
Overall, congenital malformations, deformations, and chromosomal 
abnormalities are the leading cause of infant deaths (20.1% of deaths) 
(1). Disorders related to short gestation and LBW are second, making 
up 16.6% of deaths. However, importantly, cause of death varies over 
the first year of life, and combining all causes obscures the fact that 
sudden infant death syndrome is the leading cause of death in the 
postneonatal period. 
 
Disorders related to short gestation and LBW are the leading cause of 
neonatal death (24.3% of deaths) (1). This is in contrast to the leading 
cause of postneonatal death, which is sudden infant death syndrome 
(21.8%). Congenital malformations, deformations, and chromosomal 
abnormalities are the second-leading cause of neonatal deaths (21.4%) 
and postneonatal deaths (17.5%) (1). 
 
Restricting infant mortality to deaths during the perinatal, neonatal, or 
postneonatal period may limit the etiologic heterogeneity inherent in a 
gross measure such as overall infant mortality. Also, it may be more 
likely that infants who died within 7 or 28 days, respectively, were 
living in reasonable proximity to where they were born, making 
ecological associations with environmental exposures potentially more 
meaningful. Specifically, exclusion of infants who died within 28 days 
might reduce etiologic heterogeneity due to differences in early 
prenatal care and other non-environmental factors likely to influence 
neonatal survival. 
 
When a fetus or an infant dies around the time of labor and delivery, it 
is not always clear whether to classify this event as a live birth and 
infant death, or a fetal death. Diagnostic ability for detecting signs of 
life, such as breathing or beating of the heart, pulsation of the 
umbilical cord, or definite movement of voluntary muscles after 
expulsion or extraction from the mother may vary across obstetric 
clinics.   
 
Unexplained fetal death and death related to growth restriction are the 
leading causes of fetal loss (2). Fetal death is an important contribution 
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to reproductive loss, with the rate being many times higher than the 
rate of sudden infant death syndrome among infants (1). Although the 
rate of late fetal loss (greater than or equal to28 weeks gestation) has 
been decreasing in past decades, the rate of intermediate fetal loss (20–
27 weeks gestation) has remained relatively constant (3). Markers of 
increased risk for fetal loss include pre-pregnancy obesity, lower 
socioeconomic status, non-Hispanic black race, and advanced maternal 
age. 
Use of the Measure 
 
Identifying populations with higher infant, neonatal, perinatal, and 
postneonatal mortality rates may indicate where potential 
environmental problems are. It will assist in targeting outreach 
intervention activities and improve our understanding of geographic 
variation, time trends, and demographic patterns of infant death.  
Limitations of the Measure An important limitation of this health outcome measure is the 
heterogeneity in its etiology. Environmental exposure-related causes of 
infant death are only one piece of a puzzle that includes many other 
factors, such as access to and quality of health care, competency in 
childcare, and understanding of injury prevention. 
 
The maternal residence during pregnancy and the infant’s residence 
during the first year of life are critical data for linking deaths to 
environmental hazards/exposures; these residences may differ from 
maternal residence at birth or infant residence at death. The mother 
may have lived far from the place at which she gave birth during part 
or all of the pregnancy. The infant who died may have been born and 
lived for a major portion of its life far from the place of death; it may 
be less likely that neonates and perinates who died were born and lived 
far from the place of death.  
 
NCHS currently uses a period linkage approach that links death 
certificates to birth certificates. This approach would allow 
stratification of deaths according to place of birth. However, it does 
not address the possibility that migration across states or other 
geographies occurred during pregnancy or infancy.  
Data Sources Local, state, or national vital statistics systems (birth, death, and fetal 
death records) 
Limitations of Data 
Sources 
 
It may be reasonable to assume universal reporting of live births and 
infant deaths in the United States; however, some births/deaths may be 
excluded because of the difficulty in distinguishing a death shortly 
after birth as a live birth; a death soon after birth might be reported as 
a fetal death rather than as a live birth and infant death. In addition, 
some fetal deaths may be missed in some regions, although those 
occurring at greater than or equal to28 weeks are less likely to be 
missing. 
 
Data on fetal death certificates may not provide all the information that 
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can be collected from birth certificates linked to infant deaths within 7 
days; however, many variables used for environmental health tracking 
(maternal race/ethnicity and age, place of residence) have relatively 
complete reporting on the fetal death certificate. 
 
Births and deaths will be tabulated according to maternal 
race/ethnicity, using linked data from birth certificates. 
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CONTENT DOMAIN: REPRODUCTIVE HEALTH OUTCOMES 
INDICATOR: FERTILITY 
 
Type of EPHT Indicator Health outcome 
Measure Total Fertility Rate per 1000 women of reproductive age 
Derivation of Measure(s) TFR = sum of age-specific fertility rates * 5  
Unit Rate per 1,000 women of reproductive age 
Geographic Scope State and national 
Geographic Scale State and County  
Time Period 
 
2000-current 
Time Scale 
 
Year 
Rationale The cause of approximately 10% of fertility problems is unknown, and 
environmental contaminants, including endocrine disruptors, have 
been considered major contributors. The case of diethylstilbestrol 
revealed that environmental contamination can have multi-
generational effects on reproduction that should be studied and tracked 
long-term. Several indicators have been used to track fertility on a 
global, national, state, and local level. Indicators most commonly used 
are the general fertility rate (GFR), which is defined as the number of 
live births divided by the total number of women of reproductive age 
(aged 15–44 years), and the total fertility rate (TFR). 
 
The TFR differs from the GFR in that it adjusts for age-specific 
differences in fertility.  It also shows the potential impact of current 
fertility patterns on reproduction, allowing for more valid comparisons 
of rates across time and space. 
 
Fecundity: The physical ability of a woman or couple to conceive and 
carry a child to term birth.   
Fertility: The ability to conceive a child. 
  
Use of the Measure 
 
The TFR indicates the average number of births to a hypothetical 
cohort of 1,000 women if they experienced the age-specific birth rates 
observed in a given year. Understanding the geographic distribution 
and trends in fertility will provide basic descriptive clues to changes 
that may be influenced by environmental risk factors. As more is 
learned regarding the link between adverse exposures and fertility, 
these rates will provide important background information about how 
fertility varies geographically in relation to changes in potentially 
related environmental risk factors and how it has varied over time 
within the United States. Similar to the GFR, the TFR may not be 
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specific enough to permit tracking of specific changes related to 
environmental risk factors. However, if the estimate of 10% is correct, 
this measure can be used with other measures, including ambient 
concentrations of pollutants, to examine potential associations with 
population-level changes in fertility and generate some well- informed 
hypotheses or areas for future investigations. 
Limitations of the Measure The fertility measure is influenced by social/demographic choices for 
reproduction, maternal age, parity, and social class measures, as well 
as the use of contraception and infertility treatments leading to 
multiple births. These factors all may determine variations in overall 
fertility across populations and geographic locations; therefore social 
and demographic factors would need to be controlled for to examine 
any environmental effects on total fertility. 
Data Sources Numerator: 
U.S. National Center for Health Statistics—Vital Statistics Reports 
and/or state-specific vital statistics (for more recent years of data) 
 
Denominator: 
U.S. Census Bureau 
Limitations of Data 
Sources 
 
National-level data sources may differ slightly from state-level vital 
statistics data sources 
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CONTENT DOMAIN: REPRODUCTIVE HEALTH OUTCOMES 
INDICATOR: SEX RATIO AT BIRTH AMONG SINGLETON BIRTHS 
 
Type of EPHT Indicator Health outcome 
Measure Male to Female sex ratio at birth (term singletons only) 
Derivation of Measure(s) Sex ratio=total males/total females at birth among term singleton 
births only 
Unit Ratio 
Geographic Scope State and national 
Geographic Scale State and county  
Time Period 
 
2000-current 
Time Scale 
 
Year 
Rationale Population growth is, in part, related to the number of live male 
children (1).  Numerous studies have reported changes in the ratio of 
males to females at birth; many of the studies have found a reduction 
in male relative to female births in different countries throughout the 
world (2-5).  Although the mechanism that determines the sex of the 
infant is not completely understood, some (6-12), but not all (3-4), 
have suggested that environmental hazards can affect the number of 
males.  Biological parent(s) and/or the fetus can come in contact with 
and become exposed to different hazards referred to as endocrine 
disruptors (7-8, 10, 12).  Fewer males are conceived when exposure to 
endocrine disruptors results in a decrease in testosterone.  Because 
states have accurate Vital Statistics (VS) records on the sex of live 
births, changes over time in the sex ratio of infants can be measured as 
the ratio of males to females. This ratio of total males/total females 
born in a pre-defined polygon (e.g., state, county, ZIP code, census 
tract, block group) at a certain time (one birth year or multiple years) is 
referred to as the Sex Ratio (SR). 
Use of the Measure 
 
The SR can be used to monitor the proportion of males to females in 
states, counties, or smaller-resolution polygons, when data are 
available and such analyses are justified.  Baseline data can be used to 
determine if the proportion of males is changing over time.  When the 
number of male births is the same as the number of female births, the 
SR is equal to 1.000.  Many studies have observed baseline SR values 
that are usually higher than 1.000, and closer to 1.050(1, 3, 13). In 
2002, the U.S. SR was 1.048 (1). If the SR is decreasing over time, the 
implication is that fewer males than females are born for that period of 
time. If consistent decreases in the SR occur, this outcome could be 
used to determine if such changes are the result of environmental 
hazards that can disrupt the endocrine system or some other 
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physiological system related directly or indirectly to the expression of 
the neonates’ sex at birth. 
Limitations of the Measure Unfortunately, other factors besides endocrine disruptors can affect the 
expression of sex (6, 13-15).  Decreases in male births inversely 
related to parental smoking, gestation length, parental age, and birth 
order. Reproductive practices and social morays regarding sex 
preferences—males over females, for example, can affect the observed 
SR (3, 4, 7).  Case-control studies have to be carried out to determine 
if decreases in the SR over time are due to contact with and exposure 
to endocrine disruptors; but effect modifiers have to be controlled in 
order to understand this relationship, factors that modify it need to be 
better accounted for. (8). 
Data Sources State’s VS data, CDC Wonder, CDC VS data, and U.S. Census 2000 
data in Summary File (SF) 1. 
Limitations of Data 
Sources 
 
There may be discrepancies between national and state data as noted in 
the templates for measures of prematurity and growth retardation 
above. 
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